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resumo 
 
 
Os peroxissomas são organelos multifuncionais e estão envolvidos em 
diversos processos metabólicos. As várias doenças graves provocadas por 
mau funcionamento dos peroxissomas e as crescentes evidências do seu 
envolvimento em várias patologias, desde a neurodegeneração, ao cancro e 
infeção viral, confere a este organelo um papel fundamental na saúde e 
desenvolvimento humanos. Os peroxissomas são extremamente dinâmicos, 
ajustando o seu número, morfologia e conteúdo proteico em resposta às 
necessidades da célula. A dinâmica peroxissomal, associada à sua devida 
regulação, está intimamente relacionada com a função deste organelo e, 
consequentemente, ao bem-estar humano. Assim sendo, o estudo dos 
mecanismos que regulam a biogénese e a proliferação dos peroxissomas é de 
extrema importância. Sendo a fosforilação reversível um dos principais 
mecanismos de controlo intracelular em eucariontes, tendo a PP1 um papel 
proeminente em eventos desfosforilativos, é altamente provável que seja um 
mecanismo importante na regulação também dos peroxissomas. De facto, têm 
surgido algumas evidências nesse sentido, embora sejam ainda muito 
escassas e não em células humanas. Interessantemente, um estudo em 
peroxissomas de rato revelou a presença de várias cinases e fosfatases, entre 
elas a PP1. O principal objetivo desta tese foi estudar o papel da fosforilação 
reversível nos peroxissomas humanos, através de um provável regulador da 
PP1, a Pex16p, e uma proteína potencialmente fosforilada, a Pex11pβ. Estas 
peroxinas são peças fundamentais na biogénese, crescimento e divisão dos 
peroxissomas. Os nossos estudos não confirmaram a interação putativa PP1-
Pex16p e os resíduos S11 e S38 da Pex11pβ também não se revelaram 
envolvidos na sua regulação através de eventual fosforilação. Também 
investigámos uma possível regulação da Pex11pβ através de cisteínas-chave, 
sendo que C18, C25 e C85 não estão, aparentemente, envolvidas. Uma 
possível função para a intrigante zona rica em glicinas localizada na região 
intraperoxissomal também foi estuda, traduzindo resultados inconclusivos, 
sendo que esta parece ser dispensável ao crescimento e divisão dos 
peroxissomas induzidos por Pex11pβ. Também nos debruçámos sobre as 
hélices anfipáticas localizadas no N-terminal da Pex11pβ e verificámos que a 
hélice 2 é essencial para o alongamento da membrana peroxisomal, com 
provável envolvimento no processo de dimerização. Apesar de vários 
resultados serem negativos, o nosso estudo abriu alguns caminhos em direção 
a uma melhor compreensão dos mecanismos que regulam a biogénese e 
proliferação dos peroxissomas. Novos métodos de deteção de interações 
proteína-proteína desenvolvidos recentemente poderão ser úteis para verificar 
a interação PP1-Pex16p que, provavelmente será transiente. Além disso, 
constatámos que existem outras peroxinas com motivos de ligação à PP1, 
representando assim possíveis novos elos entre mecanismos de transdução 
de sinais intracelulares e peroxissomas. Também propomos a existência de 
outros domínios na Pex11pβ envolvidos na função de alongamento, uma vez 
que a região N-terminal, por si só, não é suficiente para promover o 
alongamento da membrana do peroxissoma. Também propomos que a zona 
inter-domínios transmembranares da Pex11pβ está, pelo menos parcialmente, 
embebida na bi-camada lipídica, desafiando a topologia pré-concebida. 
Mecanismos de regulação da Pex11pβ dirigidos por cisteínas e fosforilação 
continuam também a ser hipóteses em aberto, pois outros resíduos podem 
tomar parte nesses processos. O nosso trabalho trouxe dados importantes 
para o estudo dos enigmáticos mecanismos de regulação dos peroxissomas, 
organelos essenciais à função celular, com sérias consequências na saúde 
humana. 
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abstract 
 
Peroxisomes are multifunctional organelles involved in various metabolic 
processes. The numerous severe disorders lead by peroxisomal malfunction in 
addition to the increasing evidences of the involvement of peroxisomes in 
several pathologies, from neurodegeneration to cancer and viral infection, 
renders this organelle an essential role for human health and development. 
Furthermore, peroxisomes are highly dynamic, adjusting their protein content, 
morphology and number in response to cellular needs. Peroxisome dynamics 
and their proper regulation are closely linked to organelle function and thus, 
human well-being. So that the study of the mechanisms that regulate 
peroxisomal biogenesis and proliferation is primordial. Being reversible 
phosphorylation a major intracellular control mechanism in eukaryotes with PP1 
as the prominent player in dephosphorylation events, it is very likely that it 
represents an important regulation mechanism also in peroxisomes. As a 
matter of fact, some evidences in that direction have emerged, although they 
are still very scarce and mostly not for human cells. Interestingly, a large-scale 
blot screen on rat peroxisomes revealed the presence of several kinases and 
phosphatases, being PP1 one of them. The main goal of this thesis was to 
study the role of reversible phosphorylation in human peroxisomes through a 
very likely PP1 regulator, Pex16p, and a putative phosphorylated protein, 
Pex11pβ. Pex16p and Pex11pβ are essential players in the peroxisome 
biogenesis, elongation and division. Our studies were not able to verify a 
putative interaction between PP1 and Pex16p. S11 and S38 residues of 
Pex11pβ have also been demonstrated to not be involved in its regulation by 
putative phosphorylation. The regulation by key cysteines in Pex11pβ was also 
investigated, revealing that C18, C25 and C85 are apparently not involved in 
such mechanism. A possible role for an intriguing glycine-rich stretch in the 
intraperoxisomal region of Pex11pβ was also studied, with inconclusive results, 
being that it appears to be dispensable for Pex11pβ-driven peroxisomal growth 
and division. Our study also focused on the Pex11pβ N-terminally located 
amphipathic helices, reveling Helix 2 as essential for peroxisomal membrane 
elongation, with a probable involvement in the Pex11pβ dimerization process. 
Although with several negative results, our study opened some doors towards a 
better understanding of the mechanisms that regulate peroxisome biogenesis 
and proliferation. New protein-protein interaction methods which developed 
meanwhile may be useful to verify the likely transient PP1-Pex16p interaction. 
Moreover, we verified that other peroxins have putative PP1-binding motifs, 
representing possible further interconnectors between intracellular signal 
transduction and peroxisomes. Concerning Pex11pβ mechanisms of action and 
regulation, our study raised the hypothesis that other domains are involved in 
the elongation function since we demonstrated that N-terminal region in not 
sufficient to promote peroxisomal membrane elongation. We also propose that 
the inter-transmembrane domains area may be at least partially embedded 
within the lipid bilayer, defying the preconceived topology of this region of 
Pex11pβ. We further propose that other phosphorylation- and key cysteines-
driven Pex11pβ regulation is still an open field since that other residues present 
as potentially active in such processes. Our study brought valuable insights in 
the mysterious regulation mechanisms of peroxisomes, essential organelles for 
cellular function, with serious consequences for human health. 
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1 Introduction 
1.1 Peroxisomes – an overview 
1.1.1 General features of the organelle 
Peroxisomes are single-membrane subcellular compartments that are found in virtually 
all eukaryotic organisms (Figure 1). Despite their importance for human life and health, 
they were discovered only in the middle of the 20th century, and were initially termed 
microbodies (1). Later on, the discovery that the peroxisomal matrix contains a large 
number of hydrogen peroxide (H2O2)-producing oxidases as well as catalase, a H2O2-
degrading enzyme finally coined the name “peroxisome” (2).  
 
 
The investigation of peroxisomes was considerably facilitated by the development of 
experimental methods for inducing their proliferation (6) and to detect their enzymatic 
activity, e.g. alkaline 3, 3’-diaminobenzidine (DAB) staining, which explores catalase 
activity and allowed the specific staining of peroxisomes for electron and light microscopy 
in different tissues and organisms (7). Later, their important role in lipid metabolism and 
the existence of a peroxisomal β-oxidation pathway were discovered (8). Presently, it is 
known that peroxisomes, which together with glyoxysomes, glycosomes and Woronin 
bodies, constitute the organelle family of “microbodies”, whose members are all 
evolutionarily related (9). Peroxisomes fulfil a wide range of metabolic functions (10) 
 
Figure 1: Peroxisomes 
(A) Peroxisomes with crystalline inclusions in 
tobacco leaf cells. Adapted from (3). (B) 
Peroxisomes stained by DAB (black) in rat 
hepatoma cells. Note the close association 
with the smooth ER (arrows). Adapted from 
(4). (C) Saccharomyces cerevisiae cell. Adapted 
from (5). (D) Peroxisomes in mouse 
fibroblasts, peroxisomes stained in green. 
Adapted from (4). ER, endoplasmic reticulum; 
L, lipid droplet; M, mitochondrium; N, nucleus; 
P, peroxisome; V, vacuole. Bars, 500 nm (B), 1 
μm (C) and 10 μm (D). 
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which, along with their protein composition and morphological appearance, vary among 
different species, cell types and developmental stages (11). Peroxisomes are mainly found 
as spherical or rod-like forms (0,3 to 0,5 μm in diameter), but peroxisomes can also 
appear as tubular structures with up to 5 μm of length or even as interconnecting 
compartments forming tubular networks (5). Since peroxisomes are devoid of DNA all 
peroxisomal proteins are encoded by the nuclear genome. About 61 yeast and 85 human 
genes encoding peroxisomal proteins have been identified so far. Many of them are 
enzymes with metabolic functions, while the others, the so-called peroxins, are required 
for the biogenesis and maintenance of functional peroxisomes (12). 
 
1.1.2 Metabolic functions 
Peroxisomes show a broad functional diversity, justifying its designation as “multipurpose 
organelles” (13) (see Figure 2 and Table 1 for an overview). Peroxisome-specific metabolic 
functions vary depending upon organism and cell type, as well as developmental and 
environmental conditions (reviewed in (14) and (10)). Despite their enormous plasticity 
and dynamic behavior, peroxisomes do not exist as isolated entities, but are intimately 
linked to other organelles such as lipid droplets, the endoplasmic reticulum (ER) and 
mitochondria (15, 16).  
 
Figure 2: Overview of the major 
peroxisomal metabolic pathways  
The main metabolic functions of 
peroxisomes in mammalian cells include 
β-oxidation of very long chain fatty acids, 
α-oxidation of branched chain fatty 
acids, synthesis of bile acids and ether-
linked phospholipids, and removal of 
reactive oxygen species. Peroxisomes in 
many, but not all, cell types contain a 
dense crystalline core of oxidative 
enzymes. Adapted from (17). ABCD1, 
ATP-binding cassette sub-family D 
member 1; ADHAP, alkyl-
dihydroxyacetone phosphate; DHAPAT, 
dihydroxyacetone phosphate 
acyltransferase; PMP70, 70 kDa 
peroxisomal membrane protein; ROS, 
reactive oxtgen species. 
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Table 1: Metabolic functions of mammalian peroxisomes 
Function Enzymes, substrates or products 
Peroxide metabolism, ROS/RNS metabolism* Catalase and H2O2-generating oxidases 
Lipid biosynthesis 
Ether phospholipids/plasmalogens, bile acids, 
fatty acid elongation (cholesterol and dolichol) 
Fatty acid β-oxidation* 
Very long-chain fatty acids, dicarboxylic acids, 
branched-chain fatty acids, unsaturated fatty 
acids, arachidonic acid metabolism 
Fatty acid α-oxidation Phytanic acid 
Long/very long-chain fatty acid activation  
Regulation of acyl-CoA/CoA ratio  
Glycerol biosynthesis  
Protein/amino acid metabolism* 
Biosynthesis of cysteine and sulphur 
assimilation, D-amino acid degradation, L-lysine 
metabolism, degradation of polyamines, 
proteases, transaminases 
Catabolism of purines  
Glyoxylate and dicarboxylate metabolism  
Hexose monophosphate pathway  
Nicotinate and nicotinamide metabolism  
Retinoid metabolism  
*Functional cooperation of peroxisomes with mitochondria. Adapted from (12). 
 
1.1.2.1 Lipid metabolism 
In contrast to most other functions of peroxisomes (see Table 1), which may vary 
between different species and within specific cell types in a single organism (10), fatty 
acid β-oxidation is a universal property of peroxisomes in most, if not all, organisms. In 
yeast and plants, peroxisomes are the sole site of fatty acid β-oxidation, whereas in 
higher eukaryotes it may occur in both mitochondria and peroxisomes (14, 18, 19). In 
mammalian cells very long-chain fatty acids (VLCFA, ≥C24) can only be degraded by 
peroxisomes and not by mitochondria (20). VLCFA are probably imported into 
peroxisomes as acyl-CoA esters by ABC transporters (e.g. ABCD1 = adrenoleukodystrophy 
protein, ALDP). After chain shortening by peroxisomal β-oxidation, the resulting (medium-
chain) acyl-CoA esters can be transferred to mitochondria for full oxidation to CO2 and 
H2O – one example of the close metabolic cooperation between mitochondria and 
peroxisomes (15, 16). The final degradation of fatty acids in mitochondria supplies the cell 
with ATP, as the peroxisomal β-oxidation is not coupled to an electron transfer chain. 
Instead, electrons are transferred to oxygen via FADH2, generating hydrogen peroxide 
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(H2O2, Figure 2). Therefore, the obtained energy is not used to power ATP synthesis, but is 
instead released as heat, contributing to thermogenesis (21). Besides VLCFA, other 
substrates such as prostaglandins and leukotrienes, bile acid intermediates, pristanic acid, 
certain polyunsaturated fatty acids, and the vitamins E and K are degraded by 
peroxisomal β-oxidation (14, 22). Trans-unsaturated fatty acids, i.e. those containing a 
methyl group at the C-3 position such as phytanic acid and xenobiotic compounds, cannot 
undergo β-oxidation directly and are thus first decarboxylated in peroxisomes by fatty 
acid α-oxidation (14, 23, 24). 
Additionally, anabolic processes also take place in peroxisomes. The synthesis of 
etherphospholipids such as plasmalogens is a cooperative process between peroxisomes 
and the endoplasmic reticulum (25). Plasmalogens are essential components of myelin, 
thus they account for around 80% of the white matter of the brain (26), and represent 
around 18% of the total phospholipid mass in human body (27). The formation of the 
characteristic ether linkage is catalyzed by the peroxisomal enzyme alkyl-DHAP synthase 
while further biosynthesis is conducted in the smooth ER (14). Moreover, bile acid and 
glycerol biosynthesis are also performed by peroxisomal enzymes. The synthesis of 
cholesterol and dolichol in peroxisomes is debated (14, 28, 29). 
 
1.1.2.2 ROS metabolism and other functions 
Peroxisomes contain a number of O2-consuming oxidases that produce H2O2 by oxidizing 
a large collection of substrates. H2O2 is ascribed to “reactive oxygen species” (ROS), as it 
can easily be converted into more aggressive radical species. Although ROS have been 
shown to have physiological functions (e.g. signaling), increased oxidative stress can 
provoke serious cell damage (30). Therefore a tight regulation of ROS is required. In 
addition to the enzymes involved in fatty acid α- and β-oxidation, oxidases metabolizing 
other substrates such as lactate, glycolate, other α-hydroxy acids, D-amino acids, oxalate, 
and urate (not in primates) produce H2O2 . Xanthine oxidase (XOx), an enzyme involved in 
the catabolism of purines, even produces superoxide radicals (O2
•-) (31). 
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On the other hand, antioxidant enzymes located in peroxisomes counteract the 
production of H2O2 and O2
•-, with catalase being the most prominent one (reviewed in 
Bonekamp et al., 2009 (30)) . While catalase and other enzymes (see Table 2) decompose 
H2O2, superoxide anions and hydroxyl radicals (
•OH, generated from hydrogen peroxide 
via Fenton-catalyzed reduction) are scavenged by manganese and copper-zinc superoxide 
dismutases (MnSOD, CuZnSOD) (32-35). Furthermore, the toxic metabolite glyoxylate is 
converted into glycine by alanine:glyoxylate aminotransferase (AGT), which localizes 
exclusively to peroxisomes in humans (36), and enzymes of the hexose monophosphate 
pathway are found in peroxisomes as well (37). More specialized functions are for 
instance fulfilled in the glyoxysomes of the parasite Trypanosoma, which contain enzymes 
of the glyoxylate cycle for the production of lipid-derived compounds required for 
gluconeogenesis (38), or in Woronin bodies, which seal septal pores in the hyphae of 
filamentous fungi (39). Additionally, peroxisomes are involved in several quite diverse 
processes such as penicillin biosynthesis (40), photorespiration in plants (41), or 
luciferase-based glowing of a firefly (42). 
Table 2: Overview of ROS/RNS generated in mammalian peroxisomes 
Type of ROS/RNS 
produced 
Generating reaction Produced in PO by 
Scavenged in 
PO by 
Hydrogen peroxide (H2O2 ) 
O2
•-
 + H
+
 → HO2
•-
, 2HO2
•-
 
→ H2O2  + O2
 
Acyl-CoA oxidase (several 
types), Urate oxidase, Xanthine 
oxidase, D-amino acid oxidase, 
D-aspartame oxidase, Pipecolic 
acid oxidase, Sarcosine oxidase, 
L-α-hydroxy acid oxidase, 
Polyamine oxydase 
Catalase, 
Glutathione 
peroxidase, 
Peroxiredoxin I, 
PMP20 
Superoxide anion (O2
•-
) O2 + e
-
 → O2
•-
 Xanthine oxidase 
MnSOD, 
CuZnSOD 
Nitric oxide (
•
NO) 
L-Arg + NADPH + H
+
 + O2 
→ NOHLA + NADP
+
 + H2O, 
NOHLA + ½ NADPH + ½ H
+
 
+ O2 → L-citrulline + ½ 
NADP
+
 + 
•
NO + H2O 
Nitric oxide synthase  
ROS, reactive oxygen species; RNS, reactive nitrogen species; PO, peroxisomes; NOHLA, N
ω
-hydroxy-L-
arginine. Adapted from (30). 
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1.1.3 Peroxisomal disorders  
A pivotal role of peroxisomes in human health and development is indicated by the 
existence of several devastating genetic disorders caused by impaired peroxisomal 
activity or lack of peroxisomes due to defective peroxisomal biogenesis (Table 3) (43). 
Peroxisomal disorders are clinically heterogeneous. However, they are consistently 
associated with impaired peroxisomal lipid metabolism, resulting in the accumulation of 
VLCFAs and phytanic acid, and defective synthesis of ether lipids and bile acids (17). The 
most recent proposed classification divides the peroxisomal disorders into two groups: 
peroxisome biogenesis disorders (PBDs) and peroxisome function disorders (PFDs) (44). 
Table 3: The peroxisomal disorders 
 Abbreviation 
MIM 
number 
Defective  
protein 
Mutant 
gene 
Locus 
Peroxisome biogenesis disorders PBD     
PBD-group A (Zellweger spectrum disorders):      
Zellweger syndrome 
Neonatal adrenoleukodystrophy 
Infantile Refsum disease 
ZS 
NALD 
IRD 
214100 
214110 
202370 
PEX1 
PEX2 
PEX3 
PEX5 
PEX6 
PEX10 
PEX12 
PEX13 
PEX14 
PEX16 
PEX19 
PEX26 
PEX1 
PEX2 
PEX3 
PEX5 
PEX6 
PEX10 
PEX12 
PEX13 
PEX14 
PEX16 
PEX19 
PEX26 
7q21.2 
8q21.1 
6q24.2 
12p13.3 
6p21.1 
1p36.32 
17q12 
2p14-p16 
1p36.22 
11p11.2 
1q22 
22q11.21 
PBD-group B:      
Rhizomelic chondrodysplasia punctata type 1 RCDP-1 215100 PEX7 PEX7 6q21-q22.2 
Peroxisome function disorders PFD     
Fatty acid beta-oxidation      
X-linked adrenoleukodystrophy X-ALD 300100 ALDP ABCD1 Xq28 
Acyl-CoA oxidase deficiency ACOX-deficiency 264470 ACOX1 ACOX1 17q25.1 
D-Bifunctional proteins deficiency DBP-deficiency 261515 DBP/MFP2/MFEII HSD17B4 5q2 
Sterol-carrier-protein X deficiency SCPx-deficiency – SCPx SCP2 1p32 
2-Methylacryl-CoA reacemase deficiency AMACR-deficiency 604489 AMACR AMACR 5p13.2-q11.1 
Etherphospholipid biosynthesis      
Rhizomelic chondrodysplasia punctata type 2 RCDP-2 222765 ADHAPAT GNPAT 1q42.1-42.3 
Rhizomelic chondrodysplasia punctata type 3 RCDP-3 600121 ADHAPS AGPS 2q33 
Fatty acid alpha-oxidation      
Refsum disease ARD/CRD 266500 PHYH/PAHX PHYH/PAHX 10p15-p14 
Glyoxylate metabolism      
Hyperoxaluria Type 1 PH-1 259900 AGT AGTX 2q37.3 
Bile acid synthesis (conjugation)      
Bile acid Co-A:amino acid N-acyltransferase deficiency BAAT-deficiency 602938 BAAT BAAT  
H2O2-metabolism      
Acatalasemia  115500 Catalase CAT 11p13 
From (44).  
 
PBDs fall into four main phenotypic classes. Three of them, Zellweger syndrome (ZS), 
neonatal adrenoleukodystrophy (NALD), and infantile Refsum disease (IRD) have multiple 
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complementation groups and form a spectrum (Zellweger spectrum) of overlapping 
features. The fourth group, rhizomelic chondrodysplasia punctata type 1 (RCDP-1), is a 
distinct PBD phenotype (45, 46). Zellweger spectrum diseases result from mutations in 
one of the PEX genes involved in peroxisome biogenesis. Mutations in PEX3, PEX16 and 
PEX19, which result in the complete absence of peroxisomes, cause the most severe 
phenotypes. Mutations in other PEX genes result in ghost peroxisomes, i.e. void of any 
matrix content. Features of ZS, which is the most severe end of the clinical spectrum, 
include craniofacial dysmorphism, hepatomegaly, and neurological abnormalities such as 
disruption of normal development, hypotonia, seizures, glaucoma, retinal degeneration, 
and deafness. Most Zellweger infants do not survive past one year of age due to 
respiratory compromise, gastrointestinal bleeding, and liver failure. The features of NALD 
and IRD are similar to those of Zellweger syndrome, but these disorders progress more 
slowly. Children with NALD usually die between the age of two and three years. Patients 
with IRD can live into early adulthood. RCDP-1 is clinically and genetically distinct from 
Zellweger syndrome spectrum disorders. It is characterized by distinctive facial features, 
including prominent forehead, hypertelorism (widely set eyes), and up-turned nose. 
These patients also suffer from growth failure, developmental delay, seizures, and 
congenital cataracts. Most die in early childhood. RCDP-1 is caused by mutations in Pex7, 
a chaperone for the three PTS2-containing peroxisomal matrix proteins (17, 43, 47). 
The PEX11B patients known so far presented import-competent peroxisomes, although 
enlarged and undivided. His clinical symptoms are atypical for PBDs, with normal 
biochemical parameters (48, 49). This case, together with the newborn lethal case of a 
patient with a mutation in the DLP1 gene which caused a defect in fission of both 
mitochondria and peroxisomes (50), raised the awareness for the importance of 
peroxisome (and mitochondria) morphology in health and disease (51). 
The group of peroxisome function disorders (PFDs) involves the single peroxisomal 
enzyme deficiencies and the single peroxisomal substrate transport deficiencies (43). 
PFDs can be subclassified according to which peroxisomal function/biochemical pathway 
is lost or affected, namely (a) fatty acid β-oxidation, (b) etherphospholipid biosynthesis, 
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(c) fatty acid α-oxidation, (d) glyoxylate metabolism, (e) bile acid synthesis and (f) H2O2 –
metabolism (Table 3, (44)).  
The disorders of peroxisomal β-oxidation are the most abundant among PFDs, being X-
linked adrenoleukodrystrophy (X-ALD) the most common peroxisomal disorder. X-ALD is 
the only single peroxisome substrate transport deficiency known so far and it is caused by 
mutations in the ABCD1 gene, which encodes adrenoleukodystrophy protein (ALDP). This 
protein is a half-ABC transporter and mediates the ATP-driven transport of the CoA-esters 
of VLCFAs resulting in an accumulation of these molecules (52). The main symptoms of X-
ALD are a progressive demyelination/neurodegeneration as well as adrenal insufficiency 
(53, 54). 
Apart from the inherited peroxisomal disorders, peroxisomes have been linked to other 
pathological conditions, including Alzheimer’s disease, diabetes and cancer. Santos and 
colleagues (55) demonstrated a direct link between the peroxisomal proliferation and 
neuroprotection against Aβ-driven degenerative alterations. Actually, peroxisomes seem 
to represent one of the first defense lines against oxidative stress induced by Aβ (56). The 
role of docosahexaenoic acid (DHA) in brain degeneration protection and the significant 
lower levels of plasmalogens in patients with severe dementia constitute other examples 
of the importance of peroxisomes for brain health (reviewed in (57)). Peroxisomes may 
also play noteworthy roles in type 2 diabetes by the involvement of peroxisome-
generated H2O2 in fatty acid-induced toxicity in insulin-producing pancreatic β-cells (58, 
59). Ether lipid levels are for a long time now known to be elevated in tumors (60-63) and 
recent work demonstrated that ADHAPS, a critical peroxisomal enzyme for ether lipid 
synthesis, is upregulated in several cancer cells and primary tumors. Moreover, its 
ablation impaired tumor pathogenicity; on the other hand, its overexpression elevated 
cancer cell motility, survival and tumor growth. Therefore, peroxisomes have a 
remarkable role in the generation of oncogenic signaling lipids (64). Furthermore, MCT2, 
a monocarboxylate transporter, was very recently demonstrated to be upregulated and 
localized mainly to peroxisomes in prostate cancer cells (65). Peroxisomes have also been 
liked to ageing (66-68) and antiviral response (reviewed in (69)). 
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1.2 Peroxisome biogenesis 
The study of yeast mutants with defects in biogenesis of peroxisomes led to the 
identification of a set of peroxisomal proteins, collectively referred to as peroxins or PEX 
proteins, which are required for peroxisome biogenesis (70). The peroxins can be divided 
into three groups according to their role in peroxisome biogenesis: (a) peroxins involved 
in the import of peroxisomal matrix proteins, (b) peroxins required for peroxisomal 
membrane assembly/import of peroxisomal membrane proteins (PMPs) and (c) peroxins 
regulating peroxisomal proliferation (Table 4). At present, 31 different proteins/genes 
have been discovered in lower eukaryotes, 14 in mammals and 15 in plants (without 
counting isoforms). Most of the additional peroxins present in lower eukaryotes appear 
to be specific for one species and/or functionally redundant (71).  
Table 4: Peroxisomal biogenesis proteins (Peroxins) in mammals, plants, filamentous fungi and yeast 
species 
Peroxin 
P
E
X
1
 
P
E
X
2
 
P
E
X
3
 
P
E
X
4
 
P
E
X
5
 
P
E
X
6
 
P
E
X
7
 
P
E
X
8
 
P
E
X
1
0
 
P
E
X
1
1
 
P
E
X
1
2
 
P
E
X
1
3
 
P
E
X
1
4
 
P
E
X
1
5
 
P
E
X
1
6
 
P
E
X
1
7
 
P
E
X
1
8
 
P
E
X
1
9
 
P
E
X
2
0
 
P
E
X
2
1
 
P
E
X
2
2
 
P
E
X
2
3
 
P
E
X
2
4
 
P
E
X
2
5
 
P
E
X
2
6
 
P
E
X
2
7
 
P
E
X
2
8
 
P
E
X
2
9
 
P
E
X
3
0
 
P
E
X
3
1
 
P
E
X
3
2
 
Mammals                                
Plants                                
F. fungi                                
Yeasts               
1 
         
2 
      
Peroxin function is indicated by color: blue – matrix protein import; red – membrane assembly; green – 
proliferation and division. PEX9 (absent), ORF misidentified, i.e. antisense sequence of PEX26. F, 
filamentous. 
1
Only found in Yarrowia lipolytica. 
2
PEX26 is absent in Saccharomyces cerevisiae and related 
yeast species. From (10). 
 
1.2.1 Import of matrix proteins 
All peroxisomal matrix proteins are synthesized on free polyribosomes in the cytosol and 
imported post-translationally (72). Unlike the translocation of unfolded polypeptides 
across the membranes of the ER, mitochondria, and chloroplasts (73), peroxisomes can 
transport cargoes in a folded, cofactor-bound, and/or oligomeric state (74). The specific 
import of peroxisomal matrix proteins is mediated by targeting signals which are 
recognized by cytosolic receptors. According to the model of the cycling receptor (Figure 
3), the peroxisomal matrix protein import can be conceptually divided into six steps: I) 
cargo recognition in the cytosol and (II) docking of the receptor-cargo complexes to the 
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peroxisomal membrane; (III) formation of a transient pore; (IV) cargo-translocation into 
the peroxisomal matrix; (V) ubiquitination of the receptor and (VI) deubiquitination and 
export of the receptor back to the cytosol (75).  
The sorting of proteins to peroxisomes depends on signal sequences, so called 
peroxisomal targeting signal (PTS) type 1 and type 2. PTS1, present in the majority of 
peroxisomal matrix proteins, is located at the extreme C-terminus and consists of three 
amino acids, serine-lysine-leucine (SKL), or variants of the motif fitting the consensus 
[SAC]-[KRH]-[LM] (76). Nowadays, PTS1 has been redefined as dodecamer, as additional 
amino acids might be crucial of receptor-cargo interaction (77, 78). PTS2 is N-terminally 
localized and comprised by the degenerated nonapeptide R-[LVIQ]-X-X-[LVIH]-[LSGA]-X-
[HQ]-[LA] (79). In the cytosol, the PTS1 is recognized by receptor Pex5p (Figure 3, I), which 
contains a tetratricopeptide repeat (TPR) domain for PTS1-binding (80). PTS2-harbouring 
proteins are recognized by the soluble receptor protein Pex7p, which consists of six 
tryptophan-aspartic acid (WD) repeats, preceded by a distinct N-terminal region (81). 
Unlike Pex5p, the Pex7p-mediated import pathway requires species-specific auxiliary 
proteins known as co-receptors: a longer splice variant of the PTS1-receptor Pex5p 
(Pex5pL) fulfills this function in plants (82) and mammals (83, 84). Some peroxisomal 
proteins, such as Yarrowia lipolytica acyl-CoA oxidase (85), castor bean isocitrate lyase 
(86) or mammalian Cu/Zn superoxide dismutase (87), neither contain PTS1 nor PTS2. 
These so-called non-PTS proteins can be imported into peroxisomes by binding to a 
different region of Pex5p (88) or by “piggyback” complex formation with PTS-containing 
proteins (89). A new chapter of peroxisomal targeting signals has recently been opened 
by the finding that glycolytic enzymes of the analyzed fungi and mammalian species 
containing cryptic PTS. With few exceptions, these enzymes were thought to be strictly 
cytosolic in all species. However, they contain a cryptic peroxisomal targeting signal, 
which can be generated or eliminated in a species-specific manner by ribosomal read-
through or alternative splicing (90). 
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Figure 3: Peroxisomal matrix protein import 
Model of peroxisomal matrix protein import in yeast. (I) Proteins harboring a peroxisomal targeting signal of 
type 1 (PTS1) are recognized by the import receptor Pex5 in the cytosol, (II) The cargo-loaded receptor is 
directed to the peroxisomal membrane and binds to the docking complex (Pex13p/Pex14p/Pex17p). (III) 
The import receptor assembles with Pex14p to form a transient pore and (IV) cargo proteins are 
transported into the peroxisomal matrix in an unknown manner. Cargo release might involve the function 
of Pex8p or Pex14p. (V) The import receptor is monoubiquitinated at a conserved cysteine by the E2-
enzyme complex Pex22p/Pex4p in tandem with E3-ligases if the RING-complex (Pex2p, Pex10p, Pex12p). 
(VI) The ubiquitinated receptor is released from the peroxisomal membrane in an ATP-dependent manner 
by the AAA-peroxins Pex1p and Pex6p, which are anchored to the peroxisomal membrane via Pex15p. As 
the last step of the cycle, the ubiquitin moiety is removed and the receptor enters a new round of import. 
The designation is based on the yeast nomenclature, so note that Pex17p and Pex8p do not exist in 
mammals; moreover, the function of Pex22p/Pex4p is fulfilled by UbcH5a/b/c; and, in mammals, Pex26p 
anchors Pex6p at the membrane instead of Pex15p. From (75). 
 
After cargo binding (Figure 3, I), the cargo-receptor complex docks at the peroxisomal 
membrane upon interaction with the resident docking complex, composed of the 
proteins Pex13p, Pex14p and additionally Pex17p in yeast (Figure 3, II) (91-94). In general, 
Pex14p is considered to be the initial binding partner for the cargo-bound PTS1-receptor. 
However, their exact roles are still matter of discussion (95). The current opinion for the 
mechanism on how cargo proteins enter the peroxisome is based in the concept of a 
transient pore that assembles at the peroxisomal membrane (Figure 3, III) and is 
disassembled after import, with its components being recycled for further rounds of 
protein import (96). Although the exact composition of this dynamic pore as well as the 
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driving force for cargo translocation (Figure 3, IV) remain elusive, it has been suggested 
that its major constituents are Pex14p and the PTS1-receptor Pex5p (96). Whether PTS1 
and PTS2 proteins are imported via common or distinct pores in still a major question, as 
well as if the cargo-loaded receptor remains associated with the pore (shuttle hypothesis) 
or if it is released as a soluble receptor-cargo complex into the peroxisomal matrix 
(extended shuttle hypothesis) (75). The mechanism of how the cargo is released from the 
receptors isn’t fully understood, but peroxins Pex14p (97) and Pex8p (98, 99) have been 
connected to this process. The signal sequence of a subset of the imported proteins is 
proteolytically removed after the import in peroxisomes of mammals and plants (100-
102).  
During or after dissociation of the cargo-receptor complex, the PTS1 receptor is mono-
ubiquitinated at a conserved cysteine (Figure 3, V), which serves as a signal for ATP-
dependent dislocation of the receptor from the membrane to the cytosol (103, 104). E2 
ubiquitin-conjugating enzyme is required for this modification which, in mammals, is 
assisted by UbcH5a/b/c (105). Proper mono-ubiquitination of Pex5p also depends on the 
RING-finger proteins Pex2p, Pex10p and Pex12p which are protein-ubiquitin ligases (E3) 
(106, 107). Afterwards, extraction of ubiquitinated Pex5p (Figure 3, VI) is catalyzed by 
Pex1p and Pex6p, two members of the AAA-protein family (108, 109), which in mammals 
are anchored to the peroxisomal membrane by the tail anchored protein Pex26p (110, 
111). Although the exact molecular mechanism for the exportation of ubiquitinated 
Pex5p to the cytosol is still unclear (112), the binding and hydrolysis of ATP by Pex1p and 
Pex6p is supposed to induce conformational changes that generate the force to pull the 
receptor out of the membrane (113, 114). Subsequent removal of the ubiquitin moiety 
(Figure 3, VI) is catalyzed by the ubiquitin hydrolase USP9X in mammals (115). Finally, 
Pex5p is once again available for promoting further cycles of protein transportation 
(Figure 3, VI). 
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1.2.2 Import of membrane proteins  
The import of peroxisomal membrane proteins (PMPs) occurs independently of matrix 
import via a different set of import factors. The mechanistic details are not completely 
clarified so far, but three proteins, so-called early peroxins, were identified to be required 
for peroxisomal membrane assembly in several species, including humans: Pex3p, Pex16p 
and Pex19p (116-125). The loss of any of these proteins/genes leads to complete loss of 
peroxisomes, while defects in matrix protein import result in the formation of empty 
peroxisomal “ghosts” (118, 126, 127). 
The model that better describes the peroxisomal biogenesis has been a subject for 
intense discussions as studies with conflicting results have been released (128). In 1985, 
Lazarow and Fujiki (72) suggested that peroxisomal matrix and membrane proteins were 
directly imported into peroxisomes from the cytosol, which led to the classical view that 
peroxisomes were autonomous organelles and the proposal of a “growth and division” 
model for peroxisome biogenesis. Accordingly, peroxisomes grow by import of newly 
synthesized proteins and are subsequently divided into daughter organelles (129). 
However, in 1960s, the ER was proposed to be the source of phospholipids for the 
peroxisomal membrane (130). Moreover, cell lines missing Pex3p, Pex16p and Pex19p 
that lack any detectable peroxisomal remnants are still able to restore de novo 
peroxisome formation upon reintroduction of the missing gene, involving ER. Therefore, 
an ER-dependent “de novo synthesis” model for peroxisomal biogenesis was suggested 
(119, 120, 131, 132). These two models were, for some time, apparently irreconcilable 
and both were questioned in terms of physiological importance under normal conditions 
as well as their applicability to evolutionary distant organisms, such as fungi, plants and 
mammals. Nevertheless, both models agreed that the Pex3p/Pex16p/Pex19p trio is 
fundamental to PMP import to peroxisomes and, consequently, peroxisome biogenesis 
(Figure 4, lower panel). Pex19p serves in all peroxisome-containing species as a soluble 
receptor for nascent PMPs by binding and targeting them to the peroxisomal membrane 
(128, 133). In the yeast Saccharomyces cerevisiae, Pex19p functions also in peroxisome 
inheritance (134). Pex3p is a conserved membrane-bound docking receptor for incoming 
complexes of Pex19p and its PMP cargo (135, 136). Pex3p serves also in the peroxisome 
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inheritance and degradation (137-139). Pex16p is an integral membrane-bound PMP 
receptor at the ER and peroxisomes (140-144) and is absent in all yeasts except Yarrowia 
lipolytica (Table 4). In that species Pex16p is a matrix-localized peripheral protein and 
seems to be involved in peroxisomal fission (145, 146).  
 
In latest years, several studies have been suggesting that (at least) some PMPs pass 
through the ER before being transported/routed to peroxisomes. Thus, until recently, two 
classes of PMPs1 were distinguished based on their Pex19p dependence for targeting to 
peroxisomes (75, 128). Class I PMPs require Pex19p for post-translational transport, while 
class II PMPs are Pex19p-independent and traffic to peroxisomes via the ER (148, 149) 
                                                      
1
 Confusingly, class I and class II PMPs are also known as Group II and Group I PMPs, respectively. 
 
Figure 4: Peroxisomal membrane protein 
insertion 
(upper panel) Topogenesis of peroxisomal 
membrane proteins. Two routes are proposed for 
the targeting of PMPs. Class I proteins are directly 
imported into existing peroxisomes. Class II 
proteins are first targeted to the ER, where they 
concentrate in pre-peroxisomal vesicles which 
then are targeted to existing peroxisomes or 
function as an origin for the de novo formation of 
peroxisomes. 
(lower panel) Pex19p-dependent import of PMPs. 
Class I PMPs harbor a mPTS, which is recognized 
in the cytosol by the import receptor and/or PMP-
specific chaperone Pex19p. Cargo-loaded Pex19p 
docks to the peroxisomal membrane via 
association with its docking factor Pex3p. Then 
the PMP is inserted into the membrane in an 
unknown manner but presumably with assistance 
of Pex19p, Pex3p and, in some organisms, Pex16p. 
Adapted from (147). 
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(Figure 4, upper panel). Newly translated class I PMPs bind Pex19p, which has been 
shown to bind to a range of PMPs (150-153). Pex19p is a predominantly cytosolic protein 
thought to serve as a PMP chaperone, preventing aggregation and degradation of newly 
synthesized proteins (123, 149, 154, 155). A portion of Pex19p is also found in the 
peroxisome, which led to the notion that it acts as a shuttling receptor (123, 149, 151, 
156), delivering PMPs to Pex3p which acts as a docking factor in the peroxisomal 
membrane (148). Although there is no easily recognizable consensus sequence that 
constitutes a targeting signal for PMPs (termed mPTS), several studies highlight the 
importance of a cluster of basic residues predicted to form an α-helix, adjacent to one or 
more transmembrane segments (157) and algorithms have been developed for the 
prediction of the mPTS (151, 158). Pex19p has also been characterized as both an 
insertion factor and assembly/disassembly factor at the peroxisomal membrane (152, 
154, 159). The PMPs are inserted into the peroxisomal membrane by an unknown 
mechanism and Pex19p is recycled back to the cytosol (156).  
Pex3p is the best-studied example of class II PMPs. Since its initial designation as a class II 
PMP and studies demonstrating its origin in the ER (140, 143, 149, 160-162), several  
peroxins, such as Pex2p, Pex10p, Pex11p, Pex13p, Pex15p, Pex16p, Pex26, Pex30p, 
Pex31p, Pex34p and Pex36p have been reported to traffic to peroxisomes via the ER in 
fungi, mammals and plants (133, 140-143, 163-166). However, discrepant data from the 
several studies may reflect differences in PMP biogenesis in different cell types and 
perhaps also differences in metabolic status and rates of PMP turnover (128). Pex3p in 
Saccharomyces cerevisiae has been shown to localize first in the ER and then in a 
subdomain of the ER before moving to peroxisomes. Pex19p is required for this process, 
justifying the absence of peroxisomes in pex3 and pex19 mutants. Noteworthy, this 
happens both in yeast lacking peroxisomes and in the wild-type yeast (160, 162). In a 
similar way, experiments with mammalian Pex16p demonstrated that this protein also 
traffics to peroxisomes in mammals via ER (140-143, 166) as is also required for de novo 
peroxisome synthesis (143), although a direct import route for Pex3p from the cytosol 
into the mammalian peroxisomes mediated by Pex19p and Pex16p has also been 
described (144, 167). 
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Recently, the segregation of PMPs in two classes has been challenged by the possibility of 
existence of a third class of PMPs, represented so far by Pex13p and Pex14, which sort to 
peroxisomes independently of Pex3p and Pex19p (75, 159, 167-169).  
It is now generally accepted that peroxisomes can form from the ER, however, questions 
remain about the extent and timing of this process and its role within the lifecycle of a 
peroxisome (128). In 2007, Motley and Hettema (170) provided important evidences that 
the de novo pathway largely operates under conditions where cells have lost their 
peroxisomes and, under normal conditions, division predominates. However, a conflicting 
view is that most (if not all) PMPs are delivered first to the ER (171), but there are reports 
that components required for secretory vesicle formation aren’t required for trafficking of 
PMPs (124, 172). The ability of so-called “pre-peroxisomal vesicles” to fuse in a Pex1p- 
and Pex6p-dependent manner has also been documented (173, 174) and provides a 
mechanism by which peroxisomes can be (re)formed. Actually, van der Zand et al. (174) 
demonstrated that the docking and the RING finger components of the translocon are 
kept physically separate until a late stage in biogenesis.  
To sum up, at the present time, two models for peroxisome biogenesis and PMP 
trafficking are under debate. In their extreme forms, they appear mutually exclusive: 
either (i) most, if not all, PMPs enter the ER first (171), or (ii) only very specific so-called 
class II PMPs enter the ER and form ER-derived vesicles that bring lipids and a very limited 
complement of proteins to pre-existing peroxisomes which can then divide (Figure 4) 
(175). Consensually, Pex19p is important in both scenarios, but its role has been ascribed 
differently. In the latest years, new data over this issue has been produced and the view 
of de novo formation from the ER and division as segregated and independent 
mechanisms for peroxisome biogenesis has become out of date. Although many 
questions remain to be answered, more integrated and cooperative models have been 
proposed (75, 128, 167). 
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1.3 Peroxisome proliferation – growth and division 
Regardless whether PMPs insert peroxisomes directly from cytosol or indirectly from the 
ER, peroxisomes are recognized to proliferate under a “growth and division” manner, in 
which spherical organelles form tubular structures that acquire a “beads-on-a-string”-like 
morphology prior to their fragmentation into smaller organelles (176-179). This sequence 
of events occurs in a multi-step fashion by the action of a set of evolutionarily conserved 
proteins throughout yeast, mammalian and plant systems (129). Initial elongation of the 
peroxisomal membrane is mediated by Pex11 proteins, and after subsequent constriction 
by a yet unidentified mechanism, final fission is carried out by dynamin-like GTPases (such 
as mammalian DLP1), mechano-enzymes that are recruited to the peroxisomal membrane 
by distinct adaptors (Fis1, Mff) (explored on section 1.3.2). Notably, these key 
components are shared with mitochondria (16). 
In addition, peroxisomes may also interconnect to form tubulo-reticular networks and a 
variety of morphologically distinct types of peroxisomes has been observed in different 
organs of mammalian organisms and cell lines (176, 180-187). Besides growth and 
division, more complex structures such as elongated tubules or a peroxisomal reticulum 
may be related to other peroxisomal processes (e.g. in metabolism, membrane signaling 
or stress protection), but information on the exact correlation between peroxisome 
dynamics/morphology and function is still scarce. 
 
1.3.1 The Pex11 family of proteins 
The peroxin 11 (Pex11) family is comprised of conserved membrane proteins in fungi, 
plants and mammals that control peroxisome proliferation and regulate peroxisome 
morphology, size and number (188-195). However, not all Pex11 isoforms in a given 
species promote peroxisome proliferation or even membrane elongation pointing to 
distinct functions in peroxisome biogenesis. Accordingly, membrane association and 
topology may vary across organisms, ranging from a peripheral association in 
Saccharomyces cerevisiae to multi-membrane spanning proteins in plants and mammals 
(for detailed overview, see (129)). Furthermore, and besides their partial redundancy, not 
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all Pex11 proteins can complement each other (192). ScPex11p was the first protein 
discovered being involved in proliferation or division (188, 196). Meanwhile, a large 
number of Pex11 proteins, or proteins affecting peroxisome number, have been identified 
(Pex11-type peroxisome proliferators, reviewed in (197)). Every organism studied so far 
contain several Pex11 orthologues. The three mammalian Pex11 proteins are encoded by 
different genes and termed Pex11pα, Pex11pβ and Pex11pγ. Plants (Arabidopsis thaliana) 
possess five different Pex11 isoforms, AtPex11a to AtPex11e, while yeast (Saccharomyces 
cerevisiae), filamentous fungi (Aspergillus nidulans) and trypanosomes contain three 
Pex11 family proteins (Pex11p, Pex25p and Pex27p, or TbPex11, GIM5A and GIM5B, 
respectively) (overview in (129)). Besides some exceptions (e.g. ScPex25p and ScPex27p), 
Pex11 proteins have a molecular weight of 27-32 kDa and a length of roughly 230 to 260 
amino acids. Different functions have been attributed to Pex11 proteins, such as playing a 
role in β-oxidation in Saccharomyces cerevisiae (198), organelle inheritance (199), 
membrane structure determination (200), or direct regulation of peroxisome size and 
number. Overexpression of Pex11p in Penicillium chrysogenum increases penicillin 
production (201). A common observation among all Pex11 proteins is that the modulation 
of its levels affects the number of peroxisomes (177, 188, 190, 196, 202). Generally, an 
increase of Pex11 levels induces peroxisome proliferation, while inhibition of its function 
reduces the peroxisome number or impairs peroxisome proliferation. 
In mammals, the three Pex11p isoforms control peroxisome proliferation under both 
basal and induced conditions. However, different expression patterns were observed for 
all isoforms: while Pex11pβ is constitutively expressed in all tissues, both Pex11pα and 
Pex11pγ show tissue-specific expression, but are most prominent in the liver (15, 189, 
203-208). Among the three isoforms, only Pex11pα is induced by peroxisome 
proliferators activating the nuclear transcription factor PPARα (207). Nonetheless, 
Pex11pα is dispensable for PPARα-mediated peroxisome proliferation in Pex11pα 
knockout (KO) mice suggesting functional redundancies (208). Although the Pex11pα KO 
mouse is viable, it shows reduced abundance of functional peroxisomes and aggravated 
renal interstitial lesions (209). Pex11pβ KO, however, causes neonatal lethality and 
defects similar to the Zellweger syndrome phenotype in mouse models (205), confirming 
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its role as the central regulator of peroxisome proliferation in mammals. As expected, 
peroxisome abundance in Pex11pβ KO mice is reduced, but peroxisomal protein import 
and metabolism are only slightly affected. A comparative analysis of primary neuronal 
cultures and brain samples from wild-type mice, Pex11pβ homozygous and heterozygous 
knockouts indicated a higher degree of cell death in heterozygous than in wild-type mice. 
Moreover, heterozygotes also showed delayed neuronal differentiation, indicating that 
deletion of a single allele of PEX11B already causes neuronal defects in mice (210). 
Curiously, the first PEX11B patient described has different phenotype, far less serious and 
life threatening, despite carrying a homozygous non-sense mutation, producing a 
truncated peptide with only 22 amino acids. With 26 years of age, the patient presented 
clinical symptoms atypical for peroxisome biogenesis disorders, like mild intellectual 
disability, migraine-like episodes, gastrointestinal problems and skin abnormalities. 
Patient’s fibroblasts presented peroxisomes, enlarged and undivided though. 
Notwithstanding the abnormal peroxisome morphology, his biochemical parameters 
were within the normal range (48, 51). Very recently, seven additional patients have been 
identified with null mutation in the PEX11B gene (49). All patients presented with 
congenial cataracts and the older ones had mild intellectual disability, ataxia and 
sensorineural deafness. In addition, most of them presented with short stature and 
convultions. Biochemical parameters plasma and fibroblasts did not show clear 
peroxisomal abnormalities. However, analysis of patient skin fibroblasts often revealed 
enlarged and elongated peroxisomes indicative of a defect in peroxisome division and 
proliferation. This heterogeneity among mammal species indicates that functions of 
Pex11 proteins may vary considerably among evolutionarily close species and 
extrapolations concerning this issue must be made with extra precautions.  
All mammalian Pex11 isoforms are tightly associated with the peroxisomal membrane 
and possess two predicted membrane spanning helices with both C- and N-termini 
protruding into the cytosol (177, 189, 203, 211). They are also capable of forming homo-
dimers (193, 212, 213). Heterodimers were also observed, however, no interaction of 
Pex11pα and Pex11pβ was detected (193). Furthermore, it has been also demonstrated 
that Pex11pβ interacts with Fis1 (193, 213) and Mff (214, 215), tail anchor proteins 
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involved in the recruitment of DLP1 (section 1.3.2). Interestingly, besides Pex11pβ’s 
capacity to promote peroxisome elongation upon expression, it was also observed to 
concentrate at constriction sites, indicating a non-uniform distribution of the protein at 
the peroxisomal membrane (177) (Figure 5). Pex11pβ initially localizes to spherical, pre-
existing organelles where it initiates the formation of a nose-like protrusion at one side of 
the peroxisome (216). The protrusion extends to form a membrane tubule that acquires a 
specific set of PMPs, segments and becomes import-competent for peroxisomal matrix 
proteins prior to its final fission by the action of Fis1, Mff and DLP1 (Figure 5). 
Importantly, predominantly newly-synthesized matrix proteins are imported into the 
newly formed peroxisomes, pointing to an inherent mechanism of peroxisomal quality 
control linked to growth and division (216). Transient expression of various Pex11 family 
members of different origins led to the formation of similar membrane protrusions in 
mammalian cells which developed into large stacks of peroxisomal membranes (193). This 
pattern of Pex11p-dependent formation of specific membrane subdomains and its role in 
the induction of a differential distribution of PMPs was also detected in the yeast 
Hansenula polymorpha (217). 
The membrane deforming capacities of the various Pex11 proteins were linked to the 
presence of several N-terminal motifs within Pex11p that are conserved in yeast, fungi 
and human proteins and display amphipathic properties (191). Negatively charged 
liposomes, resembling the phospholipid composition of peroxisomes, were shown to 
hyper-tubulate upon the addition of a Pex11 peptide containing the most conspicuous 
amphipathic helix of Penicillium chrysogenum. The conservation of the amphipathic 
properties and its helical structure is essential to mediate tubulation, an intrinsic property 
apparently conserved throughout species (191, 215). Thus, Pex11p-induced membrane 
remodeling is induced by the insertion of an amphipathic helix into one leaflet of the lipid 
bilayer which causes membrane asymmetry and bending (218) (Figure 5). 
In regard to the regulation of Pex11p itself by post-translational modifications and/or 
other mechanisms, monomeric ScPex11p was suggested to be inactivated by homo-
dimerization, hence dimerization was proposed to regulate membrane remodeling in a 
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redox-sensitive fashion (219). Furthermore, phosphorylation of ScPex11p at the S165/167 
residue was shown to be required for Pex11p action (220). 
 
Figure 5: Model of peroxisomal growth and division in mammalian cells 
Peroxisome proliferation in mammalian cells involves a well-defined sequence of morphological changes, 
including membrane elongation (growth), constriction, and final membrane scission. Pex11pβ initiates 
membrane remodeling and the formation of a tubular membrane extention at pre-existing peroxisomes. (a) 
Peroxisomal membrane remodeling via Pex11p in induced by the insertion of amphipathic, N-terminal 
helices into one leaflet of the lipid bilayer causing membrane asymmetry and bending (191, 221). 
Oligomerization is required for Pex11pβ function in membrane elongation and may as well stabilize 
membrane tubules. The growing membrane extention acquires a specific set of peroxisomal membrane 
proteins (e.g. Pex11pβ, Fis1), before it constricts and import of predominantly newly synthesized matrix 
proteins is initiated (216). Pex11pβ and the Mff-DLP1 complex concentrate at the sites of constriction, 
possibly driven by alterations in membrane curvature. The role of Fis1 is currently unclear. (b) Cytosolic 
DLP1 is recruited by the membrane receptor Mff. After targeting, DLP1 self-assembles into large ring-like 
structures. (c) Pex11pβ acts as a GTPase activating protein on DLP1 (222). GTP hydrolysis by DLP1 leads to 
constriction of the DLP1 ring and results in final membrane scission. From (223). 
 
1.3.2 The fission machinery 
Dynamin-like proteins (DLP or Drp, dynamin-related proteins) were the first components 
to be identified as key players in peroxisome fission (178, 212). Moreover, DLP1 was the 
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first indicated shared component of both peroxisome and mitochondrial fission (224, 
225). DLPs belong to the dynamin family of large GTPases known to function in tubulation 
and fission events of cellular membranes. These cytosolic proteins are recruited to 
organelle membranes and assemble, probably as rings or spirals, in multimeric complexes 
around constricted parts of the organelle, where they induce GTP-dependent final 
membrane scission (178, 226, 227). Thus, dynamin proteins are supposed to act as 
pinchase-like mechano-enzymes. Classical dynamins have a size of approximately 100 kDa 
and possess five domains: GTPase domain, middle domain, Pleckstrin homology (PH) 
domain, GTPase effector domain, and proline-rich domain (PRD) (228-232). DLPs lack the 
SH3-binding PRD domain and the PH domain required for membrane association. The 
middle domain functions in the higher-order assembly, which is required for the 
formation of functional multimeric spirals (233, 234). Therefore, mutations in the DLP1 
middle domain result in abnormal elongation of peroxisomes and hypertubulation of 
mitochondria (50, 235). These elongated peroxisomes still have a constricted 
morphology, indicating that DLP1 is required for final scission, but not for organelle 
constriction (179). Similar morphologies were observed in fibroblasts from a patient, 
leading to discovery of a new lethal disorder based on a mutation in DLP1 (50). In 
mammals, overexpression of DLP1 does not induce organelle fragmentation, 
demonstrating that the division is regulated by other factors. Dynamin-like mechano-
enzymes are also required for peroxisome fission in other species, such as Dnm1 (and 
Vps1) in yeast (170, 236, 237) and DRP3A, DRP3B and DRP5B in plants (192, 238, 239). 
DLP1 action is extensively regulated by protein phosphorylation, sumoylation, 
ubiquitination and S-nitrosylation (240). Notably, starvation-induced phosphorylation of 
DLP1 by Protein Kinase A was demonstrated to decrease its recruitment to mitochondria 
thus resulting in the formation of elongated mitochondrial networks that resist 
autophagic degradation (241). Very recently, a study demonstrated that both yeast and 
mammalian DLP1 (Dnm1 and Drp1, respectively) need Pex11p/Pex11pβ for final 
peroxisome scission. Pex11p/Pex11pβ physically interacts with Dnm1/Drp1 and acts as 
GTPase-activating protein (GAP), identifying a previously unknown requirement of a GAP 
in DLP1 function (222) (Figure 6). 
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Figure 6: Key fission proteins on peroxisomes and mitochondria in mammals 
Shared key components of the mitochondrial and peroxisomal fission machineries include DLP1, a large 
dynamin-like GTPase involved in final membrane scission of constricted membranes, and the DLP1-
membrane adaptors Mff and Fis1. Mff is supposed to be the major DLP1 receptor for organelle fission. 
GDAP1 can regulate both mitochondrial and peroxisomal morphology and division in an Mff- and DLP1-
dependent manner. The peroxin Pex11pβ is an exclusively peroxisomal membrane protein involved in the 
regulation of peroxisome abundance and in membrane deformation/elongation prior to fission. Pex11pβ 
can oligomerize and interacts with both Fis1 and Mff, which can homodimerize as well. Pex11pβ also 
interacts with DLP1 and acts as GTPase-activating protein. MiD51 and MiD49 are mitochondrial membrane 
adaptors which can sequester DLP1 and inhibit its function. This process may be regulated by mitochondrial 
Fis1, which interacts with TBC1D15, a Rab GTPase activating protein. Upregulation of MiD49 on 
mitochondria can deplete DLP1 from peroxisomes resulting in peroxisome elongation due to reduced 
division (red arrow). Adapted from (242). 
 
The mechanistic basis of peroxisomal membrane constriction prior to fission remains to 
be elucidated. In Yarrowia lipolytica, intra-peroxisomal lipid remodeling, and thus 
membrane constriction, was linked to the AOX-dependent modulation of YlPex16p 
activity (146). In mammalian cells, the concerted action of non-muscle myosin A, Rho 
kinase II and the actin cytoskeleton was suggested to mediate membrane constriction 
(243). 
As DLP1 lacks a PH domain for direct lipid binding, it is recruited to mitochondrial and 
peroxisomal membranes by membrane adaptor proteins. Initially, the tail-anchored 
protein Fission 1 (Fis1) was proposed to recruit DLP1 to mitochondria and peroxisomes, 
and thus mediate organelle division (213, 244, 245). The majority of Fis1 faces the cytosol 
(246) and TPR repeats in its N-terminus were suggested to facilitate protein-protein 
interactions (247, 248). Fis1 is targeted to peroxisomes in a Pex19p-dependent manner 
where it acts in complex with Pex11pβ (213, 215, 249) (Figure 6). 
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Another tail-anchored protein, the mitochondrial fission factor (Mff), was suggested to 
regulate fission of mitochondria and peroxisomes (250). Detailed analyses of Mff have 
revealed that it represents the major membrane receptor for DLP1, challenging the 
aforementioned role of Fis1 (214, 251) (Figure 6). Itoyama and colleagues (214) observed 
that overexpression of MFF increases the interaction between DLP1 and Pex11pβ, while 
knockdown of MFF, but not Fis1, abolishes that interaction. Thus, the function of Fis1 at 
mitochondria and peroxisomes has to be reconsidered. Interestingly, Mff was only 
identified in metazoans (250), thus the recruitment of the yeast DLP1 homologue Dnm1 
to mitochondria and peroxisomes is still supposed to depend on the action of yeast Fis1. 
However, yeast Fis1 requires the additional action of the soluble molecular linkers Caf4 
and Mdv1 (170, 252), two WD40 proteins that bind to yeast Dnm1 and well as Fis1. 
Additional factors involved in the recruitment and regulation of DLP1 action continue to 
emerge: MiD49 and MiD51, two novel N-terminally anchored mitochondrial membrane 
proteins, have been found to recruit DLP1, at least to mitochondria (253, 254) (Figure 6). 
Similarly to Mff, they are not found in yeast. 
Recently, ganglioside-induced differentiation-associated protein 1 (GDAP1), a glutathione 
S-transferase, was found to localize to both peroxisomes and mitochondria and to 
influence their dynamics and division (255) (Figure 6). Mutations in GDAP1 have been 
associated with Charcot-Marie-Tooth disease, the most common inherited neuropathy 
(256, 257). Loss of GDAP1 function results in peroxisomal (and mitochondrial) elongation, 
which with respect to peroxisomes is less prominent than that observed after loss of DLP1 
or Mff. On the other hand, overexpression of GDAP1 induces peroxisomal (and 
mitochondrial) division in an Mff- and DLP1-dependent manner. Whereas alterations in a 
hydrophobic domain of GDAP1 or at the C-terminal tail affect both peroxisomal and 
mitochondrial fission, N-terminal autosomal recessively inherited disease mutants are still 
able to promote peroxisome but not mitochondrial fission (255, 258). 
Whereas key division components are shared by peroxisomes and mitochondria, the key 
proteins for mitochondrial fusion (e.g. the dynamin-related GTPases Mfn1, Mfn2 or 
OPA1) are not present on peroxisomes. In contrast to mitochondria, mature peroxisomes 
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have not been observed to fuse (259, 260). However, Bonekamp and colleagues (259) 
demonstrated that transient and long-term peroxisome-peroxisome contacts occur, 
although without exchange of matrix or membrane markers. These interactions may 
contribute to the equilibration of the peroxisomal compartment in mammalian cells 
(242).  
 
1.4 Regulation of peroxisomal abundance 
The capacity of peroxisomes to adapt their morphology and number upon exposure to 
external stimuli has been known for a long time already (261). Peroxisome response to 
peroxisome proliferators (PPs) and regenerating rat liver after partial hepatectomy are 
classical models of peroxisome proliferation in mammals (182, 262). Other peroxisome 
proliferation-inducing factors in mammals include high-fat diet (263), cold exposure (264) 
and  hypolipidemic drugs as well as industrial compounds and environmental pollutants 
such as phthalates and plasticizers (265). The PP-induced peroxisome proliferation is 
commonly accompanied by an increase in both amount and activity of fatty-acid β-
oxidation enzymes (8). However, it is important to note that different species respond 
with different intensities to PPs, e.g. a massive peroxisome proliferation upon treatment 
is observed in rodents, but not in humans. Similarly, prolonged PP exposure gives rise to 
hepatocellular tumors in rodents, but not in humans (129). 
 
1.4.1 PPARs and expression of peroxisomal genes 
Peroxisome proliferation in mammals is regulated by the activation of the peroxisome 
proliferator-activated receptor (PPAR)α via changing the expression of peroxisomal genes 
(266). Long-chain fatty acids are ligands for PPARα and thus transmit signals for the 
requirement of enhanced lipid catabolism (267). The other two PPAR subtypes, β/δ and γ, 
have partially overlapping substrate specificity but don’t transmit the signals of classical 
PPs (268, 269). Notably, constitutive expression of peroxisomal genes is not dependent 
on PPARα (270). Along with fatty-acid β-oxidation enzymes, expression of genes involved 
in peroxisome proliferation, e.g. Pex11pα, is also enhanced by the activation of PPARα 
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(129). However, a potential functional compensation by the other Pex11 isoforms or by 
other, so far, unknown factors, is denounced by the PEX11A knockout mouse model 
which is capable to induce peroxisome proliferation upon treatment with PPARα-
dependent PPs (208). Ligand binding induces conformational changes in PPARα that 
allows it to form heterodimers with retinoid X receptor (RXR)α, which are capable of 
recognizing PPARα-responsive elements (PPREs) (Figure 7). PPERs not only regulate all 
peroxisomal lipid β-oxidation enzymes, but also other proteins (271). PPARα is 
moderately expressed in human, but highly in rodents (272), in which PPARα-mediated 
peroxisome proliferation was linked to carcinogenesis in liver, pancreas and testis (273), 
which was linked to increased ROS damage (274). In addition, both primate PPERs and the 
corresponding DNA-binding domain of PPARα exhibit significant sequence differences, 
possibly leading to differential activation of PPAR-controlled genes. Thus, differences in 
the regulation of peroxisome proliferation appear to have developed through a species-
specific co-evolution of PPARα and the respective DNA-binding site elements. Perhaps 
this allowed the adaptation to different physiological needs (129). Other pathways for 
peroxisome proliferation involving PPARγ and β/δ, and even in PPAR-independent way, 
have been found and shown to have relevant roles as well (129). 
 
Figure 7: Activation of peroxisome proliferation in mammals 
In most organisms, peroxisome proliferation is preceded by the induction of genes associated with fatty 
acid β-oxidation and membrane elongation (e.g. Pex11). Activation of these pathways depends on several 
environmental and developmental conditions. In mammals, PPARα and RXR coordinately bind to PPRE to 
upregulate gene expression. Other mechanisms independent of PPARα have also been described (e.g. 
PGC1α-dependent) (275). Adapted from (276). 
 
1.4.2 Protein phosphorylation in peroxisomes 
Beyond the regulation of the expression of peroxisomal genes, peroxisome proliferation 
and/or activity may be regulated by mechanisms of signal transduction, by which 
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information is spread out through the cell. Much of the molecules that transmit the 
information are molecular switches, i.e. proteins that switch from an inactive to an active 
state and vice-versa in response to signals. The largest class of molecular switches that 
occur in cells consists of proteins that are activated or inactivated by phosphorylation 
(277). In those cases, the switch is turned into one direction by a protein kinase, which 
covalently adds one or more phosphate groups to specific amino acids and into the other 
direction by a protein phosphatase, which removes the phosphate groups (Figure 8). The 
human genome encodes about 520 protein kinases and about 150 protein phosphatases. 
Each protein kinase is responsible for phosphorylating a protein or a set of proteins. On 
the other hand, some protein phosphatases are specific for only one or a few proteins, 
whereas others act on a broad range of proteins and are targeted to specific substrates by 
regulatory subunits (278). The activity of any protein regulated by phosphorylation 
depends on the balance between the activities of the kinases and phosphatases that 
phosphorylate and dephosphorylate it, respectively. There are two main types of protein 
kinases and phosphatases, distinguished by the specific target amino acids: 
serine/threonine (Ser/Thr) and tyrosine (Tyr) (279).  
 
Figure 8: Phosphoproteins that act as molecular 
switches 
A protein kinase covalently adds a phosphate from 
ATP to the signaling protein, and a protein 
phosphatase removes the phosphate. Although not 
shown, many signaling proteins are activated by 
dephosphorylation rather than by phosphorylation. 
Adapted from (279). 
 
A recent meta-analysis on Arabidopsis thaliana’s phospho-proteome driven by van Wijk 
and colleagues (280), revealed that only 1% of the cell’s phosphorylated proteins are 
localized to peroxisomes, with an enrichment in tyrosine-phosphorylated proteins, when 
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compared to other subcellular localizations. Despite this, and although the scarce data 
concerning localization of protein kinases or phosphatases to peroxisomes, 
phosphorylation seems to be an important mechanism for the regulation of peroxisome 
metabolism and biogenesis. Concerning metabolism, fatty-acid transport to peroxisomes 
was found to be regulated by phosphorylation in tyrosine residues of PMP70 and ALDP 
(281). Tanaka and colleagues (282) recently found that ScHrr25, a multifunctional 
serine/threonine kinase, phosphorylates Atg36, which recognizes superfluous 
peroxisomes and initiates pexophagy. Phosphorylation is also a regulation mechanism for 
Pex14p (283) and Pex15p (284), peroxisomal membrane proteins involved in matrix 
protein import (section 1.2.1). Peroxisome fission may also be regulated by 
phosphorylation: DLP1, a shared component of the mitochondrial and peroxisomal fission 
machinery (section 1.3.2), is phosphorylated by several kinases with consequences on 
mitochondrial morphology (285, 286) and implications on health (287-289). Moreover, 
Pex11 family proteins have been shown to be phosphorylated in Saccharomyces 
cerevisiae (220) and in Pichia pastoris (290), influencing peroxisome morphology and 
abundance. Thus, the study of the effect of phosphorylation in human Pex11p reveals to 
be crucial to understand its mechanism of action and consequent regulation of 
peroxisome biogenesis. 
 
1.4.2.1 Protein kinases and phosphatases in peroxisomes 
As previously mentioned, there aren’t many studies localizing protein kinases or 
phosphatases to peroxisomes and most of them are predictions based on bioinformatics 
and/or mass spectrometry data (291-293). However, some proteins known to interact 
with kinases and phosphatases where reported to localize to peroxisomes. Akap11 (A-
kinase anchor protein 11) of Rattus norvegicus, which possesses a PTS1 signal, was 
localized in testicular peroxisomes (294) and it is known to bind to the type II regulatory 
subunits of cAMP-dependent protein kinase (PKA), to glycogen synthase kinase-3 (GSK3) 
β, as well as to protein phosphatase 1 (PP1) catalytic subunit (295, 296). Human Limkain-
B1, a protein involved in the female meiosis and predicted to bind RNA (297), was found 
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to localize in a subset of peroxisomes (298) and a fragment of it was demonstrated to 
interact with PP1α (299). Although unpublished, Limkain-B1 was originally annotated as 
Lim-kinase 2 interactor (accession number AB012134). Matre and colleagues (300) have 
shown that, in Arabidopsis thaliana, the regulatory subunit B’θ of protein phosphatase 2A 
(PP2A), a Ser/Thr-specific phosphatase, is targeted to peroxisomes via a PTS1 signal. 
Indeed, AtPP2A targeting to peroxisomes was very recently confirmed by the same 
research group (301). Catalytic and scaffolding subunits of AtPP2A appear to be imported 
into peroxisomes by piggyback transport dependent on B’θ regulatory subunit. The 
presence of a full AtPP2A complex positively affects β-oxidation of fatty acids (301). In a 
subsequent report, Kataya and colleagues (302) identified another phosphatase that is 
targeted to peroxisomes in Arabidopsis thaliana. In this case, they found that MAP kinase 
phosphatase 1 (MKP1), a regulator for mitogen-activated protein kinases (MAPKs), 
possesses a non-canonical PTS1, which leads MKP1 to peroxisomes under stressful 
conditions. Interestingly, MAPK signaling is involved in the upregulation of catalase 
transcription and activity in salt-stressed Arabidopsis thaliana (303). Calcium-dependent 
protein kinase 1 (CPK1) was also found to localize in peroxisomes (304, 305). As in the 
previous cases, these studies on CPK1 were conducted in Arabidopsis thaliana as well.  
Aside Akap11 (294) and Limkain-b1 (298), there are no other evidences for the presence 
of protein kinases/phosphatases or its regulators at mammalian peroxisomes. However, 
the importance of studying protein phosphorylation events in the regulation of 
peroxisome abundance became evident with the study of Saleem and colleagues (306) on 
the phosphoproteome of Saccharomyces cerevisiae. In this study, phosphorylated forms 
of several signaling proteins involved in fatty acid-induced peroxisome proliferation 
where identified to increase in oleic acid-treated cells, as well as in glucose-treated 
(peroxisome proliferation-repressing) cells. The amount of the phosphorylated forms of 
some signaling molecules involved in peroxisome morphology also varied between 
treatments. Thus, protein phosphorylation seems to be a relevant mechanism of signal 
transduction on the regulation of peroxisome abundance/proliferation. 
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Another evidence of a possible role of protein kinases/phosphatases in peroxisomes was 
the discovery of the early peroxin Pex16p in a human PP1 interactome study realized by 
Esteves and colleagues (307), at the time members of the Signal Transduction Laboratory 
of the Centre for Cell Biology, University of Aveiro. This finding defines Pex16p as a 
putative PP1-interacting protein, making this possible interaction of crucial importance 
for the regulation of peroxisome biogenesis, since as Pex16p is an “early peroxin” which  
is pointed to act as a PMP receptor during the early stages of the de novo peroxisome 
formation at the ER, as well as in mature peroxisomes (140, 141, 143, 144). 
 
1.4.2.1.1 PP1 and PP1-binding motifs 
As mentioned before (section 1.4.2), there are more than 500 putative protein kinases in 
the human genome, being the great majority of these Ser/Thr-kinases (278, 308, 309). On 
the other hand, the number of putative protein phosphatases is much less, with a twist 
on the target amino acids: the majority of protein phosphatases dephosphorylate 
tyrosine residues. Serine and threonine residues are dephosphorylated by only about 40 
protein phosphatases (310-312). Whereas the numbers of protein Tyr-kinases and Tyr-
phosphatases are well balanced, intriguingly, the number of protein Ser/Thr-kinases 
(PSKs) is about ten times higher than Ser/Thr-phosphatases (PSPs). The mechanism on 
how these few PSPs manage to reverse the actions of that large number of PSKs in a 
specific and regulated manner bases on the ability of PSPs to form stable protein-protein 
complexes. This property results in the accumulation of an abundant number of 
phosphatase holoenzymes, each with its own substrate and mode of regulation (313). 
This concept has been well illustrated for protein phosphatases -1 (PP1) and -2A (PP2A), 
which belong to the phosphoprotein phosphatase (PPP) superfamily of PSPs, and together 
account for more than 90% of the protein phosphatase activity in eukaryotes (278). PP1 is 
one of the most conserved eukaryotic proteins, being over 70% similar with early-
branching eukaryotes. Its function is highly conserved as well (312). Janssens and 
colleague’s (314) data suggest that mammals may contain as many as 650 distinct PP1 
complexes and approximately 70 PP2A holoenzymes, indicating that PP1 catalyzes the 
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majority of protein dephosphorylation events in eukaryotic cells (278). CBC’s Signal 
Transduction Laboratory has published several interactome studies of PP1 in human brain 
and testis which may significantly increase the number of confirmed PP1 complexes (307, 
315, 316). 
Unlike many protein kinases, PP1 does not recognize a consensus sequence surrounding 
the phosphorylated residue. Instead, efficient substrate binding depends on docking 
motifs for PP1 surface grooves that are remote from the active site. Under controlled 
buffer conditions, the free PP1 catalytic subunit has exceptionally broad substrate 
specificity (278). However, each functional PP1 complex is thought to have a stringent 
substrate specificity, each triggering a specific cellular pathway response (310, 312, 317, 
318). The PP1 holoenzyme consists of a catalytic subunit (PP1c) and regulatory subunits 
(PP1 interacting proteins – PIPs). Mammalian genomes contain three PP1 encoding genes 
that together encode four distinct catalytic subunits: PP1α (gene PPP1CA), PP1β/δ (gene 
PPP1CB) and the PPP1CC gene splice variants PP1γ1 and PP1γ2, which differ mainly in 
their extremities (312, 319, 320). The approximately 90% amino acid sequence similarity 
between all forms of PP1c denotes a remarkable degree of evolutionary conservation, 
which is related to their essential role in the regulation of fundamental cellular processes 
(317, 319, 321). With the exception of the testis-enriched PP1γ2, all three mammalian 
isoforms are ubiquitously expressed (312, 322). 
PIPs can function as modulators of PP1 activity, determining targets and substrate 
specificity, as well as subcellular localization of the holoenzyme or may even serve as 
substrate themselves (319). PP1 has diverse effects on substrate PIPs, activating or 
deactivating them by dephosphorylation, and some of these function as PP1 activity 
regulators themselves (278). Most PIPs contain a primary PP1-docking motif, commonly 
referred to as the RVxF motif, that binds, with high affinity, to hydrophobic amino acids 
on the surface of PP1, typically remote from the catalytic site (323, 324). Several studies 
permitted further characterization of the consensus sequence, and the RVxF motif was 
redefined. Other PP1-binding motifs (PP1BMs) have been described, and these 
strengthen the interaction of the PIPs with PP1, e.g. SILK motif (see Table 5). 
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Table 5: PP1-binding motifs 
Motif Consensus sequence Reference(s) 
RVxF motifs 
[RK]-X(0,1)-[VI]-{P}-[FW] (325) 
[HKR]-[ACHKMNQRSTV]-V-[CHKNQRST]-[FW] (326) 
[KRL]-[KRSTAMVHNQ]-[VI]-{FIMYDP}-[FW] (299) 
RVxF-
supporting 
motifs 
SILK [GS]-I-L-[RK] (299, 325, 327-329) 
MyPhoNE F-X-X-[RK]-X-[RK] (299, 330) 
Apoptotic 
signature 
R-X-X-Q-[VIL]-[KR]-X-[YW] (331, 332) 
RARA R-A-R-A (333) 
Other degenerated motifs 
R-[KR]-X-H-Y (329, 334, 335) 
K-S-Q-K-W (329) 
R-N-Y-F (336) 
“X” is any amino acid; “X(0,1)” is any amino acid, present or absent; “[]” is one of those amino acids; “{}” is 
any amino acid except those. 
 
Pex16p was detected in a yeast two-hybrid (YTH) study of PP1γ using a human brain cDNA 
library and two RVxF motifs were found on its sequence (307). Despite being also present 
in the brain (322, 337), the PP1γ2 isoform is particularly enriched in the testis and sperm 
(315). Interestingly, Akap11 was found in testicular peroxisomes of Rattus norvegicus 
which, as mentioned before, is a binding partner for PKA and PP1 (294, 295). Within 
testis, peroxisomes are present in Leydig, Sertoli and germ cells and residual bodies (338-
342). Although the exact physiological role of peroxisomes in testis is still enigmatic, their 
metabolic pathways have to be of vital importance for normal spermiogenesis since adult 
X-ALD patients show impaired spermiogenesis and infertility (343). 
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2 Objectives 
Peroxisomes are ubiquitous organelles that catalyze numerous metabolic processes. The 
crucial role of peroxisomes for human health is exemplified by the severe phenotype of 
peroxisomal disorders. Some are known to derive from mutations of peroxins, genes 
involved in the dynamic processes of peroxisome biogenesis and proliferation. 
Nonetheless, these mechanisms are far from being fully understood. A multitude of 
external stimuli was identified to induce peroxisome proliferation; however, there is only 
limited knowledge on their intracellular signal transduction at the peroxisomal level. 
Being protein phosphorylation/dephosphorylation a major intracellular signal 
transduction mechanism, with PP1 as the protagonist on the majority of 
dephosphorylation events in eukaryotic cells, our study focused on the putative role of 
PP1 and phosphorylation post-translational modifications in the regulation of peroxisomal 
biogenesis and proliferation. 
The very first aim of this study was to find potential PP1-binding partners in peroxisomes 
by a screening for PP1-binding motifs among peroxins. Pex16p revealed to have several 
putative PP1-binding motifs and it was identified in a yeast two-hybrid screen on PP1. In 
addition, Pex16p is an early peroxin which function in peroxisome biogenesis is still not 
fully clear. So that Pex16p was selected to proceed our studies on the potencial role for 
PP1 in peroxisomes. On the other hand, Pex11 proteins, fundamental for peroxisome 
elongation and fission, had previously been suggested to be regulated by phosphorylation 
events in fungal cells. Being so, we selected also Pex11pβ to study the effect of 
phosphorylation in peroxisome proliferation. The specific aims of our study were the 
following: 
I. PP1-binding motifs search in human peroxins and other players in matrix protein 
import and fission machineries 
a. Study of the role of PP1 on peroxisome biogenesis via the putative 
interaction with Pex16p 
i. Verification of the putative PP1-Pex16p interaction 
ii. Manipulation of the putative PP1-Pex16p interaction 
II. Study the mechanisms of action and regulation of Pex11pβ 
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a) Study the function of two potentially phosphorylated residues 
b) Determination of Pex11pβ topology 
c) Investigation of putative functional domains/residues 
i. Glycine-rich region 
ii. Amphipathic helices 
iii. Key cysteines 
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3 Material and methods 
 
3.1 Chemicals and reagents 
 
3.1.1 Chemicals 
Chemicals (analytical or molecular biology grade) and cell culture reagents were obtained 
from commercial suppliers (Amersham Biosciences, Bayer, Bio-Rad, Bioron, Clontech, 
Fisher, Formedium, GE Healthcare, Merck, Polysciences, Roth, Sanol-Schwarz and Sigma). 
Low fat powder milk, from Nestlé, was obtained in the supermarket. 
 
3.1.2 Loading dyes and markers 
Table 6: Commercial loading dyes and markers 
Product Company 
6x Orange Loading Dye Fermentas 
O’Gene Ruler DNA Ladder Mix Fermentas 
Precision Plus Protein Standards BioRad 
 
3.1.3 Kits 
Table 7: Kits 
Product Company 
Illustra Plasmid Prep Mini Spin Kit GE Healthcare 
NucleoSpin Plasmid Macherey-Nagel 
NucleoBond Xtra Midi Macherey-Nagel 
NucleoSpin Gel and PCR Clean-up Macherey-Nagel 
Quant-iT dsDNA BR Assay Kit Invitrogen/Molecular Probes 
TNT T7 Quick Coupled Transcription/Translation System Promega 
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3.2 Immunological reagents 
Table 8:  Primary antibodies 
Antigen Technique Dilution Dilution buffer Raised in Source 
ACOX IF 1:200 PBS Rabbit (pc) 
A. Völkl, University of 
Heidelberg, Germany  
GFP (tag) 
IF 
WB 
1:200 
1:2000 
PBS, PBS Rabbit (pc) Invitrogen 
GST (tag) WB 1:1000 3% milk in TBS-T Goat (pc) 
Amersham Pharmacia 
Biotech 
Myc 9E10 
(tag) 
IF 
WB 
IP 
1:200 
1:2000 
1:200 
PBS, PBS Mouse (mc) Santa Cruz 
Pex11pβ IF 1:200 PBS Rabbit (pc) Abcam 
Pex14p IF 1:1400 PBS Rabbit (pc) 
D. Crane, Griffith 
University, Brisbane, 
Australia 
PMP70 IF 1:100 PBS Rabbit (pc) 
A. Völkl, University of 
Heidelberg, Germany 
His (tag) WB 1:1000 3% milk in PBS Mouse (mc) 
E. da Cruz e Silva, CBC, 
Aveiro, Portugal 
PP1γ 
IF 
WB 
1:1000 
1:5000 
PBS, 3% milk in 
PBS (or TBS-T) 
Rabbit (pc) 
E. da Cruz e Silva, CBC, 
Aveiro, Portugal 
PP1α IF 1:500 PBS Rabbit (pc) 
E. da Cruz e Silva, CBC, 
Aveiro, Portugal 
ACOX, Acyl-CoA oxidase 1; GFP, green fluorescent protein; IF, immunofluorescence; IP, 
immunoprecipitation; mc, monoclonal; pc, polyclonal; WB: Western blot. 
 
Table 9: Secondary antibodies 
Antigen Technique Dilution Dilution buffer Raised in Source 
Alexa-488 conjugated 
Mouse IgG 
IF 1:400 PBS Donkey Invitrogen 
Alexa-488 conjugated 
Rabbit IgG 
IF 1:500 PBS Donkey Molecular Probes 
HRP conjugated 
Mouse IgG 
WB 1:5000 PBS Goat BioRad 
HRP conjugated 
Rabbit IgG 
WB 1:5000 PBS Goat BioRad 
HRP conjugated 
Rabbit IgG 
WB 1:5000 PBS Donkey GE Healthcare 
TRITC conjugated 
Mouse IgG 
IF 1:100 PBS Donkey 
Jackson 
ImmunoResearch 
TRITC conjugated 
Rabbit IgG 
IF 1:200 PBS Donkey 
Jackson 
ImmunoResearch 
HRP, horseradish peroxidase; IgG, immunoglobulin G; TRITC, tetramethylrhodamine isothiocyanate. 
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3.3 Molecular biology reagents 
3.3.1 Plasmids 
Table 10: Commercial vectors and plasmids received as a gift 
Plasmid Expressed protein Source/Company 
pACT2 GAL4AD Clontech 
pAS2-1 GAL4BD Clontech 
pAS2-1-Clone 18 
GAL4BD-Pex16p (not full length), 
retrieved from and YTH  screen 
E. da Cruz e Silva, CBC, Aveiro, 
Portugal 
pAS2-1-PP1γ1 GAL4BD-PP1γ1 
E. da Cruz e Silva, CBC, Aveiro, 
Portugal 
pcDNA3 (empty vector) Invitrogen 
pcDNA3.1-Myc-
Pex16 
Myc-Pex16p 
G. Dodt, University of Tübingen, 
Germany 
pcDNA3.1-PP1γ1 PP1γ1 M. Fardilha, CBC, Aveiro 
pCMV-tag3A-
ACBD5.2 
Myc-ACBD5.2 
M. Islinger, University of 
Heidelberg, Germany 
pCMV-tag5A (Myc tag adding empty vector) Stratagene 
pET28b (His and T7 tags adding empty vector) Novagen 
pGEX-5X-1-Pex16 GST-Pex16p 
J. Azevedo, IBMC, Porto, 
Portugal 
pTD1-1 GAL4AD-SV40 large T antigen (aa87-708) Clontech 
pVA3-1 GAL4BD-p53 (aa72-390, murine) Clontech 
GAL4AD, GAL4 activation domain; GAL4BD, GAL4 DNA binding domain. 
 
Table 11: List of plasmid constructs already present in the laboratory 
Plasmid (vector+insert) Expressed protein Reference 
pcDNA3-Pex11β-Myc Pex11pβ-Myc Schrader et al, 1998 
pCMV-tag3A-Pex11β Myc-Pex11pβ Delille et al, 2010 
pmEYFP-C1-Pex11β YFP-Pex11pβ Delille et al, 2010 
pmEYFP-N1-Pex11β Pex11pβ-EYFP Delille et al, 2010 
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Table 12: List of plasmids constructed for this study 
Plasmid 
(vector-insert) 
Expressed protein 
Construction 
Template Primers Enzymes 
pACT2-Pex16 C-ter 
GAL4AD-Pex16p 
aa244-336 
pcDNA3.1-Myc-Pex16 
P16-244-249X 
Pex16-X-RV 
XmaI 
XhoI 
pACT2-Pex16 WT GAL4AD-Pex16p pcDNA3.1-Myc-Pex16 
Pex16-XmaI-FW 
Pex16-X-RV 
XmaI 
XhoI 
pACT2-Pex16-PP1BM1 
GAL4AD-Pex16p
PP1BM1
 
(R298A_F301A)
 pcDNA3.1-Myc-Pex16 
Pex16PP1BM1FW 
Pex16PP1BM1RV 
Pex16-XmaI-FW 
Pex16-X-RV 
XmaI 
XhoI 
pACT2-Pex16-PP1BM1&2 
GAL4AD-
Pex16p
PP1BM1&2
 
(R298A_F301A_K329A
_F332A) 
pcDNA3.1-Myc-Pex16 
Pex16PP1BM1FW 
Pex16PP1BM1RV 
Pex16PP1BM2FW 
Pex16PP1BM2RV 
Pex16-XmaI-FW 
Pex16-X-RV 
XmaI 
XhoI 
pACT2-Pex16-PP1BM2 
GAL4AD-Pex16p
PP1BM2
 
(K329A_F332A) 
pcDNA3.1-Myc-Pex16 
Pex16PP1BM2FW 
Pex16PP1BM2RV 
Pex16-XmaI-FW 
Pex16-X-RV 
XmaI 
XhoI 
pcDNA3-Pex11b-C18S-
C25S-C85S-Myc 
Pex11pβ
C18S_C25S_C85S
-
Myc 
pcDNA3-Pex11b-C18S-
C25S-Myc 
Pex11C85Sfw 
Pex11C85Srv 
KpnI 
XbaI 
pcDNA3-Pex11b-C18S-
C25S-Myc 
Pex11pβ
C18S_C25S
-Myc 
pcDNA3-Pex11b-C18S-
Myc 
Pex11C25Sfw 
Pex11C25Srv 
KpnI 
XbaI 
pcDNA3-Pex11b-C18S-
Myc 
Pex11pβ
C18S
-Myc pcDNA3-Pex11β-Myc 
Pex11C18Sfw 
Pex11C18Srv 
KpnI 
XbaI 
pcDNA3-Pex11b-C25S-
Myc 
Pex11pβ
C25S
-Myc pcDNA3-Pex11β-Myc 
Pex11C25Sfw 
Pex11C25Srv 
KpnI 
XbaI 
pcDNA3-Pex11b-C85S-
Myc 
Pex11pβ
C85S
-Myc pcDNA3-Pex11β-Myc 
Pex11C85Sfw 
Pex11C85Srv 
KpnI 
XbaI 
pcDNA3-Pex11β-S11A-
Myc 
Pex11pβ
S11A
-Myc YFP-Pex11β 
Pex11bS11Afw 
Pex11bS11Arv 
Pex11bKpnI-F 
Px11bnoStopDown 
KpnI 
BamHI 
pcDNA3-Pex11β-S11D-
Myc 
Pex11pβ
S11D
-Myc YFP-Pex11β 
Pex11bS11Dfw 
Pex11bS11Drv 
Pex11bKpnI-F 
Px11bnoStopDown 
KpnI 
BamHI 
pcDNA3-Pex11β-S38A-
Myc 
Pex11pβ
S38A
-Myc YFP-Pex11β 
Pex11bS38Afw 
Pex11bS38Arv 
Pex11bKpnI-F 
Px11bnoStopDown 
KpnI 
BamHI 
pcDNA3-Pex11β-S38D-
Myc 
Pex11pβ
S38D
-Myc YFP-Pex11β 
Pex11bS38Dfw 
Pex11bS38Drv 
Pex11bKpnI-F 
Px11bnoStopDown 
KpnI 
BamHI 
pcDNA3-Pex11βΔN40-
Myc 
Pex11pβΔN40-Myc pcDNA3-Pex11β-Myc 
Px11b-dN40-Up 
MycStopXbaI-
Down 
KpnI 
XbaI 
pcDNA3-Pex11βΔN60-
Myc 
Pex11pβΔN60-Myc pcDNA3-Pex11β-Myc 
Px11b-dN60-Up 
MycStopXbaI-
Down 
KpnI 
XbaI 
pcDNA3-Pex11βΔN70- Pex11pβΔN70-Myc pcDNA3-Pex11β-Myc Px11b-dN70-Up KpnI 
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Plasmid 
(vector-insert) 
Expressed protein 
Construction 
Template Primers Enzymes 
Myc MycStopXbaI-
Down 
XbaI 
pCMV-tag3A-Pex11β-
ACBD5 
Myc-Pex11pβ-ACBD5 
pcDNA3-Pex11β-Myc 
and pCMV-tag3A-
ACBD5.2 
Pex11βup 
P11b_ACBD5rv 
P11b_ACBD5fw 
ACBD5_Eco_rv 
BamHI 
EcoRI 
pCMV-tag3A-Pex11βΔGly Myc-Pex11pβΔGly pcDNA3-Pex11β-Myc 
Pex11βup 
Px11b-dGly-Left 
Px11b-dGly-Right 
Pex11β-wt-down 
BamHI 
EcoRI 
pCMV-tag3A-Pex16 WT Myc-Pex16p pcDNA3.1-Myc-Pex16 
Pex16-H2-FW 
Pex16-X-RV 
HindIII 
XhoI 
pCMV-tag3A-Pex16-
PP1BM1 
Myc-Pex16p
PP1BM1
 
(R298A_F301A)
 pcDNA3.1-Myc-Pex16 
Pex16PP1BM1FW 
Pex16PP1BM1RV 
Pex16-H2-FW 
Pex16-X-RV 
HindIII 
XhoI 
pCMV-tag3A-Pex16-
PP1BM1&2 
Myc-Pex16p
PP1BM1&2
 
(R298A_F301A_K329A
_F332A) 
pcDNA3.1-Myc-Pex16 
Pex16PP1BM1FW 
Pex16PP1BM1RV 
Pex16PP1BM2FW 
Pex16PP1BM2RV 
Pex16-H2-FW 
Pex16-X-RV 
HindIII 
XhoI 
pCMV-tag3A-Pex16-
PP1BM2 
Myc-Pex16p
PP1BM2
 
(K329A_F332A) 
pcDNA3.1-Myc-Pex16 
Pex16PP1BM2FW 
Pex16PP1BM2RV 
Pex16-H2-FW 
Pex16-X-RV 
HindIII 
XhoI 
pEGFP-C1-Pex16 GFP-Pex16p pcDNA3.1-Myc-Pex16 
Pex16-X-Fw 
Pex16-E-Rv 
XhoI 
EcoRI 
pET28b-Pex16 His-Pex16p* pcDNA3.1-Myc-Pex16 
Pex16-H-FW 
Pex16-X-RV 
HindIII 
XhoI 
pET28b-Pex16 C-ter 
His-Pex16p
CT
* 
 
(aa244-336) 
Cut from pGEX-4T-3-
Pex16 aa244-336 
- 
EcoRI 
XhoI 
pEYFP-C1-Pex11β 
Myc(mid) 
YFP-Pex11pβ-
Myc(mid) 
pcDNA3-Pex11β-Myc 
Pex11beta C up 
Px11b1-8mycR 
Px11b2-10mycF 
Pex11beta C down 
EcoRI 
BamHI 
pGEX-4T-3-Pex16 C-ter 
GST-Pex16p
CT
 (aa244-
336) 
pcDNA3.1-Myc-Pex16 
P16-244-249E 
Pex16-X-RV 
EcoRI 
XhoI 
*pET28 vectors also add a T7 tag between His tag and the subcloned protein. All restriction endonucleases 
were from New England Biolabs. In frame insertion and mutations of all constructs were verified by 
sequencing (Eurofins MWG Operon). DNA sequences were analysed using the software FinchTV (Geospiza 
Inc.). 
 
 
3.3.2 Primers 
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Table 13: Synthetic oligonucleotides used in this study 
Name Nucleotide sequence (5’ → 3’) 
ACBD5_Eco_rv CCCGAATTCCTTCAATTTAGTTTTCTTCTCCTTCTTTG 
MycStopXbaI-Down CCTCTAGACTACAGGTCCTCCTCG 
P11b_ACBD5fw cacctcaatcgaTGGTGGCCCTTTGAGATGTCC 
P11b_ACBD5rv caaagggccaccaTCGATTGAGGTGACTAACAGTG 
P11b1-8mycR ctcctcggagatcagcttctgctcTGGGACTCCTCCTCCAGAACC 
P11b2-10mycF aagctgatctccgaggaggacctgCCAGGGACTCCAGGAGGAGGT 
P16-244-249E GCGAATTCCAAACCCTGGCTCTTGG 
P16-244-249X GTCCCGGGTAAACCCTGGCTCTTGG 
Pex11beta C down TTGGATCCTCAGGGCTTGAGTCGTAGCCAGGG 
Pex11beta C up TTGAATTCTATGGACGCCTGGGTCCGCTTC 
Pex11bKpnI-F CAGGTACCATGGACGCCTGGGTCCGC 
Pex11bS11Afw CGCTTCAGTGCTCAGgccCAAGCCCGGGAGCGG 
Pex11bS11Arv CCGCTCCCGGGCTTGggcCTGAGCACTGAAGCG 
Pex11bS11Dfw CGCTTCAGTGCTCAGgacCAAGCCCGGGAGCGG 
Pex11bS11Drv CCGCTCCCGGGCTTGgtcCTGAGCACTGAAGCG 
Pex11bS38Afw CTGCAGAGGCATGGAGCCgctCCTGAGTTACAGAAACAG 
Pex11bS38Arv CTGTTTCTGTAACTCAGGagcGGCTCCATGCCTCTGCAG 
Pex11bS38Dfw CTGCAGAGGCATGGAGCCgatCCTGAGTTACAGAAACAG 
Pex11bS38Drv CTGTTTCTGTAACTCAGGatcGGCTCCATGCCTCTGCAG 
Pex11C18Sfw GGGAGCGGCTGtctAGGGCCGCCCAGTATG 
Pex11C18Srv CATACTGGGCGGCCCTagaCAGCCGCTCCC 
Pex11C25Sfw GCCGCCCAGTATGCTtccTCTCTTCTTGGCC 
Pex11C25Srv GGCCAAGAAGAGAggaAGCATACTGGGCGGC 
Pex11C85Sfw GATGTTGTCCTGAGATTCtccATCACTGTTAGTCACCTC 
Pex11C85Srv GAGGTGACTAACAGTGATggaGAATCTCAGGACAACATC 
Pex11βup TTGGATCCTATGGACGCCTGGGTCCGCTTC 
Pex11β-wt-down TGAATTCTCAGGGCTTGAGTCGTAGCCAGGG 
Pex16-E-Rv GCGGAATTCTCAGCCCCACATGTAGAAG 
Pex16-H2-FW GCGAAGCTTCATGGAGAAGCTGCGG 
Pex16-H-FW CATAAGCTTATGGAGAAGCTGCGGC 
Pex16-H-FW2 CATAAGCTTGCCATGGAGAAGCTGC 
Pex16NOSTOP-X GATCTCGAGGCCCCAACTGTAGAAG 
Pex16PP1BM1FW CGCTTCTCCGAGGCCgcgATCCTCgccCTGCTCCAGTTGCTG 
Pex16PP1BM1RV CAGCAACTGGAGCAGggcGAGGATcgcGGCCTCGGAGAAGCG 
Pex16PP1BM2FW GCCCACCTGGCAGgcaATCTACgccTACAGTTGGGGCTG 
Pex16PP1BM2RV CAGCCCCAACTGTAggcGTAGATtgcCTGCCAGGTGGGC 
Pex16-X-Fw GATCTCGAGCTATGGAGAAGCTGCGGC 
Pex16-XmaI-FW GTCCCGGGTATGGAGAAGCTGCGG 
Pex16-X-RV GATCTCGAGTCAGCCCCAACTGTAG 
Px11b-dGlyLeft cagttggggcagTTTCAGTCGCCGGCTACAAGC 
Px11b-dGlyRight gcgactgaaaCTGCCCCAACTGGCTCTGAAAC 
Px11b-dN40-Up TTGGTACCATGTTACAGAAACAGATTCGACAACTGG 
Px11b-dN60-Up TTGGTACCATGCTGGGTAACTCAGCAGATGCC 
Px11b-dN70-Up TTGGTACCATGGCCAAAAGAGCTGTTC 
Px11bnoStopDown TTGGATCCGGGCTTGAGTCGTAGCCAGGG 
Restriction sites are underlined, start codons are printed italic, stop codons are printed bold and 
mutagenesis codons are printed lowercase. All primers used in this study were synthesized by Eurofins 
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MWG Operon and reconstituted in DEPC-treated water (Roth) to a stock concentration of 100 pmol/µl. 
Working primer solution is diluted 1:10 (10 pmol/µl) in DEPC-treated water. 
 
3.4 Frequently used buffers and solutions 
All solutions were prepared with distilled water (RO-Pure infinity reverse osmosis water 
system) if not indicated otherwise. 
 
3-AT, for SD media 
• 1 M 3-AT, filter sterilize 
 
Amino acids dropout stock (10x), for SD media, autoclave 
• 200 mg/l L-Adenine hemisulfate salt 
• 200 mg/l L-Arginine HCl 
• 200 mg/l L-Histidine HCl monohydrate 
• 300 mg/l L-Isoleucine 
• 1000 mg/l L-Leucine 
• 300 mg/l L-Lysine HCl 
• 200 mg/l L-Methionine 
• 500 mg/l L-Phenylalanine 
• 2000 mg/l L-Threonine 
• 200 mg/l L-Tryptophan 
• 300 mg/l L-Tyrosine 
• 200 mg/l L-Uracil 
• 1500 mg/l L-Valine 
Selective SD/dropout media lack specific amino acids (e.g. SD/-Leu have all amino acids 
except L-Leucine) 
 
Ampicillin stock 
• 100 mg/ml Ampicillin, filter sterilize 
 
Blocking solution for immunofluorescence 
• 1% (w/v) BSA in PBS 
Stock: 2% 
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Blocking solution for western blots 
• 5% (w/v) milk powder (low fat) in PBS (or TBS-T) 
 
BSA stock, for protein concentration measurement 
• 1 μg/μl BSA 
 
Cell culture medium for COS-7 
• DMEM, high glucose (4,5 g/l) with L-glutamine 
• 10% (w/v) FBS 
• 100 U/ml Penicillin 
• 100 µg/ml Streptomycin 
 
Dilution/wash buffer for GFP-Trap®_M 
• 10 mM Tris-HCl, pH 7,5 
• 150 mM NaCl 
• 0,5 mM EDTA 
 
Glucose stock (20x), for SD media 
• 40% (w/v) Glucose, filter sterilize 
 
HBS – HEPES buffered saline, pH 7,15, for electroporation, filter sterilize 
• 5 g/l HEPES 
• 8 g/l Sodium chloride 
• 0,37 g/l Potassium chloride 
• 0,1 g/l Sodium phosphate dibasic 
• 1,08 g/l D(+)Glucose 
 
Homogenization buffer, pH 7,5 (for bacterial cells), autoclave if needs to be stored 
• 50 mM Tris-HCl 
• 15% Glycerol 
 
Fixative for immunofluorescence 
• 4% (w/v) paraformaldehyde in PBS, pH 7,4 
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IPTG stock, for protein expression in bacteria 
• 100 mM IPTG 
 
Kanamycin stock 
• 30 mg/ml Kanamycin, filter sterilize 
 
LB agar medium/plates, autoclave 
• 2,5% (w/v) LB-Broth Miller 
• 1% (w/v) Agar, for plates 
• 30 mg/l Kanamycin or 100 mg/l Ampicillin, if needed, added after autoclave 
 
LiAc, stock 10x, autoclave 
• 1 M Lithium acetate 
pH 7,5, adjusted with 1:5 diluted acetic acid 
 
Lysis buffer, pH 8.0 
• 25 mM Tris 
• 50 mM Sodium chloride 
• 0,5% (w/w) Sodium deoxycholate 
• 0,5% (w/v) Triton X-100 
 
Lysis buffer stock (10x) for GFP-Trap®_M (RIPA) 
• 10 mM Tris-HCl, pH 7,5 
• 150 mM Sodium chloride 
• 5 mM EDTA 
• 0,1% SDS 
• 1% Triton X-100 
• 1% Deoxycholate 
 
Mini DNA preparation solution I, pH 8, autoclaved 
• 50 mM Glucose 
• 25 mM Tris-HCl 
• 10 mM EDTA 
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Optional: 100 µg/ml RNase (alternative: water supplemented with 20 µg/ml RNase to 
resuspend the pellet) 
 
Mini DNA preparation solution II 
• 0,2 M Sodium hydroxide 
• 1% SDS 
 
Mini DNA preparation solution III 
• 3 M Potassium acetate 
• pH 4,8 with glacial acetic acid (approx. 11,5% v/v) 
 
Mounting medium for immunofluorescence 
• 3 volumes Mowiol stock 
• 1 volume Propylgalate stock 
 
Mowiol stock 
• 12 g Mowiol 4-88 
• 40 ml PBS 
• 20 ml Glycerol, stir overnight 
Centrifuge 1 hour, 15000 rpm, 4 °C 
Sodium azide added to the supernatant 
 
PBS – phosphate buffered saline, pH 7,35 
• 140 mM Sodium chloride 
• 2,5 mM Potassium chloride 
• 6,5 mM Sodium phosphate dibasic 
• 1,5 mM Potassium phosphate dibasic 
Stock: 10x concentrated (pH re-adjustment is needed after dilution) 
 
PEG 4000 stock, autoclave 
• 50% (v/v) PEG 4000 
 
PEG/LiAc 
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• 40% (v/v) PEG 4000 
• 1x TE 
• 1x LiAc 
 
Permeabilization for immunofluorescence 
• 0,2% (v/v) Triton X-100 in PBS 
 
Permeabilization for immunofluorescence 
• 1 mg/ml Digitonin stock 
• 1:400 diluted in PBS 
 
Peroxisome homogenization buffer, pH 7,4 
• 5 mM MOPS 
• 250 mM Sucrose 
• 1 mM EDTA 
(0,1% (v/v) Ethanol – for catalase activity measurement) 
 
Propylgalate stock 
• PBS 
• 2,5% (w/v) Propylgalate 
• 50% (v/v) Glycerol 
 
Protease inhibitors mix (final concentrations) 
• 0,1 mM PMSF (or 1 mM PMSF, for GFP-Trap®_M buffers) 
• 0,01 mM FOY 305 
• 0,25% (v/v) Trasylol 
 
PMSF stock 
• 0,1 M PMSF in methanol 
 
SD/dropout medium/plates, autoclave 
• 0,69% (w/v) Yeast nitrogen base 
• 1,5% (w/v) Agar, for plates 
• 10% (v/v) Amino acids dropout 10x, added after autoclave 
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• 2% (w/v) Glucose, added after autoclave 
• 15 mg/l Kanamycin, added after autoclave (facultative) 
60 mM 3-AT if needed, added after autoclave 
 
SDS-PAGE loading buffer  
• 60 mM Tris, pH 6,8 
• 2% (w/v) SDS 
• 10% (v/v) Glycerol 
• 0,005% (w/v) Bromophenol blue 
• 20 mM DTT 
• 5% (v/v) β-Mercaptoethanol 
Stock: 1x, 3x or 5x concentrated (DTT and β-Mercaptoethanol added freshly) 
 
SDS running buffer 
• 25 mM Tris 
• 190 mM Glycine 
• 0,1% (w/v) SDS 
Stock: 10x concentrated 
 
SDS solution, for cell lysis 
• 1% (w/v) SDS 
 
Semidry blotting buffer 
• 48 mM Tris 
• 39 mM Glycine 
• 0,4% (w/v) SDS 
• 20% (v/v) Methanol 
 
Stripping buffer 
• 2% (w/v) SDS 
• 62,5 mM Tris-HCl, pH 6,7 
• 100 mM β-Mercaptoethanol (added prior to use) 
 
TAE, pH 8.0 
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• 40 mM Tris 
• 20 mM Acetic acid 
• 1 mM EDTA 
Stock: 50x concentrated 
 
TE buffer, stock 10x, pH7,5, autoclave 
• 0,1 M Tris-HCl 
• 10 mM EDTA 
 
TE/LiAc 
• 1x TE 
• 1x LiAc 
 
Tris buffer for separation gel, pH 8,8 
• 2 M Tris 
 
Tris buffer for stacking gel, pH 6,8 
• 1 M Tris 
 
TBS-T – Tris buffered saline buffer, pH 8 
• 10 mM Tris 
• 150 mM Sodium chloride 
• 1 mM EDTA 
• 0,005% (v/v) Tween 20 
Stock: 10x concentrated 
 
Wash buffer I for immunoprecipitation 
• PBS, pH 7,35 
• 0,5% (w/v) Trinton X-100 
• 0,05% (w/v) Sodium deoxycholate 
 
Wash buffer II for immunoprecipitation 
• 500 mM Sodium chloride 
• 125 mM Tris-HCl, pH 8 
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• 10 mM EDTA 
• 0,5% (w/v) Triton X-100 
 
YPD medium/plates 
• 5% (w/v) YPD (supplemented with glucose) 
• 1,5% (w/v) Agar, for plates 
• 15 mg/l Kanamycin, added after autoclave (facultative) 
 
3.5 Cells 
Table 14: Cells used in this study 
Species Strain/Line Source Purpose 
Cercopithecus 
aethiops (African 
green monkey), 
kidney 
COS-7 ATCC, CRL-1651 
Overexpression of recombinant 
proteins, localization and interaction 
studies 
Cercopithecus 
aethiops (African 
green monkey), 
kidney 
COS-GFP-SKL 
G. Lüers, University of 
Marburg, Germany 
(Koch et al, 2004) 
COS-7 cells stably transfected with 
GFP-SKL – overexpression of 
recombinant proteins, localization 
and interaction studies, especially 
on peroxisomes  
Homo sapiens 
Pex16p-
deficient 
ATCC, GM06231 Complemention studies 
Escherichia coli DH5α Invitrogen DNA manipulations 
Escherichia coli XL1-Blue 
E. da Cruz e Silva, CBC, 
Aveiro, Portugal 
(Stratagene) 
DNA manipulations, recombinant 
protein expression 
Escherichia coli Rosetta (DE3) 
E. da Cruz e Silva, CBC, 
Aveiro, Portugal 
(Novagen) 
Recombinant protein expression 
Escherichia coli C41 (DE3) Lucigen Recombinant protein expression 
Saccharomyces 
cerevisiae (Yeast) 
AH109 
E. da Cruz e Silva, CBC, 
Aveiro, Portugal 
(Clontech) 
Protein-protein interaction studies 
ATCC, American Type Culture Collection, Rockville, MD, USA 
 
3.5.1 Mammalian cells 
3.5.1.1 Mammalian cell culture 
COS-7 cells were cultured in Dulbecco’s modified Eagle medium (DMEM), high glucose 
(4,5 g/l) supplemented with 10% FBS, 100 U/ml Penicillin and 100 µg/ml Streptomycin. 
Material and methods 
 
49 
 
Cells were cultured at 37 °C, 5% CO2 aeration and 95% humidity. Cell culture work was 
performed in a sterile laminar flow safety cabinet and all materials and solutions were 
sterilized by filtration, autoclaving or heat sterilization. Routinely, cells were grown in 100 
mm dishes and seeded on 18 mm Ø glass coverslips in 60 mm dishes for 
immunofluorescence experiments. 
 
3.5.1.1.1 Cell passage 
Routinely, passaging or splitting of cell was performed twice per week, after the cells 
reached confluence. Cell were washed with PBS and incubated with 2 ml trypsin EDTA 
solution (0,5 mg/ml trypsin and 0,22 mg/ml EDTA) for 3-5 minutes at 37 °C. Cells were 
resuspended in 10 ml medium and pelleted by centrifugation for 3 minutes at 200x g. The 
pellet was resuspended in medium and a fraction of this single cell suspension was 
seeded again.  
 
3.5.1.1.2 Cell freezing 
For long term storage, cells were frozen and stored in the vapour phase of liquid nitrogen. 
Cell pellets prepared as described above were resuspended in freezing medium 
containing 20% FBS and 10% DMSO. Cell suspension aliquots of 1 ml were filled into 
cryovials, slowly frozen overnight at -80 °C and subsequently transferred into the liquid 
nitrogen storage tank. For unfreezing, cells were thawed quickly by mixing with pre-
warmed culture medium, and the cells were seeded with pre-warmed medium in a 
regular dish. After adhesion of the cells to the bottom of the dish, the medium was 
changed to remove DMSO and debris. 
 
Material and methods 
50 
 
3.5.1.2 Transfection of mammalian cells 
3.5.1.2.1 PEI transfection 
24 hours before transfection cells were seeded on coverslips in 60 mm dishes. 10 µg of 
DNA were diluted in 750 µl of 150 mM sodium chloride, and 100 µl of 1 mg/µl PEI were 
diluted in 650 µl of 150 mM sodium chloride. After 15 minutes of incubation at room 
temperature, the PEI solution was added drop-wise to the DNA solution and the mixture 
was incubated for additional 15 minutes. 500 µl of the mixture were added drop-wise to 
2,5 ml medium into the cell dish and the cells were incubated for 3-6 hours at 37 °C. 
Afterwards cells were washed with PBS and incubated for 24-48 hours in fresh medium 
before fixation. 
 
3.5.1.2.2 Electroporation 
A confluent dish of cells was trypsinized as described in section 3.5.1.1.1. The cell pellet 
was washed by resuspension in 5 ml HBS buffer and re-centrifugation. The cell pellet was 
resuspended in 1 ml HBS buffer and 0,5 ml of this cells suspension were mixed with 10 µg 
DNA in a 4 mm gap electroporation cuvette. Electroporation was performed at 230 V, 
1500 µF and 125 Ω. Subsequently, the cells were quickly mixed with 1 ml of complete 
medium and seeded. 
 
3.6 Microscopy techniques 
3.6.1 Immunofluorescence 
Cells grown on coverslips were washed twice with PBS and fixed with 4% 
paraformaldehyde for 20 minutes at room temperature. The cells were washed three 
times with PBS (washing was performed in between all further incubation steps). Cellular 
membranes were permeabilized using 0,2% Triton X-100 for 10 minutes. Afterwards 
unspecific binding sites were blocked by incubation with 1% BSA for 10 minutes. 
Incubation with the primary antibodies was performed for 1 hour in a humid and dark 
environment to avoid drying of the cells, followed by incubation with the secondary 
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antibodies in the same way. If more than one protein is meant to be observed, the 
antibodies were incubated simultaneously. Antibodies were diluted in PBS (see Table 8 
and Table 9). For visualization of the cell nuclei the DNA was stained by incubation of the 
cells with Hoechst 33258 dye solution for 2-3 minutes. The coverslips were washed with 
distilled water, mounted using Mowiol and dried overnight before microscopic 
examination. Alternative permeabilization methods were also used: incubation with 
methanol for 5 minutes at -20 °C or with digitonin solution for 5 minutes at room 
temperature. 
 
3.6.2 Fluorescence microscopy 
For the observation of the immunofluorescent preparations Olympus IX81 microscope 
was used at a magnification of 1000x. Digital images were taken with the CCD Camera F-
View II and selected and optimized for contrast and brightness using Olympus Software 
Imaging Viewer and Adobe Photoshop. 
 
3.6.3 Microscope quantitative examination 
For quantification of the peroxisomal morphology, 100 cells per coverslip were 
characterized, two coverslips per experiment were analysed and each experiment was 
performed at least three times. Data analysis and preparation of diagrams were done 
using Microsoft Excel software. Data are presented as means ± standard error of the 
mean (SEM). An unpaired t-test was used to determine statistical differences between 
experimental groups. P values <0,05 are considered as significant (**) and P values <0,001 
are considered as highly significant (***). 
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3.7 Biochemical techniques 
3.7.1 Preparation of post-nuclear supernatants and peroxisome-enriched fractions 
Confluent 100 mm dishes of COS-7 cells were rinsed with PBS and the cells were 
harvested in a total volume of 5 ml PBS. The cells were pelleted by centrifugation (3 
minutes, 200x g), resuspended in 1 ml peroxisome homogenization buffer containing 
protease inhibitors (3.4) and transferred to a microcentrifuge tube on ice. The cells were 
homogenized by passing fifteen times through a 26 G 1/2 needle. Remaining intact cells 
were pelleted by centrifugation (5 minutes, 500x g, 4 °C), the supernatant was collected 
and the cell pellet was re-homogenized in 500 μl peroxisome homogenization buffer as 
described. This procedure was performed twice, and the nuclei were removed from the 
collected supernatant by centrifugation at 500x g for 5 minutes at 4 °C. The resultant 
supernatant is designated as “post-nuclear supernatant”. The mitochondria-enriched 
fraction was prepared by centrifugation at 2000x g for 10 minutes at 4 °C. The 
supernatant was centrifuged for 25 minutes at 25000x g at 4 °C to generate a 
peroxisome-enriched fraction. The pellet was shortly dried and resuspended in 100 μl of 
lysis buffer containing protease inhibitors. 
 
3.7.2 Protein precipitation 
Proteins were precipitated to concentrate samples and this was performed using 
chloroform and methanol (344). One volume of protein-containing sample (100 µl, filled 
up with water to perform the volume) was mixed with four volumes of methanol (400 µl), 
followed by mixing with one volume of chloroform (100 µl) and three volumes of water 
(300 µl). Centrifugation for 3 minutes at 16000x g separated the solution in two phases 
divided by a white interphase containing the proteins. The top aqueous phase was 
removed and discarded, and three volumes of methanol (300 µl) were added. After 
another centrifugation step (3 minutes, 16000x g) the precipitated proteins were found in 
the bottom pellet and the supernatant was discarded. The pellet was air-dried and 
dissolved, e.g. in SDS loading buffer. 
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3.7.3 Measurement of protein concentration 
3.7.3.1 Bradford method 
Measurement of protein quantification, e.g. for equal gel loading, was performed using 
the Bradford assay. Standards containing 1 to 20 µg BSA, blank and samples (1 to 10 µl) 
were filled up to 100 µl with 0,1 M NaOH . Protein assay solution (Bradford, from BioRad) 
was diluted 1:5 with distilled water and 1 ml of the solution was added to each sample. 
All standards and samples were prepared as duplicates. After 15 minutes of incubation at 
room temperature the absorption at 595 nm compared to the blank was measured. Using 
the standard curve prepared from the mean values, the protein concentration of the 
samples was calculated. 
 
3.7.3.2 BCA method 
This method was used with 1% SDS-diluted protein samples. To standards containing 2 to 
40 μg BSA and blank were added 5 μl of 10% SDS and filled with up to 50 μl with water. 1-
2 μl of 1% SDS-diluted samples were filled up to 50 μl with water. 50 ml of BCA reagent A 
were mixed with 1 ml of BCA reagent B and 1 ml of the solution was added to each 
sample. All standards and samples were prepared as duplicates. After 30 minutes of 
incubation at 37 °C the absorption at 562 nm compared to the blank was measured. Using 
the standard curve from the mean values, the protein concentration of the samples was 
calculated. The BCA reagents were from Pierce. 
 
3.7.4 SDS-PAGE 
Standard SDS-PAGE was performed with 10% or 12,5% separating and 5% stacking gels. 
To exclude oxygen, which inhibits polymerization process, the separating gel solution was 
covered with a layer of isopropanol. Gel recipes are presented in Table 15. Before loading 
of the proteins on the gel, they were denatured at 95 °C for 5 minutes in SDS-containing 
loading buffer. Gel electrophoresis in mini slap gel chambers was conducted for 
approximately 30 minutes at 80 V until the proteins entered the separation gel and 
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continued at 130 V for approximately 90 minutes or until proteins reached the desired 
separation. The gel chambers were filled with SDS running buffer. To mark protein size, a 
pre-stained molecular weight marker was used and the sample running front was 
visualized by bromophenol blue added to the loading buffer. 
Table 15: Gel solutions of SDS-PAGE 
Component 
Stacking gel Separating gel 
5% 10% 12,5% 
30% Polyacrylamide 1,66 ml 5,33 ml 6,67 ml 
2 M Tris pH 8,8 (360 mM) - 2,98 ml 2,98 ml 
1 M Tris pH 6,8 (125 mM) 1,25 ml - - 
20% SDS (0,1%) 50 μl 80 μl 80 μl 
dH2O 6,85 ml 7,55 ml 6,21 ml 
TEMED (0,1% / 0,05%) 10 μl 8 μl 8 μl 
10% APS (0,8% / 0,3%) 80 μl 48 μl 48 μl 
Total volume 10 ml 16 ml 16 ml 
Final concentrations are in brackets. 
 
3.7.5 Immunoblotting 
After separation by SDS-PAGE (section 3.7.4), proteins were transferred to a 
nitrocellulose membrane by semi-dry Western blotting (345). The membrane and two 
Whatman papers (3 mm) were soaked with semidry blotting bufferand a stack of 
Whatman paper, membrane, gel, and Whatman paper was formed. Air bubbles in 
between the layers were removed to guarantee complete transfer. The stack was put into 
a semidry transfer chamber and the proteins were blotted for 45 minutes at 12 V. 
After the transfer unspecific binding sites on the membrane were blocked by incubation 
with 5% low fat powdered milk in PBS for 1 hour, shacking. For incubation with the 
primary antibody the membrane was sealed in a plastic bag with the respective antibody 
dilution (Table 8). The incubation times and temperatures ranged from 1 hour to 
overnight  and from 4 °C to room temperature, always with shaking. Afterwards the 
membrane was washed with PBS three times for 10 minutes to remove unbound 
antibody. The incubation with the secondary antibody was performed for 1 hour at room 
temperature. For the ECL reaction, ECL1 (containing luminol) and ECL2 (phenol-containing 
enhancer) solutions were mixed at a 1:1 ratio and the membrane was incubated for 
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approximately two minutes. Film exposition, development and fixation were performed 
in a light protected room. The exposition time varied from 2 to 45 minutes, depending on 
the antibody and protein amount. Films were afterwards scanned with Bio-Rad GS-710 or 
Bio-Rad GS-800 Calibrated Imaging Densitometer. 
 
3.7.6 Protein membrane overlay 
The proteins of interest were expressed in C41 DE3 E. coli strain. The lysates were boiled 
at 95 °C for 15 minutes with appropriate amount of 3x SDS loading gel. The samples were 
subsequently separated by SDS-PAGE (section 3.7.4) and transferred to a nitrocellulose 
membrane (section 3.7.5). The membrane was blocked with blocking solution (5% milk in 
TBS-T) for 1 hour at room temperature. The membrane was overlaid with 25 pmol/μl 
purified PP1γ1 protein (346), diluted in 3% low fat milk/TBS-T, for 1 hour at room 
temperature.  After washing with TBS-T three times for 10 minutes, the bound PP1γ1 was 
detected by incubating the membrane with anti-PP1γ antibody (Table 8) for 1 hour at 
room temperature. Immunoreactive bands were revealed by incubating with horseradish 
peroxidase-conjugated secondary antibody (1:2000 in 3% low fat milk in TBS-T) for 1 hour 
at room temperature, and developed by ECL. 
 
3.7.7 Membrane stripping 
Membrane striping method was used to remove antibodies from blotted membranes. 
The membrane was submerged in striping buffer and incubated at 50 °C for 30 minutes, 
with agitation. The membrane was then washed twice, at room temperature, with a large 
volume of TBS-T, for 10 minutes with shacking. The membrane was re-blocked by 
incubation with blocking solution (5% milk in TBS-T) for 1 hour at room temperature. 
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3.7.8 Protein pull down 
3.7.8.1 Immunoprecipitation 
Protein A-coupled sepharose (PAS) beads were incubated twice overnight in PBS (5 ml 
PAS in 50 ml PBS) at 4 °C and for storage 0,1% sodium azide was added. For co-
immunoprecipitation two confluent 100 mm dishes of COS-7 cells transfected by 
electroporation (section 3.5.1.2.2) with A) 10 μg pcDNA3.1-PP1γ1 and 10 μg empty 
pcDNA3 vector; B) 10 μg pcDNA3.1-Myc-Pex16 and C) 10 μg pcDNA3.1-PP1γ1 and 10 μg 
pcDNA3.1-Myc-Pex16. After 24 hours the cells were washed with PBS and carefully 
harvested in a total volume of 5 ml PBS by scraping. All further steps were performed on 
ice. A cell pellet was prepared by centrifugation (200x g, 3 minutes) and resuspended in 1 
ml lysis buffer containing protease inhibitors. The cells were lysed by three ten seconds 
sonication steps (30 seconds of total time). The lysate was cleared by centrifugation at 
10000x g for 5 minutes, at 4 °C, and the pellet was discarded. Two 25 μl samples were 
collected and stored. A pre-clearing step was performed to avoid unspecific binding to 
PAS: the cell lysate was incubated with 50 μl PAS and rotated for 4 hours at 4 °C; the 
lysate was then centrifuged to pellet the beads at 2400x g for 5 minutes at 4 °C; the 
supernatant was transferred into a new tube and a 25 μl sample was collected and 
stored; the beads were washed twice with wash buffer I and wash buffer II and stored; a 
100 μl sample of the supernatant of the first wash was collected into a new tube. The rest 
of the pre-cleared lysate supernatant was divided into two new tubes with equal volumes 
(for immunoprecipitation and negative control, without antibody). Anti-Myc antibody was 
added to a final concentration of 1:200 into one of the pre-cleared supernatant tubes (no 
antibody was added to the other tube – negative control). Both tubes were incubated for 
1 h at 4 °C with over-head rotation. Afterwards, 50 μl of PAS were added to each tube and 
incubated overnight at 4 °C with over-head rotation. The tubes were then centrifuged at 
2400x g for 5 minutes at 4 °C and a 25 μl supernatant sample was collected from each 
tube and stored. The beads were washed twice with wash buffer I and wash buffer II and 
stored. A 50 μl sample of the supernatant of the first wash was collected into new tubes 
and stored. For the separation by SDS-PAGE (section 3.7.4), 40 μl of 3x Lämmli buffer 
were added to each sample of beads and boiled for 5 minutes at 95 °C. The other samples 
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were precipitated by chloroform-methanol method (section 3.7.2) and the pellets were 
resuspended in 25 μl 3x Lämmli buffer (3.4) and boiled for 5 minutes at 95 °C. 
 
3.7.8.2 GFP-Trap
®
_M 
GFP-Trap®_M (from Chromotek) contains a small GFP-binding protein covalently coupled 
to the surface of magnetic beads, enabling the purification of a protein of interest fused 
to GFP or GFP variants. COS-7 cells were transfected by electroporation (section 3.5.1.2.2) 
with GFP vector which induces the expression of a GFP-fused protein, and incubated at 37 
°C for 16-24 hours. Cells transfected by electroporation with an empty GFP-expression 
vector were used as negative control. The cells were rinsed twice with PBS and harvested 
by scraping with a rubber policeman in 2 ml of PBS per dish. The cells were pelleted by 
centrifugation (200x g for 3 minutes) and resuspended in 100-200 µl of lysis buffer. The 
tubes were placed on ice for 30 minutes and extensively pipetted every 10 minutes. The 
cell lysates were spun at 17000x g for 15 minutes at 4 °C. The supernatant was 
transferred to a pre-cooled tube and the volume adjusted to 500-1000 μl with 
dilution/wash buffer. The protein concentration on the lysates was measured by Bradford 
method (section 3.7.3.1) and 75 μg of each sample were collected for western blot 
analysis (input fraction). For equilibration, the magnetic beads were resuspended by 
vortexing and 25 μl of bead slurry were transferred into 500 μl of dilution/wash buffer. 
The beads were magnetically separated until the supernatant was clear. The supernatant 
was discarded and the beads were washed two times more with 500 μl ice cold 
dilution/wash buffer. 1500 μg of lysate were added to equilibrated GFP-Trap®_M beads 
and incubated at 4 °C for two hours under constant mixing by rotation. Both lysis and 
dilution/wash buffers were supplied with protease inhibitors. Afterwards, the beads were 
magnetically separated until the supernatant was clear. For western blot analysis, 75 μl of 
the supernatant were collected (non-bound fraction), and the remaining supernatant was 
discarded. The beads were then washed two times with 500 μl of dilution/wash buffer. 
The beads were resuspended in 60 μl of 3x SDS loading buffer (3.4) and boiled at 95 °C for 
10 minutes (bound fraction). The beads were magnetically separated and discarded. The 
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input and non-bound fractions were denatured by mixing with the necessary volume of 
3x SDS loading buffer and boiled at 95 °C for 5-10 minutes. Input, bound and non-bound 
fractions of GFP-fused protein and GFP alone control were separated by SDS-PAGE 
(section 3.7.4) and analysed by western blot with the appropriated antibodies (section 
3.7.5). 
For protein pull down using a cross-linker, DSP was used. Prior to cell harvesting, each 10 
cm dish was incubated with 4 mg of DSP, dissolved in 40 μl DMSO + 10 ml PBS solution, 
for 45 minutes, at room temperature. The dishes were then rinsed three times with PBS 
and the cells were harvested. The following procedures were performed as described 
above. 
 
3.8 Molecular biology techniques 
3.8.1 DNA subcloning 
The DNA subclonings performed for this study were made as follows: the cDNA (or a 
portion of it) to be subcloned was used as template for a PCR (section 3.8.3) in which 
restriction endonuclease (RE) recognition sites and/or mutations were inserted. The PCR 
product was separated and the expected band purified in agarose gels (sections 3.8.4 and 
3.8.5). The purified PCR product and the selected vector were then digested with the 
insertion enzymes (section 3.8.6) and purified in agarose gel (sections 3.8.4 and 3.8.5). 
The vector and insert fragments were ligated (section 3.8.7) and ligation product inserted 
in E. coli (section 3.8.8) for amplification (section 3.8.9) and selection of positive clones 
(sections 3.8.11 and 3.8.13). The selected positive clone was re-cultured (section 3.8.9) 
and isolated by kit mini preparation (section 3.8.11 and Table 7) in order to obtain a high 
quality DNA for sequencing (section 3.8.14). After confirmation of insert’s frame and 
presence/absence of mutations, a high quality kit midi (Table 7) preparation was 
performed to conduct the subsequent assays. 
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3.8.2 Primer design 
In general, the plasmids constructed for this study, were created by cDNA amplification 
by PCR (section 3.8.3) using a pair of forward and reverse primers which contained 
recognition sites for restriction endonucleases. The primers annealed to the cDNA on the 
beginning and the end of the area to be amplified by 15 to 20 nucleotides. Some 
nucleotides were added upstream and downstream the RE recognition sites to improve 
cutting efficiency and maintain the frame, respectively. The primer pairs were designed to 
have melting temperatures as close as possible. 
For site-directed mutagenesis (section 3.8.3.1), in which one to three bases were mutated 
in order to change an amino acid, (e.g. Pex11pβ-S11A-Myc), both forward and reverse 
primers contain the desired mutation and anneal to the same sequence on opposite 
strands of the plasmid. The primers were designed to have 30-45 bases and a melting 
temperature (Tm) of ≥78 °C. The desired mutation was in the middle of the primer with 
10-15 bases of correct sequence on both sides. The following formula was used to 
calculate Tm of mutational primers (N = primer length in bases; %GC, i.e. percentage of 
guanines and cytosines, and %mismatch are whole numbers): 
 = 81,5 + 0,41(%) − 675/ −%ℎ	 
 
3.8.3 PCR  
The PCRs performed for cloning in this study are listed with template, primer pair, 
restriction endonucleases cutting sites and target vector in Table 12. For standard PCR 
conditions see Table 16 and Table 17. For site-directed mutagenesis PCR condition see 
Table 18 and Table 19. The DNA polymerase, the MgSO4 25 mM and the dNTPs were from 
Novagen. The PCR components were mixed in DEPC-treated water (ROTH). 
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Table 16: Standard PCR assembly 
Component Amount 
Template 100 ng 
Primer forward (10 pmol/µl) 1 µl 
Primer reverse (10 pmol/µl) 1 µl 
dNTPs mix (2 mM each) 5 µl 
MgSO4 (25 mM) 3 µl 
10x Buffer 5 µl 
KOD Hot Start DNA polymerase (1 U/µl) (Novagen) 1 µl 
H2O x µl 
Final volume 50 µl 
 
 
Table 17: Standard PCR protocol 
Step Temperature Time Cycles 
Denaturation and activation 95 °C 2 min 1 cycle 
First 
amplification3 
Denaturation 95 °C 30 s 
5 – 7 cycles Annealing1 43 °C – 62 °C  20 s 
Elongation2 (1 min/kb) 70 °C 20 s – 1 min 30 s 
Second 
amplification3 
Denaturation1 95 °C 30 s 
25 – 30 cycles Annealing2 62 °C – 70 °C  20 s 
Elongation (1 min/kb) 70 °C  20 s – 1 min 30 s 
Final elongation 70 °C  10 min 1 cycle 
Cooling 4 °C ∞  
1
 Annealing temperature was adjusted to the respective primer pair. 
2
 Elongation time was adjusted to 
template length. 
3
 The PCR reaction is divided in two parts because in the first cycles the whole primer 
doesn’t anneal to the template due to the extensions to add RE recognition sites or other sequences (i.e. 
mutagenesis PCRs). 
 
3.8.3.1 Site-directed mutagenesis 
Some cDNAs were mutated for this study using the site-directed mutagenesis technique, 
following the general guidelines of the instruction manual of the QuikChange® Site-
Directed Mutagenesis Kit, from Stratagene.  The mutations were inserted by PCR (section 
3.8.3), using mutational primers (section 3.8.2) to amplify the whole plasmid. Afterwards, 
1 µl of DpnI (New England Biolabs) was added to the PCR product and incubated at 37 °C 
for approximately 3 hours. DpnI is a restriction enzyme that cleaves exclusively 
methylated DNA. Therefore only template DNA, which was amplified from a dam+ E. coli 
strain (XL1-Blue or DH5α), was digested. Afterwards, 1 µl to 4 µl of the digested PCR 
product were used to transform bacteria (section 3.8.8) to get single-cell colonies. Three 
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isolated colonies were then selected and cultured (section 3.8.9) to amplify and isolate 
the plasmid (section 3.8.11) for sequencing (section 3.8.14) and selection of the clone 
with the desired mutation. The mutated cDNA was subsequently re-cloned into a fresh 
vector. If the vector to be inserted in was the same, no PCR amplification was used, the 
insert was separated from the backbone vector by digestion (sections 3.8.6 and 3.8.5) and 
ligated (section 3.8.7) with fresh digested vector. Selection of positive clones was done as 
described in section 3.8.13. 
Table 18: Site-directed mutagenesis PCR assembly 
Component Amount 
Template 50 ng 
Primer forward (10 pmol/µl) 125 ng 
Primer reverse (10 pmol/µl) 125 ng 
dNTPs mix (2 mM each) 5 µl 
MgSO4 (25 mM) 3 µl 
10x Buffer 5 µl 
KOD Hot Start DNA polymerase (1 U/µl) (Novagen) 1 µl 
H2O x µl 
Final volume 50 µl 
 
 
Table 19: Site-directed mutagenesis PCR protocol 
Step Temperature Time Cycles 
Denaturation and activation 95 °C 30 s 1 cycle 
Amplification 
Denaturation 95 °C 30 s 
16 cycles Annealing 55 °C 1 min 
Elongation1 (1 min/kb) 70 °C 5 min 45 s – 7 min 
Final elongation 70 °C 15 min 1 cycle 
Cooling 4 °C ∞  
1 
Elongation time was adjusted to template length. 
 
3.8.4 Agarose gel electrophoresis 
Agarose was dissolved in TAE buffer by boiling in a microwave. The solution was cooled 
down until being hand-hot, ethidium bromide was added (0,5 µg/ml) and the gel was 
poured into a horizontal gel chamber containing a comb to form loading wells. Routinely, 
0,8-1% (w/v) agarose gels were used. DNA samples were mixed with 6x loading buffer and 
a DNA ladder was used to mark DNA sizes (Table 6). Separation was performed at 60-130 
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V and for 30-60 minutes. Digital images were taken using Alpha Innotech AlphaImager HP 
device and quantifications were made with the provided software. 
 
3.8.5 DNA gel extraction 
PCR products and other DNA samples were isolated from agarose gels (section 3.8.5) 
using a gel extraction kit (Macherey-Nagel, Table 7). The DNA bands visible with UV light 
in the agarose gel were sliced with a scalpel and transferred to a reaction tube. Agarose 
was melted at 50 °C and the DNA was extracted with spin columns (Table 7). Elution was 
performed using 30-50 µl of distilled water. 
 
3.8.6 Digestion with restriction enzymes for DNA subcloning 
PCR products extracted from the agarose gel (total volume) and the target vector (2 µg – 
5 µg) were digested with the same two enzymes. Routinely, restrictive digestions for DNA 
subcloning were performed according to Table 20, at 37 °C, for approximately 24 h, 
separately, inactivating the first restriction enzyme (65 °C, 20 min) in between. 
Afterwards, successful digestion was checked on an agarose gel, the DNA was isolated 
and used for ligation. All the enzymes were from New England Biolabs. 
Table 20: Standard RE reaction for DNA subcloning 
Component Amount 
DNA (PCR product or vector) x µl 
Restriction endonuclease I 1,0 µl 
Restriction endonuclease II (added after some hours) 1,0 µl 
100x BSA (100 ng/µl; optional, depending on the enzymes) 0,5 µl 
10x Buffer1  5,0 µl 
H2O x µl 
Final volume 50 µl 
1 
The buffer used was the one recommended by New England Biolabs for double digestion with the selected 
enzymes. 
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3.8.7 DNA Ligation 
To combine vector and insert DNAs both were enzymatically ligated using the T4 DNA 
ligase (from New England Biolabs). The digested vector and insert molecules were mixed 
by a ratio of 1:3. In some cases, depending on the sizes of both vector and insert, the 
ratios of 1:6 or 1:9 were also used. The reaction was assembled according to Table 21 and 
incubated at 16 °C overnight. Two negative controls were performed: vector without 
ligase and vector with ligase. 5 µl of the ligation products were transformed and amplified 
in E. coli (sections 3.8.8 and 3.8.9) and screened for correct ligations by RE digestion 
(section 3.8.13). 
Table 21: Standard ligation reaction 
Components 
Negative controls 
Ligation 
Vector without ligase Vector with ligase 
Vector  25 ng 25 ng 25 ng 
Insert - - x ng* 
T4 Ligase (400 U/µl) - 1 µl 1 µl 
10x Ligation buffer 2 µl 2 µl 2 µl 
H2O x µl x µl x µl 
Total volume 20 µl 20 µl 20 µl 
*The amount of insert depends on its size and on the ratio vector:insert used 
 
3.8.8 Bacterial transformation 
50 µl of competent E. coli were mixed with the DNA (e.g. from a ligation reaction) and 
incubated on ice for 20 minutes. After a 90 seconds heat shock at 42 °C, the bacteria were 
chilled on ice (2 minutes, approximately) and 900 µl LB medium without antibiotics was 
added, followed by 30 min – 1 h shacking incubation at 37 °C. The cells were then 
centrifuged (1 minute at 12000x g) and the pellet resuspended in 50 µl – 100 µl of 
leftover supernatant LB medium. The suspension was spread on a LB agar plate 
containing a selective antibiotic using glass beads and grown overnight at 37 °C. 
 
3.8.9 Bacterial culture 
For cloning and amplification of DNA plasmids of Escherichia coli (XL-1 blue, DH5α or C41 
strains) cultures were used. The bacteria were cultured in LB medium containing a 
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selective antibiotic (100 µg/ml ampicillin or 30 µg/ml kanamycin) at 37 °C and 200 rpm in 
a shaking incubator. Long-time storage of E. coli cultures was performed as 25% glycerol 
mixtures at -80 °C. For single-cell colonies bacteria were spread on LB agar plates (with 
selective antibiotic) and incubated overnight in a 37 °C incubator. Plates were short-term 
stored at 4 °C and the bacterial colonies were used for inoculation of liquid cultures (2 ml 
– 5 ml). 
 
3.8.10 Protein expression in bacteria 
E. coli strain C41 was transformed (section 3.8.8) with bacterial expression vectors 
containing the cDNAs of interest. One single colony was inoculated in 5 ml LB-containing 
selective antibiotic and incubated at 37 °C, overnight, with shaking. As control, one single 
colony of non-transformed bacteria was inoculated as well. Afterwards, 150 µl of these 
pre-cultures were inoculated in 20 ml of LB with antibiotic and incubated at 37 °C until 
OD600 reached 0,5-0,6. Each culture was divided in two batches: two test tubes were filled 
with 5 ml of this culture and 20 µl of 100 mM IPTG (final concentration of 0,4 mM) were 
added to one of the batches of each culture (induced batch). All tubes (induced and non-
induced) were then incubated at 18 °C, overnight, with shaking. Two 1,5 ml aliquots of 
each batch of each culture were harvested by centrifugation at 12000x g for 1 minute and 
the supernatants discarded. The dried pellets were frozen at -20 °C until further analysis. 
One aliquot of each induced cell pellet was used to separate the proteins in soluble and 
insoluble fractions. To do this, the pellets were resuspended in 300 μl of homogenization 
buffer and sonicated in 5 seconds cycles until light was able to pass through the sample. 
The sonication was performed on ice. The cell lysates were centrifuged at 4000 xg, 4 °C 
for 10 minutes. The supernatants (soluble fractions) were transferred into new tubes. The 
pellets (insoluble fractions) were resuspended in 100 μl of homogenization buffer (section 
3.4). The pellets don’t solubilize but can be resuspended). 
To obtain total protein extracts, the other aliquot of each culture pellet was resuspended 
in 100 μl of SDS 1% and sonicated as previously described. The protein concentrations 
were measured by the BCA method (section 3.7.3.2). 
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3.8.11 Plasmid isolation 
Plasmid DNA was isolated from E. coli cultures in two different amounts; as small scale 
(mini) preparation from 3 ml to 5 ml cultures or as large scale (midi) preparation from 200 
ml cultures. Large scale preparations were performed using midi kit (Macherey-Nagel, 
Table 7). Mini preparations for sequencing or DNA testing purposes were performed 
using a mini kit (GE Healthecare or Macherey-Nagel, Table 7) and the plasmid DNA eluted 
in 50 µl of water. Mini preparations for colony screening after cloning were done 
according to the following protocol: 1,5 ml – 3 ml E. coli cultures inoculated from single 
colonies were grown overnight and sedimented by centrifugation at 12000x g for 2 
minutes. The supernatant was carefully removed and the pellet was completely 
resuspended in 100 µl cold solution I. 200 µl of room temperature solution II were added 
and mixed by inverting the tube five times. 150 µl of cold solution III were added, the 
tube carefully inverted for mixing, and incubated on ice for 3 to 5 minutes. The 
precipitate formed was removed by centrifugation at 17000 – 20000x g, 4 °C for 10 
minutes and the supernatant was transferred to a new tube. The DNA was precipitated by 
addition of 1 ml (approximately 2 volumes) 100% ethanol, incubation at room 
temperature for 2 minutes and centrifugation at 17000 – 20000x g, 4 °C for 5 minutes. 
The supernatant was removed and 1 ml 70% ethanol was added, the tube was vortexed 
and centrifuged at 17000 – 20000x g, 4 °C for 5 minutes. After supernatant removal and 
air-drying, the pellet was resuspended in 50 µl of water supplemented with 20 µg/ml 
RNase. Alternatively, RNase can be added to solution I at 100 µg/ml. DNA concentrations 
of midi and column mini preparations were measured as described in section 3.8.12. 
 
3.8.12 Measurement of DNA concentrations 
DNA concentration of column midi and mini preparations were measured in two different 
ways, either using the Qubit fluorometer and the respective fluorometric assay (Table 7) 
or by measuring the optical density at wavelengths of 260 nm and 280 nm. The DNA 
preparations were diluted in water in order to achieve OD260/280 between 0,1 and 1. An 
OD260 of 1 corresponds to approximately 50 μg/μl of double stranded DNA. The ratio 
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OD260:OD280, which provides an estimate of the purity of the nucleic acid, was between 
1,8 and 2,0. Water was used as blank. 
 
3.8.13 Screening of positive DNA clones by restriction analysis 
To find positive clones 5 to 15 isolated bacterial colonies transformed with the ligation 
product were selected and its plasmid DNA extracted. This DNA was analysed by digestion 
with one or two restriction enzymes which cut in specific sites (see Table 22), giving an 
expected and distinguishable band pattern after separation by agarose gel 
electrophoresis (section 3.8.4). Typically, the selected enzyme cut the vector and the 
insert. The insertion enzymes were used in some cases. Empty vector (negative control) 
was also digested in parallel. 
Table 22: Standard RE reaction for screening of clones 
Component Amount 
DNA 1 µl – 3 µl 
Restriction endonuclease I 0,1 µl – 0,2 µl 
Restriction endonuclease II (if needed) 0,1 µl – 0,2 µl 
100x BSA (100 ng/µl; optional, depending on the enzymes) 0,1 µl 
10x Buffer1  1 µl 
H2O x µl 
Final volume 10 µl 
A master mix without the DNA was prepared, divided, and the DNA added in the end to each aliquot. The 
tubes were incubated at 37 °C for 2 h – 5 h. 
 
3.8.14 DNA sequencing  
The sequencing of all the constructs made for this study was conducted by Eurofins MWG 
Operon following their instructions. The sequencing primers were also provided by them.  
 
3.8.15 Yeast co-transformation for protein-protein interaction assays 
The yeast co-transformation assay was used to test protein-protein interactions and was 
performed following the guidelines of the small-scale LiAc yeast transformation 
procedure from Clontech’s Yeast Protocols Handbook (PT3024-1). The vectors and 
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plasmids for positive controls are described in the Clontech’s MATCHMAKER Gal4 Two-
Hybrid Vectors Handbook (PT3062-1). Competent cells were prepared by inoculating one 
colony of Saccharomyces cerevisiae strain AH109, in 1 ml of YPD and vigorously vortexed 
to disperse cell clumps. The suspension was transferred into a flask containing 50 ml of 
YPD and incubated at 30 °C for 16 h – 18 h with shacking at 250 rpm until it reached the 
stationary phase (OD600 > 1). 20 ml to 40 ml of this overnight culture was transferred to a 
flask containing 300 ml of YPD in order to get a cell suspension with an OD600 of 0,2 – 0,3. 
This culture was incubated for 3 hours, at 30 °C, with shacking at 230 rpm. At this point, 
the culture’s OD600 was between 0,4 and 0,6. The cells were then placed in 50 ml tubes 
and centrifuged at 1000x g for 5 minutes, at room temperature. The supernatants were 
discarded and the cells pellets were thoroughly resuspended in sterile distilled water. The 
cells were pooled into one tube (final volume of 25 ml – 50 ml) and centrifuged again at 
1000x g for 5 minutes, at room temperature. The supernatant was discarded and the cell 
pellet resuspended in 1,5 ml freshly prepared sterile 1x TE/1x LiAc.  
The plasmid DNAs to be inserted in the cells were prepared by mixing 0,1 µg of plasmid 
DNA (for simultaneous co-transformations, using two different plasmids, 0,1 µg of each 
plasmid were used) with 0,1 mg of herring testes DNA (previously boiled) in a 1,5 ml tube. 
Then, 100 µl of fresh yeast competent cells were added to each tube and well mixed by 
vortexing. 600 µl of PEG/LiAc solution were added to each tube and vortexed at high 
speed for 10 seconds. After incubation at 30 °C for 30 minutes with shacking at 200 rpm, 
70 µl of DMSO were added to each tube and gently mixed by inversion. The cells were 
then heat shocked for 15 minutes at 42 °C, in a water bath, and chilled on ice for 1 to 2 
minutes. Afterwards, the cells were centrifuged for 5 seconds at 17000x g at room 
temperature, the supernatants discarded and the cells resuspended in 200 µl – 500 µl of 
1x TE buffer.  
The selection of the desired transformants was made by plating 100 µl of each 
transformed cells tube on SD agar plates with the respective amino acid(s) dropout. Cells 
transformed with pAS2-1 and pACT2 backbone vectors are able to grow in dropout 
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medium without tryptophan and leucine amino acids (SD/-T-L), respectively. The plates 
were incubated up-side-down at 30 °C for 2 to 4 days, until colonies appeared. 
To verify protein-protein interactions double transfected cell colonies and controls were 
re-picked into SD/dropout agar plates without histidine and/or adenine and with X-α-Gal 
(from BD Biosciences). 3-AT was added to some plates (to a final concentration of 60 mM) 
to suppress leaky HIS3 expression. Kanamycin antibiotic was added to YPD and plates to a 
final concentration of 15 mg/l in order to reduce the growth of some contaminants. 
 
3.9 In silico analysis 
For in silico analyses of DNA and protein several online and offline programs were used as 
well as databases (see Table 23). References for the programs can be found in the 
respective websites. 
Table 23: Databases and online and offline programs used for the in silico analyses 
Purpose Program/database URL 
Protein information search 
UniProtKB www.uniprot.org 
NCBI Protein Database www.ncbi.nlm.nih.gov/protein 
Peroxisome protein information search PeroxisomeDB 2.0 www.peroxisomedb.org/home.jsp 
Protein motifs prediction 
ELM elm.eu.org 
MotifScan myhits.isb-sib.ch/cgi-bin/motif_scan 
ScanSite3 scansite3.mit.edu 
Protein motifs canonical sequences 
screen 
ScanProsite prosite.expasy.org/scanprosite 
Protein molecular weight prediction Compute pI/Mw web.expasy.org/compute_pi 
Human protein-protein interactions 
search 
HIPPIE cbdm.mdc-berlin.de/tools/hippie 
Protein alignments Clustal Omega www.ebi.ac.uk/Tools/msa/clustalo 
Protein and DNA blasts BLAST blast.ncbi.nlm.nih.gov/Blast.cgi 
Gene information search NCBI GenBank www.ncbi.nlm.nih.gov/genbank 
DNA sequencing files analysis FinchTV (offline) 
www.geospiza.com/Products/finchtv.sh
tml 
Primer melting temperature calculation OligoCalc 
www.basic.northwestern.edu/biotools/
oligocalc.html 
Buffer determination for double DNA 
restrictions 
NEB Double Digest 
Finder 
www.neb.com/tools-and-
resources/interactive-tools/double-
digest-finder 
Plasmid map design 
Clone Manager 
(offline) 
www.scied.com/pr_cmbas.htm 
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3.10 Figure preparation 
All figures of the present work were prepared using the software Adobe Photoshop CS6. 
In microscopy figures, manipulations in brightness and contrast parameters were made 
by a mask layer clipped to all layers or groups of layers from the same experiment. 
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4 Results 
4.1 PP1 as a potential regulator of peroxisome biogenesis via interaction with 
Pex16p 
Phosphorylation/dephosphorylation is a well-known molecular switch mechanism used to 
tightly regulate the active/inactive state of proteins. Although with unclear role, 
phosphorylation have been already demonstrated to be a post-translation modification in 
two players of the peroxisomal matrix import machinery – Pex14p and Pex15p (283, 284). 
Other peroxisome biogenesis players were shown to be phosphorylated as well, such as 
DLP1 (285, 286) and Pex11 family proteins (220, 290). So far, only the protein 
phosphatases PP2A and MKP1 and the kinase CPK1 were localized to peroxisomes, in 
Arabidopsis thaliana (300-302, 304). The only direct link of protein kinases/phosphatases 
and mammallian peroxisomes discovered so far is Akap11 and Limkain-b1, both PP1 
interactors (295, 296, 298, 299). Human Pex16p was also identified as a putative PP1-
interacting protein (PIP) by another research group of CBC, University of Aveiro (307). PP1 
belongs to the PPP superfamily of protein Ser/Thr-phosphatases which contributes with 
more than 90% of protein phosphatase activity in eukaryotes (313, 347).  
In a collaborative approach of our group, Signal Transduction group from CBC and the 
company Kinexus Bioinformatic Corporation (www.kinexus.ca), a large-scale blot screen 
for kinases and phosphatases in highly purified peroxisomal fractions from rat liver was 
made, with very interesting results (unpublished data). The fractions were obtained from 
8 weeks old rats either untreated (controls) or bezafibrate fed for either 3 or 10 days2. 
Bezafibrate is a peroxisome-proliferator agent often used to analyse selected aspects of 
peroxisome biogenesis or lipid metabolism (348). An astonishing number of kinases (31 
out of 78 tested) and phosphatases (11 out of 28 tested) were detected in the fractions. 
Although in a less expressive amount than other phosphatases (e.g. PP2A) or kinases (e.g. 
MKK6), all three PP1 isoforms were detected, being PP1γ the most abundant one. A 
significant variation on PP1 amount between the control and the three days bezafibrate-
                                                      
2
 The rats weighted approximately 250 g each and the treated rats were fed with 250 mg/kg of bezafibrate. 
The fractions were prepared by Markus Islinger in the University of Heidelberg, Germany. 
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treated fractions was also detected (41%, 27% and 36% decrease for PP1α, PP1β and 
PP1γ, respectively). This result suggests a possible role of PP1 in the down-regulation of 
peroxisome proliferation, i.e. the proteins involved in the proliferation may need to be 
phosphorylated to become active and vice-versa.  
In a yeast two-hybrid (YTH) screen using PP1γ in a human brain cDNA library, Esteves and 
colleagues identified Pex16p as a putative PP1 binding protein (307). They tested full 
length PP1γ1, full length PP1γ2 and the specific C-terminal 39 amino acids of PP1γ2. One 
clone of Pex16p was detected in the full length PP1γ2 YTH. Pex16p has 3 PP1-binding 
motifs, two RVxF and one SILK, an RVxF-cooperating motif (see section 1.4.2.1.1). The 
presence of these motifs re-enforced the confidence on a putative interaction between 
PP1 and Pex16p, making Pex16p a potential PIP, bringing PP1 to the vicinity of potential 
Ser/Thr dephosphorylation targets in the peroxisomal membrane.  
All PEX16 patients described up today had mutations that somehow affected the C-
terminus of the protein (118, 349-351) (see section 1.1.3). Intriguingly, none of the 
mutations directly affected any known functional motifs of Pex16p (120, 141, 152, 352). 
However, the RVxF motifs identified in human Pex16p localize in the very C-terminus, 
turning them into good candidates to be functional PP1-binding motifs with implications 
on Pex16p function and in health. 
 
4.1.1 Several peroxins have putative PP1-binding motifs 
To identify potential PIPs in peroxisomal membrane, we screened all known human 
peroxins for PP1-binding motifs. The sequences were retrieved from UniProtKB database, 
loaded on the ScanProsite server and screened for the PP1-binding motifs’ consensus 
sequences listed on Table 5 (Figure 9, Supplementary Table 1). The peroxins that returned 
no hits for PP1-binding motifs were Pex5pL, Pex11pβ, Pex14p and Pex19p. Pex2p and 
Pex6p have only RVxF-cooperating motifs. The peroxins considered more likely to be true 
PIPs were Pex3p, Pex10p and Pex16p because they presented both RVxF and RVxF-
cooperating motifs. Importantly, Pex1p, Pex5p, Pex7p, Pex10p, Pex13p and Pex26p 
isoform 1 were recognized by RVxF canonical sequences that are more specific, making 
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those peroxins also good candidates for PIPs. Interestingly, human UbcH5a/b/c, an 
ubiquitin-conjugating enzyme that ubiquitinates PTS1 receptor Pex5p during the 
receptor-recycling step of matrix protein import (105), also revealed to have two RVxF 
motifs (Supplementary Figure 1, Supplementary Table 2). Human Fis1, DLP1, Mff and 
GDAP1, players in the peroxisomal (and mitochondrial) fission were also screened for 
PP1-binding motifs and all off them returned no hits (Supplementary Table 3). 
 
Figure 9: Several human peroxins possess PP1-binding motifs. 
The sequences were collected from UniProtKB database and loaded in the ScanProsite program as well as 
the PP1-binding motifs canonical sequences listed on Table 5. Green triangles point matches with RVxF 
motifs. Dark blue triangles point matches with the SILK motif and light blue boxes point matches with other 
RVxF-cooperating motifs. Bar, 100 amino acids. For more detailed information, such as sequences and 
position of the matches within the proteins see Supplementary Table 1. 
 
4.1.2 Pex16p as a potential PP1 interacting protein 
Along with Pex3p and Pex19p, Pex16p is generally referred as an “early” peroxin because 
of its essential role in the initial steps of peroxisome biogenesis (353). However, the 
precise roles of these peroxins appear to vary considerably depending on the organism. 
For instance, besides the role on PMP reception of Pex19p (128, 133) and Pex3p (135, 
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136), they have been implicated in peroxisome inheritance in yeast (134, 137). Pex3p 
serves also in the degradation of yeast peroxisomes (138). Nonetheless, Pex16p seems to 
possess the most diverse set of functions, ranging from a matrix-localized, peripheral 
membrane protein involved in peroxisomal fission in the yeast Yarrowia lipolytica (145, 
146), to an integral membrane-bound PMP receptor at the ER and peroxisomes in 
mammals (140, 143, 144) and plants (141, 142). Notably, Pex16p homologues are absent 
in some well characterized model organisms, including Saccharomyces cerevisiae (71) and 
Caenorhabditis elegans (354). The studies on Pex16p have helped to develop the current 
working models for peroxisome biogenesis, shedding significant light on the role that ER 
plays in this process in evolutionarily distant organisms (355). The species wherein this 
peroxin has been best studied are Yarrowia lipolytica, Arabidopsis thaliana and Homo 
sapiens. Pex16p was first identified in Yarrowia lipolytica, where it was found to be 
peripherally associated with the inner surface of the peroxisomal membrane and was 
referred to play a role in peroxisomal fission (145). YlPex16p was also one of the first 
PMPs experimentally shown to target indirectly to peroxisomes via the ER (356). In 
Arabidopsis thaliana, Pex16p is also among the class II PMPs that sort to peroxisomes via 
the ER and possesses two predicted transmembrane domains (142). AtPex16p has been 
pointed out to be a receptor for Pex3p and class I PMPs (142). Likewise, human Pex16p 
also has two transmembrane domains and a topological orientation whereby both N- and 
C-terminus face the cytosol (352). HsPex16p is also distinct from YlPex16p as it does not 
appear to be directly involved in regulating peroxisome division, but, instead, functions as 
a PMP receptor during the early stages of the de novo peroxisome formation at the ER, as 
well as in mature peroxisomes (143, 144). Consistent with this, the loss of HsPex16p, 
unlike YlPex16p, results in the complete absence of any peroxisomal structures (352). 
More recently, studies have demonstrated that HsPex16p is capable to recruit several 
PMPs, such as Pex3p, Pex34p, Pex26p, Pex10p, Pex11βp and Fis1 to the ER (140, 141). 
This property seems to be conserved at least between mammals and plants (141). Despite 
the similarities, Pex16p homologs from metazoans, yeast and plants are separated into 
distinct clades (Figure 10), indicating early diversification and perhaps functional 
specialization (355). 
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Figure 10: Phylogenetic analysis of Pex16p 
sequences from selected evolutionarily 
diverse species 
Each protein is labeled based on its respective 
Genus and species, and circles represent 
Pex16p proteins of the metazoans (red), yeast 
(blue) and plants (green) that form distinct 
clades. Branch lengths of the tree are 
proportional to divergence with the “10” scale 
bar representing a 10% change. Sequence 
alignments were carried out using either 
CLUSTALW (357) and the phylogram was 
generated using the program TreeView 
(v1.6.6). Genbank® accession numbers are as 
follows: Homo sapiens (BAA88826.1), Rattus 
norvegicus (NP_001012088.1), Mus musculus 
(NP_660104.2), Drosophila melanogaster 
(NP_649252.1), Neurospora crassa 
(XP_963884.2), Danio rerio (NP_001020340.1),
Gallus gallus (XP_421125.3), Penicillium 
chrysogenum (ABH11422.1), Yarrowia 
lipolytica (AAB41724.1), Arabidopsis thaliana 
(NP_566053.1), Oryza sativa (EEC72380.1). 
Adapted from (355). 
 
 
4.1.2.1 Pex16p from other species also have PP1-binding motifs 
Pex16p homologs were also screened for PP1-binding motifs (Figure 11, Supplementary 
Table 5). The species were selected based on organisms expressing Pex16p that are listed 
in Peroxisome DB 2.0 (www.peroxisomedb.org). The sequences were collected from 
UniProtKB database and screened for PP1-binding motifs using the ScanProsite server. 
The PP1-binding motifs’ canonical sequences are listed in Table 5. 
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Figure 11: Homologs of Pex16p from different organisms also have predicted PP1-binding motifs 
Sequences are ordered by percentage of similarity when compared with human Pex16p and by taxa. 
Similarity was calculated by alignment using the Clustal Omega program (Supplementary Table 4). The 
sequences were screened for PP1-binding motifs using the canonical sequences listed on Table 5. Green 
boxes represent matches with RVxF motifs. Dark blue boxes represent matches with the SILK motif and light 
blue boxes represent other RVxF-cooperating motifs. For more detailed information, such as sequences and 
position of the matches within the proteins see Supplementary Table 5. 
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PP1-binding motifs were found in almost all the screened sequences, even in 
evolutionarily distant species (Figure 11). Anopheles gambiae Pex16p has two RVxF motifs 
while Drosophila melanogaster Pex16p doesn’t have any PP1-binding motif, but they 
share only 44,21% similarity (Supplementary Table 4), reflecting the extraordinary 
diversity among insects. Noteworthy, Drosophila pex16 mutant, although reflecting broad 
symptoms of PBDs, it doesn’t exhibit the infant death seen in Zellweger syndrome 
patients (358). Ciona intestinalis (tunicate) Pex16p does not possess a RVxF motif either; 
however, this is the most distant metazoan among the screened sequences. Within 
plants, only Arabodipsis thaliana Pex16p has an RVxF motif, nonetheless, it shares only 
45,46% similarity with Oryza sativa Pex16p (Supplementary Table 4), which may indicate 
that Pex16p in these plant species has slightly different structure and/or function. Even 
with a similarity of only 56,89% Xenopus tropicalis Pex16p conserves one RVxF and SILK 
motifs. Curiously, most fungi also have RVxF motif, but it is positioned within the N-
terminus. Yarrowia lipolytica Pex16p even has a SILK motif, although C-terminally 
localized. Noteworthy, YlPex16p is known to have a completely different topology from 
HsPex16p, without transmembrane domains and faced into the peroxisome lumen (145, 
146).  
The presence of PP1-binding motifs in most of HsPex16p homologs may indicate that a 
putative interaction with PP1 is of significant importance, implying that PP1 may have a 
role in peroxisome biogenesis through interaction with Pex16p.  
 
4.1.2.2 PP1-binding motifs may be affected in PEX16 patients 
4.1.2.2.1 RVxF motifs localize in the C-terminus 
The two RVxF motifs of Pex16p localize at the residues 298-301 and 329-332 (Figure 12). 
Henceforward and for simplicity, first and second RVxF motifs are named PP1-binding 
motif 1 (PP1BM1) and PP1-binding motif 2 (PP1BM2). The RVxF-cooperating SILK motif 
localizes at the residues 63-66. SILK motif, with the consensus sequence [GS]-I-L-[RK], is 
present in several PP1 regulators and it usually occurs N-terminally to the RVxF motif. 
Furtermore, SILK motif docking site within PP1 differs from one of RVxF motif (β-sheets 
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12 and 13) (299). In Pex16p, the SILK motif is 231 and 262 amino acids apart from 
PP1BM1 and PP1BM2, respectively. Although very distant, Pex16p has two 
transmembrane domains (TMDs) and is supposed to expose both N- and C-termini to the 
cytosol (Figure 13) (120, 352). This topology might allow the SILK motif to become close 
enough to the PP1BMs to simultaneously interact with PP1. 
 
Figure 12: Human Pex16p and PP1-binding motifs 
SILK motif (blue), PP1BMs (green), putative transmembrane domains (yellow). The underlined residues 
correspond to exon 11a, which in variant 2 are substituted by the residues 
TSQRAASPCLPARPHTQPWSPPAFLPGHP, reaching a total length of 346 amino acids. 
 
The PEX16 gene is localized at chromosome 11p12-p11.2 and consists of 11 exons. In 
humans, two different mRNA variants of PEX16 are produced as a result of alternative 
splicing, each with an alternative exon 11 (exon 11a and exon 11b). Pex16p variant 2, 
which harbours exon 11b, has a different C-terminus from residue 318, with a total length 
of 346 amino acids (Figure 12). Consequently, variant 2 possesses only PP1BM1. Both 
transcription variants are expressed in human fibroblasts, of which variant 1 containing 
exon 11a is the most abundant (350). The present work was focused on variant 1 which, 
in this document, is named solely Pex16p. 
In addition to the transmembrane domains (120, 352), other domains have been 
identified (Figure 13). Residues 59-219 revealed to be necessary for the interaction with 
Pex19p (152). Moreover, residues 66-81 were demonstrated to be responsible for the 
targeting to peroxisomes and residues 83-103 for the PMP recruitment to the ER (141). 
Notably, all this domains localize in the N-terminus. Until now, no functional domains 
were identified within the cytosolic C-terminus. 
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Figure 13: Pex16p predicted topology and 
functional domains 
Boxes represent specific regions: SILK (aa 63-
66), SILK domain; PO-trg (aa 66-81),
peroxisome targeting domain; PMP-recruit (aa 
83-103), PMP recruitment domain; TMD1 (aa 
110-131), transmembrane domain 1; TMD2 (aa 
222-243), transmembrane domain 2; PP1BM1 
(aa 298-301), PP1-binding motif 1; PP1BM2 (aa 
329-332), PP1-binding motif 2. Dashed area (aa 
59-219) represents the necessary zone for 
interaction with Pex19p. 
 
4.1.2.2.2 Mutations of PEX16 patients affect the C-terminus 
So far, ten patients with mutated PEX16 gene have been reported (118, 349-351). Four of 
these patients belong to complementation group D, carrying the most severe form of 
Zellweger spectrum diseases, Zellweger syndrome (ZS). The first to be identified had a 
nonsense mutation, introducing a stop codon at position 176 (352) (Figure 14, a). Other 
two ZS patients, although unrelated, both carried a splice site mutation, which caused a 
frameshift at codon 298 introducing a stop codon at position 336 (349) (Figure 14, b). The 
latter ZS patient to be identified also carried a splice site mutation, which caused a 
frameshift at position 121 and an immediate stop at 122 (351) (Figure 14, c). Fibroblasts 
of all of the four patients presented the typical ZS cell phenotype caused by mutations of 
PEX3, PEX16 and PEX19, characterized by the total absence of peroxisomes. Remarkably, 
the other six PEX16 patients presented an unexpected mild variant of peroxisome 
biogenesis disorder. These patients developed progressive spastic paraparesis and ataxia 
in the preschool years (with a characteristic pattern of progressive leucodystrophy and 
brain atrophy); latter developed also cataracts and peripheral neuropathy. Plasma 
analysis revealed biochemical abnormalities suggesting a peroxisomal disorder. 
Surprisingly, their fibroblasts showed import-competent peroxisomes, which were 
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increased in size but reduced in number (350). From these six patients, five homozygotic 
mutations of PEX16 were identified: patients 1 and 2, siblings, carried a single-nucleotide 
deletion in exon 11a, provoking a frameshift and introducing a stop codon at position 356 
(Figure 14, e) (exon 11b is intact in both patients); patient 3 carried an in frame deletion 
of a valine at position 252 (Figure 14, f), affecting both variants; patient 4 carried a 
missense mutation leading to the substitution of a threonine for a proline at position 289 
(Figure 14, g), affecting both variants; patient 5 carried a missense mutation leading to 
the substitution of a cysteine for a tyrosine at position 331 (Figure 14, h), affecting only 
variant 1; patient 6 carried a large intragenic deletion leading to the expression of three 
splice variants, causing frameshifts from positions 296 (with a stop at position 328) and 
318 (with stop codons at positions 355 and 455) (Figure 14, i). Despite the differences in 
the mutations, these patients had similar fibroblasts, all with import-competent, reduced 
in number and enlarged peroxisomes. 
 
Figure 14: PEX16 mutations identified in PBD patients 
(a) Schematic representation of wild type Pex16p (variant 1) and (b-h) Pex16p mutations of reported 
patients. Known and putative domains are depicted: SILK (aa 63-66), SILK domain; PO-trg (aa 66-81), 
peroxisome targeting domain; PMP-recruit (aa 83-103), PMP recruitment domain; TMD1 (aa 110-131), 
transmembrane domain 1; TMD2 (aa 222-243), transmembrane domain 2; PP1BM1 (aa 298-301), PP1-
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binding motif 1; PP1BM2 (aa 329-332), PP1-binding motif 2. Dashed area (aa 59-219) represents the 
necessary zone for interaction with Pex19p. Red areas indicate frameshifted parts of the proteins.  
Fibroblasts from patients carrying the mutations represented by (b), (c) and (d) were peroxisomes lacking 
(118, 349, 351); fibroblasts from patients carrying the mutations represented by (e) to (i) contained import-
competent peroxisomes which were  reduced in number and enlarged (350).  
 
All the patients had mutations that affected solely the C-terminus, not involving any of 
the up to date known functional domains. The exceptions are the first and the last 
patients identified (Figure 14, b and d), which do not have the TMD2 or both TMDs (118, 
351).  However, the patients described by Shimozawa and colleagues (349) harbour both 
TMDs and approximately half of the cytosolic C-terminus (Figure 14, c) but Pex16p 
function is equally extensively affected. This can be due to the lack of the last 39 amino 
acids and/or the changed C-terminus may structurally affect its function. The intriguing 
cases reported by Ebberink and colleagues (350) suggest that Pex16p function in those 
patients is just mildly affected. These results indicate that, besides membrane assembly, 
Pex16p may be involved in morphology and division of peroxisomes.  
So a question arises: which functional domains are localized in the C-terminus? Can PP1-
binding motifs and a consequent interaction with PP1 be the answer? Curiously, in the 
case represented by letter e in Figure 14, the frameshift starts exactly in the PP1BM2. 
Also in the case represented by i in Figure 14, no PP1BM2 is present in any of the 
transcript variants. In the case where a tyrosine is substituted by a cysteine in position 
331 (Figure 14, h), a single amino acid is changed in the RVxF motif. This change occurs in 
the most variable residue of the RVxF motif and a cysteine is accepted in this position by 
all published consensus sequences (Table 5). Actually, tyrosine is an excluded residue for 
this position in the more specific consensus sequences, but less sensitive though. Tyrosine 
is an aromatic amino acid and cysteine is not, but both are hydrophobic and uncharged. 
In any case, it is curious to notice that a single amino acid mutation can affect Pex16p’s 
function as extensively as a frameshift from residue 298. These clinical cases lead us to 
conclude that some crucial domain(s) are localized in the more distal C-terminus of the 
protein. Also noteworthy are the other two cases, in which a single in frame deletion 
(Figure 14, f) and a single amino acid substitution (Figure 14, g) also affect Pex16p 
function, causing a similar phenotype. In the latter case, a proline in substituted by a 
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tyrosine. Proline is an amino acid with exceptionally rigid conformation, which influences 
protein secondary structure. This way, the substitution of proline by any other amino acid 
may considerably affect protein’s structure and, possibly, its function. In the case of this 
patient (Figure 14, g), the proline-to-tyrosine substitution affects the distal C-terminus, 
another evidence that some functional domain in this area is being influenced. On the 
other hand, such structural changes in the protein may affect its stability and/or influence 
its degradation rate. 
 
4.1.3 PP1-Pex16p binding studies do not prove the putative interaction  
For this study, several PEX16 mutants were created (Figure 15) to serve as tools to clarify 
the putative PP1-Pex16p interaction and its role in peroxisome biogenesis. Being the first 
and fourth residues of the RVxF motif the most conserved ones (299), we considered that 
substituting these residues for alanines would be sufficient to interfere with the potential 
binding of Pex16p to PP1. These mutants were inserted in mammalian (pCMV-tag3A, 
pEGFP-C1), yeast (pACT2) and bacterial (pET28b, pGEX-4T-3) expression vectors. Cloning 
strategies are described in Material and methods, Table 12. 
 
Figure 15: Pex16p mutants generated for this study
 
Residues depicted in red are the ones that were mutated. Yellow-shaded areas correspond to 
transmembrane domains (TMD). 
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To confirm a protein-protein interaction between Pex16p and PP1, different approaches 
were established and applied. As Pex16p was identified in a yeast two-hybrid screen with 
PP1γ2 (307), PP1γ isoform was the one elected to perform the studies on the putative 
Pex16p-PP1 interaction. In the cases in which the splice isoforms needed to be 
discriminated, e.g. experiments in which PP1γ overexpression is induced, PP1γ1 was the 
selected isoform because PP1γ1, contrary to PP1γ2, is ubiquitously expressed (312). 
  
4.1.3.1 Two co-immunoprecipitation techniques give inconclusive results 
One of the chosen protein-protein techniques to investigate the PP1-Pex16p interaction 
was pull-down by co-immunoprecipitation (co-IP). Two approaches were tested, both by 
Pex16p overexpression in COS-7 cells. In one of them were used antibody-coupled beads 
(section 4.1.3.1.1) and in the other one were used magnetic beads coupled to a GFP-
binding peptide – GFP-Trap_M® system from Chromotek (section 4.1.3.1.2). This peptide 
is derived from the antigen-binding domain of alpaca-raised anti-GFP antibody. In co-
immunoprecipitation assays, the results can be influenced by several parameters, such as 
buffers, temperature, antibodies, tags, expression levels, etc. For this study, several setup 
conditions were tried and the following two sections report the clearer results from the 
multiple co-immunoprecipitation experiments that were executed. 
 
4.1.3.1.1 PP1γ1 co-immunoprecipitates with Myc-Pex16p 
COS-7 cells were transfected with the respective plasmids encoding either A) PP1γ1, B) 
Myc-Pex16p or C) PP1γ1 and Myc-Pex16p (Figure 16, panel I). The overexpressed PP1γ1 
was untagged. In previous experiments we observed that the transfection with pcDNA3.1-
PP1γ1 alone promoted a very high level of PP1γ1 expression, provoking its aggregation 
and high cell morbidity, which didn’t occur while co-transfected with pcDNA3.1-Myc-
Pex16 (data not shown). Given that, cells from group A were co-transfected with both 
empty and PP1γ1-coding cDNA expression plasmids. The transfection was verified by 
immunofluorescence (Figure 16, panel I). The IP (Figure 16, panel II) was performed with 
anti-Myc antibody as described in section 3.7.8.1.  
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Figure 16: PP1γ1 co-immunoprecipitates with Myc-Pex16p 
COS-7 cells were transfected  with (A) PP1γ1, (B) Myc-Pex16p or (C) both. Panel I: immunofluorescence with 
anti-PP1γ (A1 and C2) and anti-Myc (B1 and C1) antibodies. Nuclei were labelled with Hoechst 33258. Bars, 
20 μm. Panel II: Co-immunoprecipitation on cell lysates with anti-Myc antibody conjugated with protein-A-
sepharose beads. The fractions were separated by 12,5% SDS-PAGE and blotted to a nitrocellulose 
membrane. Immunoblotting was performed with anti-PP1γ (top) and anti-Myc (bottom) antibodies. L, 
lysate; PC, pre-cleared beads; IP, immunoprecipitation beads with (+) and without (–) antibody. 
 
To avoid unspecific binding to the beads, all lysates were subjected to a preclearance step 
by incubation of the lysates with beads without antibody (Figure 16, panel II, PC). 
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Afterwards, each precleared lysate was divided into two tubes and incubated with beads 
with and without anti-Myc antibody (Figure 16, panel II, IP+ and IP–, respectively). The 
latter was used as negative control to verify that PP1γ1 did not bind unspecifically to the 
beads. Group A was not expected to present any band on the IP lanes because the IP was 
made with anti-Myc antibody. Nonetheless, it was used as negative control to rule out 
any unspecific binding to the beads due to PP1γ1 overexpression (Figure 16, panel II, A). 
On group B, which cells overexpressed Myc-Pex16p alone, PP1γ is not detected in the IP 
with antibody (Figure 16, panel II, top, B, IP+). This means that endogenous PP1γ was not 
co-precipitated with Myc-Pex16p. However, PP1γ co-precipitated with Myc-Pex16p on 
group C, which cells overexpressed both PP1γ1 and Myc-Pex16p (Figure 16, panel II, top, 
C, IP+). Due to the fact that PP1γ1 and Myc-Pex16p have similar molecular weights, all 
samples were split in two and ran in separate gels to enable western blots with both anti-
PP1γ (Figure 16, panel II, top) and anti-Myc antibodies (Figure 16, panel II, bottom). Anti-
Myc labeling allowed verifying the expression of Myc-Pex16p and its specific binding to 
the beads. 
 
4.1.3.1.2 PP1γ does not co-immunoprecipitate with GFP-Pex16p 
Protein pull down using the GFP-Trap®_M method is very similar to immunoprecipitation 
with antibody-coupled beads; however, instead of an antibody, magnetic agarose beads 
are covalently coupled to a small GFP-binding protein. This technique is claimed to enable 
fast, reliable and one-step precipitations of a protein of interest fused to GFP or GFP 
variants. This system uses only the antigen-binding domain of alpaca-raised antibodies 
(359). This way, no heavy-chain bands appear in the gels and blots, possibly covering 
bands of interest. Another advantage of this system would be the use of GFP-tagged 
Pex16p, which significantly increases its molecular weight allowing using the whole 
fractions to detect Pex16p and PP1γ. Given this, we decided to use this approach to 
further verify the result from the conventional immunoprecipitation (previous section).  
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Figure 17: PP1γ does not co-immunoprecipitate with GFP-Pex16p 
COS-7 cells were transfected with (A) GFP and (B) GFP-Pex16p. Panel I: immunofluorescence with anti-
Pex14 (A1-A3, B1-B3) antibodies. Nuclei were labelled with Hoechst 33258. Bars, 20 μm. Panel II: co-
immunoprecipitation on 1500 μg of cell lysates with GFP-binding protein-coupled magnetic beads. Non-
transformed cells were harvested and lysed as well. 75 μg of protein of non-transformed (NT), input (I) and 
non-bound (NB), and the whole bound (B) fraction were separated by 12,5% SDS-PAGE and blotted to a 
nitrocellulose membrane. Immunobloting was performed with anti-PP1γ (top) and anti-GFP (bottom) 
antibodies. 
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For this approach, COS-7 cells were transfected by electroporation with either pEGFP-C1-
Pex16 or empty pEGFP-C1 vector as negative control. The transfection was verified by 
immunofluorescence with anti-Pex14 and anti-PP1γ antibodies (Figure 17, panel I). GFP-
Pex16p was targeted to peroxisomes (Figure 17, B1-B3), however, they are fewer and 
enlarged when compared to non-transfected cells or cells transfected with pEGFP-C1 
empty vector, which can be due to GFP-induced clustering. In addition, being Pex16p an 
early peroxin involved in PMP import to peroxisomes, GFP-Pex16p overexpression could 
induce alterations on peroxisome morphology and number. Moreover, the cell mortality 
was very high. 
The co-immunoprecipitation was performed as described in section 3.7.8.2. The lysates of 
the transfected cells (input fraction, Figure 17, panel II, I) were incubated with the 
magnetic beads, which were afterwards magnetically pelleted. The pellets constituted the 
bound fractions (Figure 17, panel II, B) and the supernatants the non-bound fractions 
(Figure 17, panel II, NB). The fractions were separated by SDS-PAGE and blotted to a 
nitrocellulose membrane. Immunoblotting was performed with anti-PP1γ antibody 
(Figure 17, panel II, top). PP1γ is present, as expected, on input and non-bound fractions 
at its predicted size, 37 kDa. PP1γ was not present in the bound fraction of the GFP 
control. However, PP1γ was not detected in the bound fraction of GFP-Pex16p as well. 
The membrane was even re-incubated with a more powerful ECL substrate (from BioRad) 
and exposed for a longer time, but PP1γ was still undetectable in the bound fractions. To 
confirm the presence of GFP and GFP-Pex16p in the bound fractions, the membrane was 
subsequently incubated with H2O2 for 30 minutes at 37 °C to erase the ECL signal and the 
membrane was re-blocked and incubated with anti-GFP antibody. As expected, GFP 
expressed at very high levels and was pulled down by the magnetic beads. GFP-Pex16p 
band was at the predicted size (66 kDa), but its expression level was considerably lower, 
and only a fraction of it bound to the beads. 
The experiment was repeated either using a cross-linker or using a buffer with lower 
amount of detergents (10 mM Tris/Cl pH 7,5; 150 mM NaCl; 0,5 mM EDTA; 0,5% NP-40), 
but the results remained negative (not shown).  
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4.1.3.2 Pex16p does not interact with PP1γ1 in co-transformed yeast 
The yeast co-transformation assay to probe protein-protein interactions uses the fact that 
most eukaryotic transcription activators have two functionally independent domains, the 
DNA-binding domain (BD), that recognizes a specific DNA sequence in the promoters of 
different genes, and activation domain (AD), which brings the transcriptional machinery 
to the promoter vicinity (360). Interaction of the BD fusion with the AD fusion positions 
the AD in the proximity of the reporter gene, thus activating its transcription (Figure 18). 
In the present work, AD (aa 768-881) and BD (aa 1-147) elements of GAL4, a yeast 
transcription factor involved in galactose metabolism, were fused with the two 
potentially interacting proteins, Pex16p and PP1γ1 respectively, and co-introduced into 
yeast cells that possess several reporter genes that were made to be transcriptionally 
dependent on activation through a binding site to the BD. Interacting proteins allow co-
transfected yeast to grow in synthetic media lacking histidine and/or adenine by the 
activation of the reporter genes HIS3 and ADE2, respectively.  Interacting proteins also 
activate the reporter gene MEL1, which promotes the expression of α-galactosidase that 
is secreted to medium. X-α-Gal is a chromogenic substrate, which can be added to the 
medium and is hydrolysed by α-galactosidase causing yeast colonies to turn blue.  
 
Figure 18: The yeast two-hybrid system 
Two chimeric proteins are expressed in yeast: (A) GAL4 DNA-
binding domain (BD) fused to a bait protein. The BD-bait 
hybrid protein can bind to upstream activation sites (UAS) 
but cannot activate transcription. (B) GAL4 activation 
domain (AD) fused to a prey protein. The AD-prey protein 
cannot recognize the UAS, thus, alone is not capable of 
initiating transcription. (C) When the bait and the prey 
interact, BD and AD are brought together and can activate 
reporter gene transcription.  
pACT2 and pAS2-1 yeast expression vectors were used in this 
assay to generate GALAD- and GAL4BD-fused proteins, 
respectively. pACT2 contains LEU2, a nutritional gene that 
allows yeast auxothophs to grow on synthetic media lacking 
leucine amino acid. On the other hand, pAS2-1 contains 
TRP1 gene that allows the growth in tryptophan-lacking
media. pVA3-1 and pTD1-1 plasmids, encoding GAL4BD-p53 
(aa72-390, murine) and GAL4AD-SV40 large T antigen (LT-
AG, aa87-708) respectively, were used as positive control. 
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The previously generated pAS2-1-PP1γ1 construct (encoding GAL4BD-PP1γ1) that was 
used in the YTH screen of human brain cDNA library (307) was used in this study as bait as 
well. pACT2-Clone 18 (encoding GAL4AD-Clone 18), extracted from the YTH, was also 
used in order to reproduce the YTH results and test possible auto-activation of reporter 
genes. In addition to GAL4AD-fused wild-type Pex16p, other Pex16p versions were used: 
(a) with mutated PP1BMs and (b) cytosolic C-terminal tail (see Figure 15). The PP1BMs 
mutants were tested to verify if these domains were responsible for the putative PP1γ1-
Pex16p interaction. On the other hand, despite pACT2 vector adding a nuclear targeting 
signal to the GAL4AD-fused proteins, the two transmembrane domains could arrest 
Pex16p to enter the nucleus and activate the transcription of the reporter genes. To 
overcome this possible setback, we also used a truncated Pex16p version containing 
solely the cytosolic C-terminal tail (aa244-336) (352), i.e. without the transmembrane 
domains but with the RVxF PP1-binding motifs. Table 24 summarizes the constructs that 
were used in this assay. 
Table 24: List of constructs that were used in the protein-protein interaction assay by yeast co-
transformation 
 Plasmid name Encoded recombinant protein 
Baits 
pAS2-1 GAL4AD 
pAS2-1-PP1γ1 GAL4AD-PP1γ1 
pVA3-1 GAL4AD-p53 (aa 72-390) (murine) 
Preys 
pACT2 GAL4BD 
pACT2-Clone 18 GAL4BD-Clone 18 (Pex16 YTH clone) 
pACT2-Pex16 GAL4BD-Pex16p 
pACT2-Pex16 PP1BM1 GAL4BD-Pex16pPP1BM1 (R298A_F301A) 
pACT2-Pex16 PP1BM2 GAL4BD-Pex16pPP1BM2 (K329A_F332A) 
pACT2-Pex16 PP1BM1&2 GAL4BD-Pex16pPP1BM1&2 (R298A_F301A_K329A_F332A) 
pACT2-Pex16 C-ter GAL4BD-Pex16pCT (aa244-336) 
pTD1-1 GAL4BD-SV40 LT-AG (aa 87-708) 
 
The plasmids were inserted in the AH109 strain of Saccharomyces cerevisiae following the 
method described in section 3.8.15. To select transformed and co-transformed yeasts, 
cells were plated and incubated for 2-4 days at 30 °C in a synthetically defined medium 
supplemented with amino acids, excluding leucine (SD/-L), tryptophan (SD/-T) or both 
(SD/-T-L), according to the vectors that were inserted. Three single colonies transformed 
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with the desired plasmid(s) were then re-picked to the same SD/Dropout (SD/DO) which 
they have been collected from and incubated again for 2-3 days at 30 °C in order to get a 
higher and fresh amount of yeast to be re-picked later on into SD/DO interaction selective 
media. The SD/DOs that were used to select the yeasts with activated interaction 
reporter genes lacked histidine and/or adenine. 3-AT was used in some plates to supress 
leaky HIS3 expression and to obtain a more accurate His- phenotype. X-α-Gal was added 
to some plates as well. Yeasts were grown on interaction selective plates for 3-6 days at 
30 °C. 
In a first stage, the preys alone were inserted in yeast and grown in selective media and 
with X-α-Gal additive to test if they themselves were able to activate reporter genes. 
Empty pACT2 vector, encoding GAL4AD, was used as negative control; GAL4AD-p53 + 
GAL4BD-SV40 LT-AG was used as positive control (Figure 19, panel A). None of the yeasts 
transformed with the preys or bait alone were able to grow on interaction selective 
medium or to turn blue in the presence of X-α-Gal, meaning that they were unable to 
activate the reporter genes (Figure 19, panel A). This allowed us to use them further for 
the protein-protein interaction assay with PP1γ1 (Figure 19, panel B). 
To perform the protein-protein interaction assay, baits and preys were co-inserted into 
the yeast. Several negative controls were used: GAL4BD + GAL4AD, GAL4BD-PP1γ1 + 
GAL4AD and GAL4BD + GAL4AD-Pex16p wild-type/mutants. GAL4BD-p53 + GAL4AD-SV40 
LT-AG was used as positive control. GAL4BD-PP1γ1 + GAL4AD-Pex16p wild-type/mutants 
were used to verify PP1γ1-Pex16p putative interaction (Figure 19, panel B). As expected, 
the negative controls GAL4BD + GAL4AD and GAL4BD-PP1γ1 + GAL4AD did not grow in 
the interaction selective media. However, they presented some minor growth on SD/-T-L-
H plates due to leaky HIS3 expression, which is completely supressed by the addition of 3-
AT. 
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Figure 19: Protein-protein interaction assay by yeast co-transformation using strain AH109 reveals no 
interaction between PP1γ1 and Pex16p 
The yeast growth media (agar plates) were composed by a synthetically defined medium supplemented 
with amino acids, excluding leucine (-L), tryptophan (-T), histidine (-H) and/or adenine (-A). 3-AT, added to 
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some plates, acts as leaky HIS3 expression suppressor. X-α-Gal was added to some plates to test the 
activation of MEL1 reporter gene.  The pictures were taken after 2-6 days incubation at 30 °C. For this 
figure, one representative clone of each co-transformed yeast was selected. Panel A: self-activation control. 
Panel B: protein-protein interaction assay. 
 
Yeasts co-transformed with GAL4AD-Clone 18 and GAL4BD were able to grow on SD/-T-L-
H-A and SD/-T-L-A and to degrade X-α-Gal (Figure 19, panel B). The growth was inhibited 
on SD/-T-L-H by 3-AT. Although GAL4AD-Clone 18 alone was not able to self-activate the 
reporter genes (Figure 19, panel A), the presence of GAL4BD, although not recombined 
with another protein, allowed these yeasts to activate some of the reporter genes. The 
other negative controls, GAL4BD + GAL4AD-Pex16p wild-type/mutants did not activate 
any reporter gene (Figure 19, panel B). 
When co-expressed with GAL4BD-PP1γ1, any of the GAL4AD-fused Pex16p versions were 
able to activate the reporter genes, even the truncated version. This means that none of 
the Pex16p versions interacted with PP1γ1 in our experimental set-up (Figure 19, panel 
B).  
 
4.1.3.3 PP1γ1 does not overlay in blot with Pex16p 
The protein blot overlay technique involves fractionating proteins on SDS-PAGE, blotting 
to a membrane, and the incubating with a probe of interest. Is this work, the probe used 
was purified PP1γ1, which was then visualized by antibody. 
For this study, we examined several methods to express Pex16p. One of the methods 
used was the in vitro translation, using the kit TNT T7 Quick Coupled 
Transcription/Translation System from Promega. Two plasmids were used, pET28b-Pex16 
and pET28b-Pex16 C-ter, (encoding His-Pex16p and His-Pex16pCT). The expression was 
induced both in the presence and absence of recombinant Pex19p. In every case, there 
was no detectable expression (data not shown). 
In vivo expression in mammalian cells was also approached. Two 10 cm confluent dishes 
of COS-7 cells were transfected by electroporation with pcDNA3.1-Myc-Pex16 plasmid, 
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encoding Myc-Pex16p. Non-transfected COS-7 cells were used as negative control. The 
cells were harvested and post-nuclear supernatants were prepared. The protein 
concentration of both samples was determined by the Bradford method and two 100 μg 
portions of each sample were precipitated by chloroform-methanol and separated by 
12,5% SDS-PAGE. The gels were blotted onto nitrocellulose membranes. One of the 
membranes was used for immunoblotting with anti-Myc antibody to control for Myc-
Pex16p expression (Figure 20, top).  
 
 
As expected, the lane of the transfected cells (Figure 20, left) shows a protein band 
around 37 kDa, the predicted size for Myc-Pex16p. The other membrane was overlaid 
with purified PP1γ1 and labelled with anti-PP1γ antibody (Figure 20, bottom). 
Endogenous PP1γ, expressed in both transfected and non-transfected cells, should be 
labelled in the blot because anti-PP1γ antibody was used. However, this band would be 
indistinguishable from putative PP1γ1 overlaid on Myc-Pex16p because Myc-Pex16p and 
PP1͏γ͏ have very similar expected molecular weight. Nonetheless, in case of positive 
interaction, the band intensity was expected to be significantly distinct due to the 
overexpression of Myc-Pex16p in transfected cells. However, both lanes displayed a 
similar band pattern, revealing no evident interaction between Myc-Pex16p and PP1γ1. 
Moreover, the overlay showed a significant amount of “unspecific” bands. This may be 
explained by the very high number of proteins that bind to PP1 (307). To try to 
circumvent this problem, the overlay was repeated, with peroxisome-enriched fractions 
using the same parameters. This was expected to significantly reduce “unspecific” 
 
Figure 20: Protein blot overlay in 
mammalian cell lysates shows no 
interaction between PP1γ1 and Myc-Pex16p 
100 μg of post nuclear supernatants of COS-7 
cells transfected with Myc-Pex16p and non-
transfected (NT) were separated by 12,5% 
SDS-PAGE and blotted to nitrocellulose 
membranes. WB: western blot using anti-
Myc antibody. Overlay: protein blot overlay 
with purified PP1γ1 and detection with anti-
PP1γ antibody. 
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binding, but too many bands were still visible after immunoblotting and no differences 
between transfected and non-transfected cells were detected (data not shown). The 
problem concerning the similar molecular sizes of Pex16p and PP1γ1 could be overcome 
by the expression of Pex16p with a larger tag. By the time this assay was performed, a 
Pex16p-GFP construct was available but, as GFP was localized at the C-terminus, nearby 
the PP1BMs, it could potentially interfere with the PP1γ1-Pex16p interaction.  
Pex16p was also expressed in bacteria. Several E. coli strains (XL-1 Blue, Rosetta DE3 and 
C41 DE3) were transformed with pET28b-Pex16 and tested under different conditions, 
such as temperature, incubation time and IPTG concentration (data not shown). His-
Pex16p did not express under any of the tested conditions or strains. For this reason, 
pGEX family vectors were used. pGEX vectors add a glutathione S-transferase (GST) tag at 
the N-terminus of the protein as well as a protease cleaving site in between. These 
vectors are commonly used for protein purification. On the other hand, since GST 
composes a very large tag, it could reduce possible toxicity of the target protein. In fact, 
unlike His-Pex16p, it was possible to express GST-Pex16p, in Rosetta DE3 (vestigially) and 
C41 DE3. The C41 DE3 strain is used to generate membrane proteins that are difficult to 
express. Another approach to overcome this difficulty was to generate a construct 
without the transmembrane domains (Figure 15). This way, we generated the pGEX-4T-3-
Pex16 C-ter, which encodes GST-Pex16CT. The resulting fusion protein conserves the 
PP1BMs but lacks the transmembrane domains. Empty pGEX-4T-3 vector and non-
transformed cells were used as negative controls. The determined optimal conditions for 
the expression were induction with 0,4 mM IPTG and overnight incubation at 18 °C.  
In order to verify the molecular masses of the expressed proteins and to evaluate the 
expression levels in order to optimize the overlay experiment, one of the prepared 
aliquots were lysed, separated on 12,5% SDS-PAGE (equal protein amounts) and 
immunoblotted with anti-GST antibody (data not shown). The molecular masses were as 
expected. GST and GST-Pex16pCT presented much higher expression levels than GST-
Pex16p, indicating that a higher amount of the latter’s lysate should be loaded for the 
subsequent protein blot overlay.  
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For the overlay (Figure 21) we used the stored aliquots of C41 DE3 induced to express 
GST, GST-Pex16p and GST-Pex16pCT. As negative control, non-transformed cells were 
used. Total protein was obtained by resuspending and sonicating the pellets in 100 μl 1% 
SDS. As a well-known PIP, Nek2A (307) was used as positive control: 1% SDS lysate of 
Rosetta DE3 transformed with pET28c-Nek2A and induced to express the resulting 
recombinant His-Nek2A was used in this experiment (kindly provided by Luis Gregório, 
CBC, University of Aveiro). Protein concentration measurement of all samples was done 
by the BCA method. 1% SDS lysate of rat cortex was used as control for the anti-PP1γ 
antibody (kindly provided by Sara Esteves, CBC, University of Aveiro). In this sample, a 37 
kDa band was expected, corresponding to the endogenous PP1γ in the rat cortex. The 
SDS-PAGE was loaded with different amounts of each sample, considering the expression 
levels of each recombinant protein observed previously (data not shown). After 
separation, the proteins were blotted to a nitrocellulose membrane and overlaid with 25 
pmol/μl purified PP1γ1. Overlaid PP1γ1 was detected by subsequent incubation with anti-
PP1γ antibody (Figure 21, panel A). The membrane was afterwards stripped and re-
probed with anti-GST and anti-Myc antibodies (Figure 21, panel B).  
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Figure 21: Protein blot overlay in bacterial lysates shows no interaction between PP1γ1 and GST-Pex16p 
or GST-Pex16
CT
 
C41 DE3 bacteria were transformed and induced to express GST, GST-Pex16p and GST-Pex16p
CT
. 1% SDS 
buffer and sonication was used to lyse the cells and obtain total protein. Lysates of non-transformed (NT) 
and GST expressing bacteria were used as negative controls. Pre-prepared lysate of Rosetta DE3 
transformed and induced to express His-Nek2A was used as positive control. Rat cortex lysate was used as 
control for anti-PP1γ antibody. The amount of protein (in μg) of each cell lysate loaded in the gel is 
indicated by the numbers on the top of each lane. The lysates were separated by 12,5 % SDS-PAGE and 
blotted to a nitrocellulose membrane. Panel A: the membrane was blocked and overlaid with 25 pmol/μl 
purified PP1γ1; the overlaid PP1γ1 was detected by subsequent incubation with anti-PP1γ antibody. Panel 
B: the membrane was stripped, cut and re-probed with anti-GST (left) and anti-His (right) antibodies. Panel 
C: merge image with the protein overlay (red) and the immunoblot (green). The signal of PP1γ1 overlay on 
His-Nek2A was so strong that the membrane stripping was not completely effective to remove it, which led 
to the emergence of a ghost band superimposed to His-Nek2A band. 
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On the overlay blot (Figure 21, panel A) two bands between 25 kDa and 37 kDa appear in 
all bacterial samples, including the non-transformed (NT) ones, indicating that they are 
unspecific. In the lane loaded with rat cortex lysate there is a band at the expectable size 
of 37 kDa, indicating that the anti-PP1γ antibody was functional (Figure 21, panel A). As 
expected, His-Nek2A gives a very strong overlay signal (Figure 21, panel A). This band 
overlaps with the His-Nek2A band on the immunoblot (Figure 21, panels B and C). GST-
Pex16p and GST-Pex16pCT samples do not present any band overlapping to the 
corresponding bands on the immunoblot, revealing no overlay with PP1γ1 (Figure 21, 
panel C).  
Despite the samples were continuously handled on ice, there was some extent of protein 
degradation. Although no protease inhibitors were added to the lysis buffer, it was a 
denaturing buffer (1% SDS), making protein degradation by the action of proteases after 
cell lysis not expectable. It is likely that the observed protein degradation happens within 
the cells. As a matter of fact, pGEX vectors add a protease recognition site between the 
GST tag and the sub-cloned proteins. 
 
4.1.4 Manipulation of the putative PP1-Pex16p interaction does not change 
peroxisome dynamics  
 
4.1.4.1 Pex16p overexpression in COS-7 cells does not change endogenous PP1α and 
PP1γ sub-cellular localization 
One of the first questions raised in this study was whether the overexpression of Pex16p 
in mammalian cells would influence the subcellular localization of PP1 which, during 
interfase, localizes in the cytoplasm and enriched in the nucleus (361). To test the 
overexpression and localization of Myc-Pex16p, COS-7 cells were transfected with 
pcDNA3.1-Myc-Pex16 by the PEI method and endogenous Pex14p was labelled as a 
marker for peroxisomes (Figure 22). Overexpressed Myc-Pex16p co-localizes with Pex14p, 
indicating that it is correctly targeted to the peroxisomal compartment.  
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Figure 22: Overexpressed Myc-Pex16p localizes to peroxisomes 
COS-7 cells were transfected with Myc-Pex16p and processed for immunofluorescence microscopy using 
anti-Myc (A1 and B1) and anti-Pex14 (A2 and B2) antibodies. Nuclei were labelled with Hoechst 33258. Bars, 
20 μm. 
Then, COS-7 cells were transfected with the same construct and endogenous PP1γ and 
PP1α proteins were labelled with the respective antibodies (Figure 23). Comparing 
transfected and non-transfected cells one cannot see any difference in the subcellular 
localization of both PP1α and PP1γ. Moreover, no co-localization is visible between 
Pex16p and PP1, which could mean that the amount of PP1 in peroxisomes is too low 
and/or the putative interaction has a transient nature, which could make it difficult to 
detect by fluorescence microscopy. 
 
Figure 23: Overexpression of Myc-Pex16p does not change PP1 sub-cellular localization 
COS-7 cells were transfected with Myc-Pex16p and processed for immunofluorescence with anti-Myc (A1 
and B1) and  anti-PP1α (A2) or anti-PP1γ (B2) antibodies. Nuclei were labelled with Hoechst 33258. Bars, 20 
μm. 
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4.1.4.2 Overexpression of Pex16p PP1BMs mutants in COS-7 cells does not change 
peroxisomal morphology or number 
In parallel to the interaction assays, experiments were performed in order to unravel the 
physiological role of a putative interaction between PP1γ1 and Pex16p. First, wild-type 
and PP1BMs mutants (see Figure 15) were cloned into the mammalian expression vector 
pCMV-tag3A, which adds a Myc tag N-terminally. COS-7 cells stably expressing GFP-SKL 
(COS-GFP-SKL), which display green fluorescent peroxisomes were transfected by PEI with 
the wild-type and the mutated versions of PEX16 (Figure 24). Observing the peroxisomes 
from transfected cells, there are not visible differences in peroxisome morphology, size or 
number between cells expressing with any of Myc-Pex16p PP1BMs mutants and Myc-
Pex16p. However, GFP-SKL is a matrix protein, so an alteration of the membrane could 
not be visible in this approach.  
Thus, COS-7 cells were transfected with Myc-Pex16p and Myc-Pex16pPP1BM1&2, which carry 
mutations in both RVxF motifs (see Figure 15). The cells were then labelled with anti-
Pex14 and anti-ACOX antibodies to label membrane and matrix, respectively (Figure 25). 
Similarly to the experience with COS-GFP-SKL cell (Figure 24), no differences were visible 
concerning peroxisome morphology, size and/or number between cells expressing Myc-
Pex16p and Myc-Pex16pPP1BM1&2. Nonetheless, a possible interaction between PP1 and 
Pex16p could not influence the peroxisomal number or morphology. Moreover, a 
difference could be only visible under specific conditions or stimuli. On the other hand, 
COS-7 cells endogenously express Pex16p, which could surpass the effect of the 
overexpression of a mutated Pex16p version. 
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Figure 24: Overexpression of Myc-Pex16p with mutated PP1BMs does not change peroxisomal 
morphology or number 
COS-GFP-SKL cells were transfected by PEI to express Myc-Pex16p, as well as Myc-Pex16p with mutations in 
the first RVxF motif (Myc-Pex16p
PP1BM1
) or in the second (Myc-Pex16p
PP1BM2
) or in both (Myc-
Pex16p
PP1BM1&2
). The cells were labelled with anti-Myc antibody. Bars, 20 μm. 
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Figure 25: Overexpression of Myc-Pex16p with both PP1BMs mutated does not change peroxisomal 
morphology or number 
COS-7 cells were transfected by PEI to express Myc-Pex16p, a well as with mutations on both RVxF motifs 
(Myc-Pex16p
PP1BM1&2
). The cells were labelled with anti-Myc and anti-Pex14 or anti-ACOX antibodies. Nuclei 
were labelled with Hoechst 33258. Bars, 20 μm. 
 
4.1.4.3 Pex16p PP1BMs mutants are able to complement the peroxisomal phenotype 
in Pex16p-deficient cells 
The re-introduction of Pex16p in Pex16p-deficient cells is known to complement its 
phenotype characterized by the total absence of peroxisomes (118, 120, 350). In order to 
test if Pex16p with mutated RVxF motifs was able to complement the phenotype and 
result in de novo synthesis of peroxisomes, Pex16p-deficient cells were transfected with 
Myc-Pex16p wild-type and with mutated PP1BMs. This work was made in collaboration 
with the group of M. Fransen in the University of Leuven, Belgium. The cells were 
transfected using the Neon® Transfection System and fixated four days after transfection. 
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The cells were labelled with anti-Pex14 (Figure 26) and anti-catalase (not shown) 
antibodies. Both wild-type and mutated versions were able to restore peroxisomes 
biogenesis. Co-localization of Pex14p and catalase (not shown) indicated that the newly-
formed peroxisomes were also import-competent. In our study, despite the peroxisomes 
from the complemented cells do not appear absolutely normal, one cannot see 
differences between the wild-type and any of the mutated versions. This result clearly 
demonstrates that the putative PP1-binding sites within Pex16p are not essential for the 
de novo formation of peroxisomes. 
 
Figure 26: Pex16p PP1BMs mutants are able to complement the phenotype in Pex16p-deficient cells 
Pex16p-deficient cells were transfected using the Neon® Transfection System to express Myc-Pex16p, as 
well as Myc-Pex16p with mutations in the first RVxF motif (Myc-Pex16p
PP1BM1
) or in the second (Myc-
Pex16p
PP1BM2
) or in both (Myc-Pex16p
PP1BM1&2
). The cells were fixated four days after transfection and 
labelled with anti-Pex14 antibody. Bars, 20 μm. With kind support of M. Fransen, Univ. of Leuven, Belgium. 
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4.1.5 Discussion 
Protein phosphorylation represents one of the most common post-translational 
modifications in eukaryotes. It affects 30-70% of all cellular proteins and some cellular 
processes are associated with thousands of phosphorylation events, the majority of which 
are highly dynamic owing to their ability to be rapidely reversed by protein phosphatases 
(278). The protein Ser/Thr phosphatase PP1 has been pointed to be the catalyzer for the 
majority of protein phosphorylation events in eukaryotic cells (278, 314). As PP1 does not 
recognize a consensus sequence surrounding thephosphorylated residue, efficient and 
specific substrate binding depends on regulatory subunits, so-called PP1-interacting 
proteins (PIPs) (319). Most PIPs contain a primary PP1-docking motif and some even 
possess interaction-strengthening motifs (see Table 5, section 1.4.2.1.1). 
The signal transduction mechanisms that may regulate peroxisome biogenesis and 
proliferation are yet to be discovered. Being phosphorylation/dephosphorylation a major 
signal transduction mechanism and PP1 the major player, we investigated a possible role 
for PP1 in peroxisome biogenesis and proliferation by searching for possible PIPs among 
peroxins and other important players on the matrix import and fission machineries 
(section 4.1.1). We identified PP1-binding motifs in several peroxins (Figure 9) and 
considered Pex3p, Pex10p and Pex16p the most likely to be true PIPs since they harbor 
primary and strengthening PP1-docking motifs. In parallel, another evidence emerged 
pointing out to a putative interaction between PP1 and Pex16p: Pex16p was identified in 
a yeast two-hybrid screen for PP1γ2 interactors in human brain (307). Moreover, all three 
PP1 isoforms were identified in a large scale blot screen on highly purified rat liver 
peroxisome fractions. Altogether, we considered Pex16p as very likely to be a PP1-
interacting protein, possibly regulating PP1’s activity during peroxisome biogenesis. 
One of the aims of this work was to verify the putative PP1-Pex16p interaction by binding 
studies. Several techniques were used; however, we could not confirm the interaction. 
We used two pull-down techniques, co-immunoprecipitation using anti-Myc antibody and 
GFP-binding peptide coupled to magnetic beads. In the first case, we used COS-7 cells 
overexpressing PP1γ1 and/or Myc-Pex16p. The fraction from double transfected cells 
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presented a positive result, pointing to a true interaction between PP1γ1 and Myc-
Pex16p. However, no interaction between Myc-Pex16p and endogenous PP1γ was 
verified (Figure 16). On the second case, we used COS-7 cells overexpressing GFP-Pex16p 
in a GFP-Trap_M® system, with negative results (Figure 17). The same experiment using a 
cross-linker also turned negative (data not shown). In addition to the pull-down assays, 
other approaches were applied to unravel whether PP1 interacts with Pex16p. GST-
tagged Pex16p expressed in bacteria was separated by SDS-PAGE, blotted to 
nitrocellulose membrane and was afterwards overlaid with purified PP1γ1. Both full 
length and cytosolic C-terminal tail versions of Pex16p gave a negative result (Figure 21). 
The interaction was also verified in yeast, mimicking the conditions of the YTH assay in 
which Pex16p was identified. Several Pex16p versions were used: full length, cytosolic C-
terminal tail and with mutated PP1-binding motifs. In all cases, we did not verify an 
interaction (Figure 19). Moreover, we also used the clone collected from the YTH screen 
and verified that it was able to self-activate the reporter genes. This raises the possibility 
of Pex16p being a false-positive. PP1α and PP1γ cellular sub-localization in mammalian 
cells was also verified and no co-localization with peroxisomes was found, both in 
Pex16p-tranfected an untransfected cells (Figure 23). 
Several aspects could have been improved in each approach individually. In the pull-down 
assays, a crosslinker could have been used in the co-IP with anti-Myc antibody in order to 
enhance the signal on co-transfected cells or pull-down endogenous PP1γ. Nonetheless, 
this was done in the GFP-Trap_M® assay with negative results. An inverse approach could 
have been tried, using PP1 as bait instead of Pex16p. However, this approach was 
rejected right at the beginning because of the multitude of PP1-binding proteins that exist 
in the cell, which could complicate the observation of a possible PP1-Pex16p interaction. 
In the GFP-Trap_M® assay, we verified that GFP-Pex16p had a considerably low binding 
rate to the beads. Increasing the amount of protein bound to the beads would raise the 
visibility of a possible interaction. However, raising even more the amount of total protein 
would be very difficult, since we verified that GFP-Pex16p-transfected cells had an 
extremely high level of death rate, obligating us to use a very high number of culture 
dishes. Actually, artefacts (such as peroxisome agglomeration) and miss-targeting of 
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overexpressed Pex16p were relatively common in Pex16p-overexpressing cells (data not 
shown) and an interaction between PP1 and Pex16p could possibly be hampered by this 
fact. Perhaps the use of expressing vectors with weaker promoters could overcome this 
issue. Both co-immunoprecipitation assays would benefit from the use of positive 
controls. Ideally, Pex16p-binding partners should have been used to verify the 
effectiveness of the pull-down. Anti-Pex3p and anti-Pex19p antibodies were being 
planned to be used for that purpose; however, temporal limitations precluded us to 
execute these controls on the co-IPs in time to be included in this dissertation. In general, 
all the experiments could have been further optimized in several parameters, such as 
buffers and incubation times or temperatures. 
Regardless of the improvements that could have been done to each approach 
individually, completely different techniques were used, recurring to an whole panoply of 
tools: mammalian/yeast/bacterial cells; native/denaturing conditions; diverse detection 
techniques, such as immunoblot and activation of reporter genes. Taken together, we 
could affirm that the putative PP1-Pex16p interaction does not occur; however, we are 
able to identify reasons for the negative results in each protein-protein interaction 
detection method that was used. For example, the overlay method was executed under 
denaturing conditions, which may hamper the interaction. On the other hand, full length 
Pex16p expression in bacteria was extremely low, which could reduce a positive signal to 
undetectable levels. PP1γ1 also did not overlay with Pex16pCT – however, this peptide 
lacks the SILK motif, which can be essential for the interaction. The same principle applies 
to the experiments in yeast: Pex16pCT does not have the transmembrane domains, which 
may prevent the full length protein to enter the nucleus and activate the reporter genes 
and justify the negative result. Pex16pCT is presumably soluble; nonetheless, the lack of 
the SILK motive could render the PP1-Pex16p complex not stable enough to activate the 
reporter genes. The overexpression of Pex16p in mammalian cells provoked, in many 
cases, the occurrence of artefacts, such as peroxisome agglomeration or miss-targeting to 
ER (data not shown). This could prevent the interaction either by altering the 
physiological conditions needed for it to occur or by sequestration of the overexpressed 
protein in inaccessible structures. In every case, a possible transient nature of the 
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putative PP1-Pex16p interaction may prevent its detection. In addition, one or more 
specific stimulus may be required for the interaction to occur, such as peroxisome 
proliferation-induction stimulus, e.g. ROS. 
Nonetheless, other approaches could be attempted. Membrane-based yeast two-hybrid 
(MYTH) is a technique based on the split-ubiquitin protein complementation assay and 
detects protein interactions directly at the membrane, thereby allowing the use of full-
length integral membrane proteins and membrane-associated proteins as baits to hunt 
for interaction partners (362). Very recently, a membrane-based two-hybrid system 
(MaMTH) was developed for mammalian cells (363). Similarly to MYTH, MaMTH allows 
the detection of protein-protein interactions of full-length integral membrane proteins 
based on the split-ubiquitin complementation assay. However, using mammalian cells, 
better in vivo mimicking conditions are achieved, as protein-protein interactions may be 
dependent on, for example, post-translational modifications to occur. Moreover, the 
system can be used to track the effect of certain stimuli or post-translational 
motifications, e.g. phosphorylation, on a given protein-protein interaction. Another 
approach could be the co-separation in a native gel. In this technique, in vitro translated 
proteins are incubated with the putative binding partners and separated in native gels. A 
shift in the protein molecular weight would indicate a positive interaction. In this 
technique radiolabeled proteins can be used, which detection is much more sensitive 
than immunoblot. For this work, in vitro translation of Pex16p was attempted, without 
success. However, this experiment needed further adjustments and/or other conditions, 
such as the presence of peroxisome-like membranes. 
Besides the verification of PP1-Pex16p interaction, other experiments were done in 
parallel to manipulate the putative interaction and verify its effect in mammalian cells. To 
achieve that, Myc-Pex16p was overexpressed in COS-7 cells and the PP1 sub-cellular 
localization was verified and compared with non-transfected cells – no differences were 
found (Figure 23). Nonetheless, Myc-Pex16p constructs carrying mutations in the RVxF 
motifs were overexpressed as well. No differences were found between cells transfected 
with Myc-Pex16p and any of the PP1BMs mutants concerning peroxisome morphology or 
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number (Figure 24 and Figure 25). This does not necessarily mean that they do not 
interact. Influencing the putative interaction may not have an effect on these parameters. 
As mentioned before, one or more specific stimuli may be required in order for the 
interaction to occur and to provoke visible differences. As Pex16p function is still unclear, 
finding those stimuli may be a challenge. One of the few facts known about Pex16p is that 
its re-introduction in Pex16p-deficient cells complements the peroxisome-lacking 
phenotype (118, 120, 350). We verified that Myc-Pex16p with mutated RVxF motifs were 
able to complement Pex16p-deficient cells, suggesting that the putative PP1-binding sites 
within Pex16p are not essential for the de novo formation of peroxisomes (Figure 26). 
Actually, the re-introduction of mutant Pex16p from the PEX16 patients with mild 
symptoms also complemented the phenotype in Pex16p-deficient cells, although the 
peroxisomes had altered morphology and number, like in patient fibroblasts (350). Recent 
advances on the study of Pex16p function (140, 141) opened new routes for future 
research on putative PP1-Pex16p interaction, guiding to possible conditions needed for 
the interaction to occur. 
In summary, our results suggest that PP1 does not interact with Pex16p and the PP1-
binding motifs seem to be irrelevant for Pex16p function, at least under the tested 
conditions. Nonetheless, two questions still need to be clarified: 1) which functions or 
motifs are being affected in PEX16 patients and 2) what are the roles of kinases and 
phosphatases that have been shown or suggested to be targeted to peroxisomes? The 
answer to the first question is primordial to further understanding the molecular 
mechanism of Pex16p function – a mysterious yet fundamental peroxin. We analyzed the 
human Pex16p sequence (accession number Q9Y5Y5) via the ELM server to search for 
possible functional domains within the C-terminus and some interesting ones were 
identified. Two of them, localized within residues 313-323, are recognized by SH3 (Src 
Homology 3) domains. SH3 domains mediate protein-protein interactions and are 
involved in several and diverse biological processes, e.g. signal transduction and organelle 
assembly. This domain is abrogated in some patients, namely the ones with sequence 
frameshifts (Figure 14). ELM also found several putative phosphorylation sites by proline-
directed kinases, e.g. MAPK, in the intraperoxisomal region of Pex16p. Curiously,  MAPK 
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phosphatase 1 (MKP1) has been found to be targeted to peroxisome in plants (302). 
Another one of these sites is the residue S288 which is next to P289, mutated to 
threonine in one of the patients (Figure 14). On one hand, the mutation P289T may avoid 
S288 putative phosphorylation because the motif is no longer recognized by the proline-
directed kinases. On the other hand, phosphorylated [ST]-P domains are recognized by 
Pin1, a peptidyl-prolyl cis/trans isomerase. This protein interconverts prolines between cis 
and trans conformations, provoking structural alterations and plays a role as post-
phosphorylation control in regulating protein function. Intriguingly, ELM did not identify 
any domain involving valine in position 252, which is deleted in one of the patients (Figure 
14). Resuming, the C-terminal tail of Pex16p seems to be an important object of study to 
understand Pex16p function which seems to have been neglected up today. Allying 
bioinformatics tools and directed mutagenesis, the Pex16p C-terminus could be 
extensively studied, which would certainly clarify Pex16p function and molecular 
mechanisms of action. 
As protein phosphorylation/dephosphorylation reactions are an ancient and ubiquitous 
mechanism for signal transduction, peroxisomes are likely not an exception. This way, it is 
urgent to identify the protein kinases and phosphatases that act on peroxisomes as well 
as their binding partners and substrates. PP1, as the most conserved eukaryotic protein 
(312) and catalyzing the majority of protein dephosphorylation events in eukaryotic cells 
(278), is certainly an unneglectable phosphatase which role on peroxisomes needs to be 
extensively studied. Indeed, its presence on peroxisomes was suggested by the large-
scale blot screen with highly purified peroxisome fractions from rat liver. Nevertheless, 
PP1 activity is regulated by binding partners that often target PP1 to certain locations 
within the cell, bringing it to the vicinity of its substrate(s). Previous data suggested that 
Pex16p could be a PP1 interacting protein, turning Pex16p into a possible player in 
peroxisomal signaling cascades. As Pex16p is an early peroxin, this putative interaction 
could have a primordial role in peroxisome biogenesis.  Although this study was not able 
to confirm the interaction, this it not a closed chapter, as many experiments and 
approaches can still be done as discussed earlier. Nevertheless, we verified that other 
peroxins represent possible PP1 interacting proteins, as they also possess PP1-binding 
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motifs. This way, other proteins are also good options in the study of the possible role for 
PP1 in the regulation of peroxisome biogenesis and/or proliferation. Interestingly, PP2A 
and MKP1 were very recently identified to be targeted to peroxisomes in Arabidopsis 
thaliana (301, 302). Nonetheless, their targeting seems to be conditioned to certain 
stimuli. MKP1 is targeted to peroxisomes only under stressful conditions. Probably not a 
coincidence, MAPK signaling is involved in the upregulation of catalase transcription and 
activity and H2O2 production under oxidative stress conditions (302, 303). Along with 
CDK1 (304), PP2A (301) and MKP1 (302) are the only kinases/phosphatases identified to 
be targeted to peroxisomes. However, this was observed in Arabidopsis thaliana and has 
been associated to the regulation of peroxisomal metabolism. The protein 
kinases/phosphatases involved in the regulation of peroxisome biogenesis and 
proliferation in mammals are completely unknown. The possible connection of Pex16p 
and/or other peroxins with PP1 is then a very important line of study to better 
understand peroxisome function in mammalian cells. 
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4.2 Regulation of Pex11pβ during peroxisome proliferation 
Protein of Pex11 family is known to control peroxisome proliferation and to regulate 
peroxisome morphology, size and number across fungi, plants and mammals (188-195). 
However, the mechanisms that regulate the function of Pex11 proteins during 
peroxisome proliferation are still obscure. It has been demonstrated in yeast, that 
Saccharomyces cerevisiae ScPex11p and Pichia pastoris PpPex11p are regulated by 
phosphorylation (220, 290). Phospho-mimicking “off” and “on” mutants either interfered 
with peroxisome division giving rise to enlarged and clustered peroxisomes (constitutively 
dephosphorylated), or resulted in hyperdivision (constitutively phosphorylated) of 
peroxisomes. Furthermore, the phosphorylation of S173 in PpPex11 also influences its 
interaction with Fis1 (290). This project aimed to contribute to an investigation on 
whether phosphorylation events contribute to the regulation of human Pex11pβ and 
consequently peroxisome proliferation, focusing on selected putative phosphorylation 
sites (Figure 27). 
 
Figure 27: Human Pex11pβ protein sequence (accession number O96011) 
Yellow and blue residues correspond to transmembrane domains and a glycine-rich region, respectively 
(211). H1, H2 and H3 – predicted amphipathic helices (191). S11 and S38 – potential conserved 
phosphorylation sites. C18, C25 and C85 – cysteine residues with a putative role in Pex11pβ conformation 
and/or dimerization. Light and dark green-shaded residues correspond to hydrophobic and very 
hydrophobic amino acids (364). 
 
On the other hand, dimerization of Pex11 has also been identified in fungi as a 
mechanism to regulate its function. Marshall and colleagues (219) suggested that ScPex11 
is inactivated by homodimerization. Moreover, one of ScPex11 cysteines was identified to 
be involved in the homodimer formation, suggesting that ScPex11 may regulate 
membrane remodeling in a redox-sensitive fashion.  Human Pex11pβ has also been 
Results 
112 
 
shown to self-interact forming homodimers (193, 211-213), controlling its activity. 
Moreover, HsPex11pβ possesses cysteine residues (Figure 27) which present as possible 
players in the dimer formation, hence this project also aimed to investigate whether 
these residues interfer with Pex11pβ-driven peroxisome proliferation. 
To further comprehend the mode of action and regulation of human Pex11pβ, its 
topology was also studied. As mentioned in the introduction of this dissertation (section 
1.3.1), the topology of Pex11 proteins varies considerably across organisms (129). All 
mammalian isoforms, including HsPex11pβ, are tightly associated with the peroxisomal 
membrane and possess two predicted membrane spanning helices with both C- and N-
termini protruding into the cytosol (177, 189, 203, 211) (Figure 28). Nonetheless, the 
intra-peroxisomal region between the two transmembrane domains facing to the 
peroxisomal matrix is still unclear, since we do not know if this region fully embeds within 
the peroxisomal matrix or if (at least parts of) it interacts with the matrix site of the 
peroxisomal membrane or even if it is buried within the membrane. Moreover, a glycine-
rich region between the transmembrane domains of HsPex11pβ was identified (Figure 27) 
and it was targeted in our studies to clarify its role in peroxisome proliferation and to 
better understand the topology of Pex11pβ. 
 
Figure 28: Pex11pβ predicted topology and 
functional domains 
Boxes represent specific regions: H1 (aa 3-8), Helix 1; 
H2 (aa 14-31), Helix 2; H3 (aa 45-75), Helix 3; TMD1 
(aa 90-110), transmembrane domain 1; TMD2 (aa 
230-255), transmembrane domain 2; Gly, glycine-
rich region (aa 159-182), dashed area corresponds to 
the epitope recognized by an anti-Pex11β antibody 
(aa 110-140) (see Table 8). Pex11pβ-induced 
peroxisomal membrane remodeling may be driven 
by the insertion of one or more amphipathic helices 
into one leaflet of the lipid bilayer.  
 
 
Another important topology aspect of Pex11p is the presence of regions located within 
the N-terminus that display amphipathic properties (Figure 27 and Figure 28). In vitro 
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studies indicated that these amphipathic helices were shown to be essential to mediate 
membrane tubulation, a property apparently conserved throughout species (191, 215). 
Thus, membrane asymmetry and bending caused by the insertion of one or more 
amphipathic helices into one leaflet of the lipid bilayer (218) seems to be the mechanism 
of Pex11p-induced peroxisomal membrane remodeling. This work aimed to complement 
and verify these findings by mutational studies of the N-terminus of HsPex11pβ in vivo. 
 
 
Figure 29: PEX11β mutants created for this study 
Residues depicted in red are the ones that were mutated. Boxes represent specific regions: H1 (aa 3-8), 
Helix 1; H2 (aa 14-31), Helix 2; H3 (aa 45-75), Helix 3; TMD1 (aa 90-110), transmembrane domain 1; TMD2 
(aa 230-255), transmembrane domain 2; Gly, glycine-rich region (aa 159-182). 
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To perform our studies towards a better understanding of Pex11pβ topology and 
regulation during peroxisome proliferation, we created several mutants. A schematic 
view of these mutants is depicted in Figure 29. To study the effect of those mutations on 
Pex11pβ function in promoting peroxisome elongation, we took advantage of the known 
effect of overexpression of wild type Pex11pβ in mammalians cells, which induces 
prominent elongation of peroxisomes, followed by division into spherical organelles over 
time (177, 179, 216). 
 
4.2.1 A glycine-rich region within Pex11pβ is dispensable for peroxisomal growth and 
division 
We observed that human Pex11pβ contains a glycine-rich region at aa positions 159-182 
(Figure 27), between the transmembrane domains and, based on several topology studies 
including from our group (211), it is exposed to the peroxisomal matrix. Curiously, this 
glycine-rich stretch is absent in Pex11pα and Pex11pγ (Supplementary Figure 2). To 
examine if this region (which also contains proline residues) is required for Pex11pβ 
function, we deleted those 30 amino acids resulting in the construct Myc-Pex11pβΔGly 
(Figure 29) and compared the effect of its expression with the wild type version, Myc-
Pex11pβ. Expression in COS-7 cells showed proper targeting to peroxisomes as revealed 
by immunofluorescence microscopy (Figure 30, D-F, J-L). However, deletion of the 
glycine-rich region had no effect on peroxisome elongation and subsequent division over 
time when compared to controls expressing wild type Myc-Pex11pβ (Figure 30, M). Our 
data demonstrate that the glycine-rich region within Pex11pβ is dispensable for the 
targeting to peroxisomes as well as membrane elongation and division. 
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Figure 30: A glycine-rich internal region specific for 
human Pex11pβ is dispensable for peroxisome 
elongation and division 
COS-7 cells were transfected by electroporation with 
Myc-Pex11pβ (A-C and G-I) and Myc-Pex11pβΔGly (D-
F and J-L), and were processed for 
immunofluorescence microscopy 6h, 12h (A-F), 24h, 
48h and 72h (G-L) after transfection using anti-Myc (A, 
D, G, J) and anti-Pex14 (B, E, H, K) antibodies. Nuclei 
were labelled with Hoechst 33258. The transfected 
cells were quantitatively evaluated for peroxisome 
morphology (M). Data are from five independent 
experiments and are presented as means ± SEM. No 
significant differences were found between the 
mutants and wild-type, for all time points. Bars, 20 
μm. 
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4.2.2 An inter transmembrane region of Pex11pβ may be buried within the 
peroxisomal membrane 
Our research group has recently published a thorough analysis of the membrane topology 
of Pex11pβ at the peroxisomal membrane (211), which confirms that it possesses two 
transmembrane domains at amino acids 90-110 and 230-255. The data also 
demonstrated that Pex11pβ is an integral membrane protein with N- and C-termini 
directed towards the cytosol and the intra-peroxisomal region between the two 
transmembrane domains facing the peroxisomal matrix. However, one cannot rigorously 
exclude that parts of this region may interact with the matrix site of the peroxisomal 
membrane, or are partially buried within the membrane. Indeed, several N- and C-
flanking amino acids of the glycine-rich region have hydrophobic properties (Figure 27). 
In the present work we have demonstrated that a glycine-rich stretch within the intra-
peroxisomal region is dispensable for the properties of Pex11pβ to promote membrane 
elongation and division of peroxisomes (section 4.2.1). Taking advantage of this fact, we 
generated a construct in which the central 10 amino acids of the glycine-rich stretch were 
substituted by the sequence EQKLISEEDL, which corresponds to a Myc tag (Figure 29). 
With this experiment, we intended to further clarify Pex11pβ topology. We transfected 
COS-7 cells with YFP-Pex11pβ-Myc(mid), which were processed for immunofluorescence 
microscopy using different permeabilization techniques and antibodies (Figure 31). To 
obtain complete and selective permeabilization of the peroxisomal membrane, methanol 
and digitonin were used, respectively. As peroxisomal markers, we used AOX, a matrix 
protein which is inaccessible to the antibody in digitonin-permeabilized cells; Pex14p and 
PMP70, membrane proteins which are accessible to the antibody in either 
permeabilization conditons. YFP-Pex11pβ-Myc(mid) co-localized with all the peroxisomal 
markers AOX (Figure 31, G-I), Pex14p (not shown) and PMP70 (not shown) in methanol-
permeabilized cells, indicating that the fusion protein was correctly targeted to 
peroxisomes. Co-localization between YFP-Pex11pβ-Myc(mid) and anti-GFP antibody in 
both methanol- and digitonin-permeabilized cells was also observed (not shown), which 
confirms the expected topology with the Pex11pβ N-terminus facing towards the cytosol. 
As also observed in a previous study from a member of our research group, anti-Pex11β 
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antibody, directed against the internal site aa 110-140, was unable to label YFP-Pex11pβ-
Myc(mid) in cells permeabilized with digitonin, confirming that this region resides in the 
intra-peroxisomal part of the fusion protein (211, 365). However, an intriguing 
observation was that the Myc epitope was accessible to the anti-Myc antibody in both full 
and selective permeabilization conditions (Figure 31, A-F). The lack of anti-AOX signal in 
digitonin-permeabilized cells confirmed that peroxisomal membrane was not 
permeabilized by this detergent (Figure 31, J-L).  
 
Figure 31: A Myc epitope inserted between the Pex11pβ transmembrane domains is accessible from the 
cytosol under selective permeabilization conditions 
COS-7 cells were transfected by PEI with YFP-Pex11pβ-Myc(mid), permeabilized with either methanol (A-C, 
G-H) or digitonin (D-F, J-L) and labelled with anti-Myc (A-F) or anti-AOX (G-L) antibodies. Nuclei were 
labelled with Hoechst 33258. Bars, 20 μm. Panel M, schematic representation of the YFP fusion protein YFP-
Pex11pβ-Myc(mid). YFP, yellow fluorescent protein; H1, helix 1; H2, helix 2; H3, helix 3; TMD1, 
transmembrane domain 1; Myc, Myc tag; TMD2, transmembrane domain 2; dashed area, anti-Pex11pβ 
epitope. 
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Although the Myc tag could influence the three-dimensional structure of Pex11pβ and 
impair a proper insertion into the membrane, this finding may suggest that a part or the 
entire internal region between the transmembrane domains is buried within the 
membrane bilayer (Figure 32). As a matter of fact, excluding the glycine-rich stretch, the 
inter-transmembrane domain region is as rich in hydrophobic residues as the 
transmembrane domains and the amphipathic helices (Figure 27), possibly allowing this 
region (or a portion of it) to bury within the lipid bilayer. 
 
Figure 32: Predicted Pex11pβ topology based of the 
experiments with YFP-Pex11pβ-Myc(mid) 
Boxes represent specific regions: H1 (aa 3-8), Helix 1; 
H2 (aa 14-31), Helix 2; H3 (aa 45-75), Helix 3; TMD1 
(aa 90-110), transmembrane domain 1; TMD2 (aa 
230-255), transmembrane domain 2; Myc, Myc tag 
added substituting the middle 10 amino acids from 
the glycine-rich region (aa 159-182, blue box), dashed 
area corresponds to the epitope recognized by an 
anti-Pex11β antibody (aa 110-140). Pex11pβ-induced 
peroxisomal membrane remodeling may be driven by 
the insertion of one or more amphipathic helices into 
one leaflet of the lipid bilayer. 
 
 
4.2.3 Serine residues S11 and S38 are not involved in the regulation of Pex11pβ by 
putative phosphorylation 
The information on the regulation mechanisms of Pex11 proteins is still very scarce. The 
emergence of evidences pointing to phosphorylation events as one of those mechanisms 
in yeast (220, 290) elevated the need to investigate this matter in human cells, as 
Pex11pβ has a crucial role in peroxisome proliferation, with impacts on health (48, 49, 
51). To identify potential phosphorylation sites in human Pex11pβ, a member of our 
research group performed an in silico analysis using various prediction tools that either 
calculate putative phosphorylation sites within the protein or screen for potential kinase 
binding sites. The results were combined with a homology screen of various Pex11pβ 
protein sequences examined for conservation of putative phosphorylation sites. Several 
conserved sites were identified at positions S11, S38, S70, S154, S160, S168, and T178 
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within the human protein, which showed high probability for possible phosphorylation 
(Supplementary Figure 3) (211). 
In this project, we focused our study on residues S11 and S38, which are present in the 
cytosolic portion and are thus potentially accessible to cytosolic kinases. Individual point 
mutations were generated by site-directed mutagenesis. We converted the respective 
serines to alanines to block putative phosphorylation, resulting in the constructs 
Pex11pβS11A-Myc and Pex11pβS38A-Myc (Figure 29). Furthermore, to generate phospho-
mimicking (constitutively phosphorylated) versions we mutated the sequences encoding 
S11 or S38 to aspartate, resulting in the constructs Pex11pβS11D-Myc and Pex11pβS38D-Myc 
(Figure 29). The wild type and mutant Pex11pβ versions were overexpressed in COS-7 
cells and alterations of peroxisome morphology were analyzed at different time points by 
immunofluorescence microscopy using anti-Myc and anti-Pex14 antibodies (Figure 33). As 
expected, wild type Pex11pβ-Myc induces a prominent elongation of peroxisomes which 
is followed by division into spherical organelles over time (Figure 33, A1-2). A similar 
pattern of morphological alterations was observed in all generated mutants. No enlarged 
or otherwise altered morphologies were detected and division proceeded normally over 
time for all mutants. Unlike the observations in fungi (220, 290), neither phospho-off 
mutants (S11A and S38A) promotes hypertubulation nor phospho-on mutants (S11D and 
S38D) promotes hyperdivision. These findings indicate that modifications of S11 and S38 
have no impact on peroxisome elongation or division, but do not exclude that other 
putative phosphorylation sites within Pex11pβ may modulate its activity. Parallel work 
performed by another member of our research group indicated that, under the 
experimental conditions applied so far (e.g. by phospho-labelling), human Pex11pβ is 
presumably not phosphorylated (365). 
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Figure 33: Phospho-mimicking mutants of Pex11pβ have no effect on peroxisome elongation and division 
COS-7 cells were transfected by electroporation with Pex11pβ-Myc (A), Pex11pβ
S11A
-Myc (B), Pex11pβ
S11D
-
Myc (C), Pex11pβ
S38A
-Myc (D), Pex11pβ
S38D
-Myc (E). Cells were fixed after 24h (A1-E1), 48h and 72h (A2-E2), 
processed for immunofluorescence and labelled with anti-Myc (green) and anti-Pex14 (red) antibodies. 
Nuclei were labelled with Hoechst 33258. The transfected cells were quantitatively evaluated for 
peroxisome morphology (F). Data are from three independent experiments and are presented as means ± 
SEM. No significant differences were found between the mutants and wild-type, for all time-points. Bars, 20 
μm. 
 
 
4.2.4 The predicted amphipathic helix 2 within the first 40 N-terminal amino acids of 
Pex11pβ is required to elongate the peroxisomal membrane 
Pex11 proteins possess conserved amphipathic regions which are supposed to play 
important roles in membrane remodeling and peroxisome proliferation (191). Indeed, the 
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N-terminal 80 amino acids of Pex11pβ, containing three potential α-helices, have been 
shown to be indispensable for peroxisome proliferation activity (213). Helix 1 is only 
composed of 6 residues, whereas Helix 2 and Helix 3 display larger amphipathic stretches 
with Helix 3 being the largest one (Figure 27). Opalinski and colleagues (191) 
demonstrated that Helix 3 is able to tubulate membranes in vitro and this is conserved 
among species, as it was demonstrated for several fungal Pex11 proteins and for human 
Pex11pα. To study the potential role of the helices in the regulation of Pex11pβ in vivo, 
we generated N-terminally truncated versions (Pex11pβΔN40-Myc, Pex11pβΔN60-Myc, 
Pex11pβΔ70-Myc, Figure 29) and analyzed their effect on peroxisome morphology 
compared to the expression of Pex11pβ-Myc (Figure 34). Upon expression in COS-7 cells, 
all truncated fusion proteins localized to peroxisomes, as shown by co-localization with 
the peroxisomal marker PMP70. Interestingly, cells expressing the truncated versions did 
not exhibit a prominent elongation of peroxisomes (Figure 34, M). This is in contrast to 
the expression of full-length Pex11pβ-Myc, which typically induced a significant 
membrane elongation. Whereas the ΔN60 and ΔN70 truncations remove all helices, the 
ΔN40 truncation leaves Helix 3 intact (Figure 29). This indicates that although peptides 
matching Helix 3 are capable of elongating liposomal structures in vitro, also Helix 2 (and 
possibly region H1) is required for peroxisome elongation in living cells. 
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Figure 34: Intact first 40 N-terminal amino acids of 
Pex11pβ are required to elongate the peroxisomal 
membrane 
COS-7 cells were transfected by PEI with Pex11pβ-Myc 
(A-C) and the N-terminal deletions Pex11pβΔN40-Myc 
(D-F), Pex11pβΔN60-Myc (G-I) and Pex11pβΔ70-Myc 
(J-L). Cells were processed for immunofluorescence 
microscopy after 24h using anti-Myc (A, D, G, J) and 
anti-PMP70 (B, E, H, K) antibodies. Nuclei were 
labelled with Hoechst 33258. The transfected cells 
were quantitatively evaluated for peroxisome 
morphology (M). Data are from three independent 
experiments and are presented as means ± SEM (** 
p<0,01, compared to wild-type). Bars, 20 μm. 
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Interestingly, a parallel study from our research group confirmed the importance of Helix 
2 by mutating the alanine at position 21 into a proline, which breaks the helical structure 
of region H2. Similarly to the N-terminally truncated versions, the expression of this 
mutant (Pex11pβ-MycA21P) did not result in prominent peroxisome elongation (211). Our 
group also studied the effect of the truncation of the first 40 amino acids and the A21P 
mutation on the dimer formation capacity of Pex11pβ. Interestingly, while Pex11pβ-Myc 
was able to form dimers, Pex11pβΔN40-Myc and Pex11pβ-MycA21P were unable to do so 
(211). These findings strongly support that the Helix 2 within the first 40 amino acids of 
Pex11pβ participates in homodimer formation.  
 
4.2.5 Pex11pβ-mediated peroxisomal elongation do not rely solely on the N-terminal 
region 
Unlike the studies performed in vitro (191), we have demonstrated that Helix 3 is not 
sufficient to induce prominent peroxisome elongation (section 4.2.4). However, Opalinski 
and colleagues (191) also reported that incubation of small unilamellar vesicles with 
bacterial lysates expressing the entire soluble N-terminal domain of PcPex11p also 
resulted in membrane tubulation. To verify if this in vivo and with human Pex11pβ, we 
generated a fusion protein containing the N-terminal domain of HsPex11pβ (aa 1-93) and 
the C-terminally located transmembrane domain of rat ACBD5 (aa 471-506) (Figure 29). 
ACBD5 (acyl-CoA-binding domain-containing protein 5) was chosen because it is a tail-
anchored protein which is exclusively targeted to peroxisomes in mammalian cells and 
contains one transmembrane domain (348). 
We verified that this chimeric protein (named Myc-Pex11pβ-ACBD5) was targeted to 
peroxisomes as confirmed by its co-localization with PMP70. However, unlike with Myc-
Pex11pβ, cells transfected with Myc-Pex11pβ-ACBD5 were unable to elongate 
peroxisomes (Figure 35). We suggest that the predicted amphipathic helices alone, even 
within a peptide correctly targeted to peroxisomes, are not sufficient to elongate 
peroxisomes in vivo.  
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4.2.6 The N-terminal cysteines C18, C25 and C85 are not essential for membrane 
elongation 
Phosphorylation/dephosphorylation is the most prominent post-translational 
modification used as regulation mechanism. Nonetheless, versatile redox modifications of 
key cysteine residues are stepping forward as a non-negligible distinct class of 
modifications which can often work in concert with other regulation mechanisms (366). 
Among the twenty common amino acids in proteins, cysteine is one of the two least 
Figure 35: Pex11pβ-mediated peroxisomal elongation 
do no rely solely on the N-terminal region 
COS-7 cells were transfected by PEI with Myc-Pex11pβ (A-C) or 
Myc-Pex11pβ-ACBD5 (D-F). Cells were processed for 
immunofluorescence microscopy after 24h using anti-Myc (A, 
D) and anti-PMP70 (B, E) antibodies. Nuclei were labelled with 
Hoechst 33258. The transfected cells were quantitatively 
evaluated for peroxisome morphology (G). Data are from 
three independent experiments and are presented as means ± 
SEM (*** p<0,001, compared to wild-type). Bars, 20 μm. 
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abundant yet the most conserved residue that is frequently present in functionally 
important sites (367). Cysteine residues serve numerous functions, such as protein 
activity regulation and structure determination. Regulatory cysteines modulate protein 
activity by changing their redox state, which may involve reversible intra- and 
intermolecular disulfide bonds. Structural cysteines participate in protein structure and 
folding through formation of stable disulfide bonds (367).  
A redox-sensitive homodimerization of ScPex11p regulated by a key cysteine has been 
proposed by Marshall and colleagues (219) some time ago. Given that, we considered 
that a study on human Pex11pβ cysteines and their importance for Pex11pβ function 
could bring important clues towards understanding how Pex11pβ is regulated during 
peroxisome proliferation. Human Pex11pβ possesses eight cysteines, with C18, C25 and 
C85 localized in the cytosolic N-terminal region (Figure 27) and considered a priority for 
this study. To analyze whether those cytosolic cysteines contribute to Pex11pβ function 
of promoting peroxisome proliferation, we generated several mutants: single 
(Pex11pβC18S-Myc, Pex11pβC25S-Myc and Pex11pβC85S-Myc) was well as double 
(Pex11pβC18S_C25S-Myc) and triple mutants (Pex11pβC18S_C25S_C85S-Myc). Upon expression in 
COS-7 cells, all versions were properly targeted to peroxisomes as demonstrated by 
immunofluorescence microscopy using anti-Myc and anti-Pex14 antibodies (single 
mutants not shown) (Figure 36, A-I). When compared to wild-type Pex11pβ-Myc, the 
triple and double mutations did not interfere with the property of Pex11pβ to elongate 
peroxisomal membranes as confirmed by statistical evaluation (Figure 36, J). Similar 
results were obtained with the single mutants (not shown). These findings indicate that 
the three cysteines within the N-terminus of Pex11pβ are not essential for membrane 
elongation, as they probably do not contribute to its structure by the formation of 
disulfide bonds. 
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Figure 36: Mutations on N-terminal cysteines within 
Pex11pβ do not affect peroxisome membrane 
elongation 
Fig x. Mutations on N-terminal cysteines within 
Pex11pβ do not affect peroxisome membrane 
elongation. COS-7 cells were transfected by PEI with 
Pex11pβ-Myc (A-C) Pex11pβ
C18S_C25S
-Myc (D-F) and 
Pex11pβ
C18S_C25S_C85S
-Myc (G-I), and were processed for 
immunofluorescence microscopy proximately 30h 
after transfection using anti-Myc (A, D, G) and anti-
Pex14 (B, E, H) antibodies. Nuclei were labelled with 
Hoechst 33258. The transfected cells were 
quantitatively evaluated for peroxisome morphology 
(J). Data are from three independent experiments and 
are presented as means ± SEM. No significant 
differences were found between the mutants and 
wild-type. Bars, 20 μm. 
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4.2.7 Discussion 
Pex11 proteins in yeast, plant and animal cells contribute to the formation of 
peroxisomes and regulation of their abundance (129, 194, 197, 368). Mammalian 
Pex11pβ has been shown to elongate and proliferate peroxisomes in conjunction with the 
peroxisomal division machinery and has been proposed to possess membrane 
remodeling/deforming properties (191, 215). Its loss is embryonically lethal in knockout 
mice (205), but on the other hand, in humans, several patients with milder clinical 
phenotypes but several disabilities have been reported (49, 51, 350). Thus, there is 
currently great interest in the molecular and biochemical characterization of Pex11 
proteins, their mode of action and regulation of peroxisome abundance. 
Within this project, we carried out a series of experiments that complemented previous 
knowledge as well as work from other members of our research group towards a better 
understanding of the mechanisms involved in the regulation of Pex11pβ function as well 
as its mode of action. Regardless the diverse topologies proposed for Pex11 proteins in 
different organisms (190, 219), studies from our group clearly confirmed the previous 
evidences based on in silico analysis and differential permeabilization experiments that 
pointed to human Pex11pβ as being a transmembrane protein with two membrane 
spanning domains and with both N- and C-termini facing the cytosol (177, 189, 211). 
Nonetheless, it was unclear if the region between the transmembrane domains is 
embedded in or interacting with the peroxisomal membrane or, by the opposite, it fully 
stands out from the membrane and reaches into the peroxisomal matrix. Within this 
region, we observed a glycine-rich stretch of thirty amino acids (which also contains three 
proline residues) that is absent in Pex11pα and Pex11pγ. This unique feature led us to 
wonder if this particular region had a role in the function of Pex11pβ to promote 
membrane elongation and division of peroxisomes. However, deletion of the entire 
glycine-rich stretch revealed it to be dispensable for those functions of Pex11pβ (Figure 
30). Using this information, we designed an experiment that could help us to clarify the 
topology of the intraperoxisomal region of Pex11pβ – we substituted the middle ten 
amino acids from the glycine-rich area by a Myc tag and performed a selective 
permeabilization study. That study revealed that the Myc tag is exposed to the cytosol 
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and not to the peroxisomal matrix (Figure 31). Based on this finding, we suggest that the 
area between the transmembrane domains may be at least partially buried into the lipid 
bilayer (Figure 32). The inter-transmembrane region flanking the Gly-rich stretch is very 
rich in hydrophobic residues (Figure 27), which could allow that region to interact to or 
even embed into the membrane. This can possibly help to explain why Pex11pβ is 
extracted from peroxisomal membrane by postfixation Triton X-100 treatment (211, 369), 
since Pex11pβ may not completely cross peroxisomal membrane. 
The insertion of the Myc tag could significantly alter the structure of Pex11pβ, hampering 
a proper insertion in the membrane and, consequently, alter Pex11pβ function. 
Overexpression of YFP-Pex11pβ is known to promote peroxisome elongation and division 
(216). Analyzing the differentially permeabilized cells, one cannot conclude that YFP-
Pex11pβ-Myc(mid) mutant had the same effect. However, to undoubtedly clarify that, a 
time-course experiment comparing with wild type YFP-Pex11pβ could be done. 
This study also revealed that S11 and S38 are not involved in the regulation of Pex11pβ by 
putative phosphorylation. This is consistent with the fact that Pex11pβ has not been 
demonstrated to be phosphorylated so far. Although Pex11 proteins from fungi were 
shown to be phosphorylated (220, 290, 370), the phosphorylation sites are not conserved 
among organisms and, in Hansenula polymorpha, phosphorylation do not regulate 
Pex11p localization and function (370). It is possible that other mammalian Pex11 
isoforms, i.e. Pex11pα and Pex11pγ) are phosphorylated and/or other diverse regulatory 
mechanisms have evolved. Nonetheless, the potential phosphorylation sites of human 
Pex11pβ have not been exhaustively studied. Indeed, we have chosen S11 and S38 
residues because those localize in the cytosolic N-terminal part of Pex11pβ and because 
they localize in the first 40 amino acids that we had already observed to be essential for 
Pex11pβ function. Internally localized putative phosphorylated residues were not 
selected for this study due to the fact that no kinases or phosphatases have been 
localized in the matrix of mammalian peroxisomes so far. However, the topology studies 
with the internally tagged YFP-Pex11pβ-Myc(mid) raised the possibility that the glycine-
rich are may be exposed to the cytosol instead of to the matrix. Actually, the potential 
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phosphorylation targets S160, S168 and T178 localize within the glycine-rich area, turning 
them into interesting targets for further studies on Pex11pβ putative phosphorylation. 
Interestingly, YFP-Pex11pβ-Myc(mid) protein does not possess the S168 residue and, as 
mentioned before, this protein seems to be unable to promote peroxisome proliferation 
(although more extensive studies are needed). A possible malfunction of this protein 
could be due to the absence of the possible phosphorylation target S168. 
The amphipathic Helix 3 of Pex11 proteins from several fungal species and human 
(Pex11pα) was suggested to play the central role in membrane elongation as it was able 
to elongate small unilamellar vesicles in vitro (191). However, no evidences for that was 
obtained in vivo mammalian cells. Given that and to further characterize human Pex11pβ, 
we made N-terminally truncated versions that eliminated the first 40 (ΔN40), 60 (ΔN60) 
and 70 (ΔN70) amino acids. In all cases, the loss of those amino acids abolished 
membrane elongation of peroxisomes (Figure 34). Whereas the ΔN60 and ΔN70 
truncations disrupt all helices, the ΔN40 truncation leaves Helix 3 intact (Figure 29). This 
means that Helix 2 within the first 40 amino acids is crucial for membrane elongation. This 
assumption was further supported by the work of other member of our team 
demonstrating that breaking the helical structure of Helix 2 by mutating alanine at 
position 21 into a proline (A21P) was sufficient to inhibit peroxisome elongation (211). 
Moreover, ΔN40 and A21P mutant versions of Pex11pβ were demonstrated to prevent 
homodimer formation which is presumed to be a prerequisite for membrane retention 
and elongation of the peroxisomal membrane (211, 213). Marshall and colleagues (219) 
suggest that, by the contrary, the active form of ScPex11p is the monomeric one. So, 
further studies are needed to undoubtedly verify which form is active in human Pex11pβ 
as dimerization/oligomerization seems to be an activity regulation mechanism for this 
peroxin. 
Another important protein activity regulatory mechanism is the versatile modification of 
key cysteine residues. These residues may either contribute to protein structure by 
establishment of stable inter- and intramolecular disulfide bonds. On the other hand, 
reversible bonds may be established in response to redox state alterations as cysteine 
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residues possess a thiol group (366). In this study we demonstrated that the N-terminally 
located cysteines C18, C25 and C85 are not essential for peroxisome membrane 
elongation (Figure 36). Given that Pex11pβ self-interactions in co-immunoprecipitation 
studies are lost in the presence of Triton X-100 (212), it is unlikely that these residues 
contribute to dimer formation by covalent bonds, which is in line with our results on 
mutational studies on the aforementioned cysteine residues. Nonetheless, it is possible 
that transient, intra- or intermolecular disulfide bridges occur which may change or 
stabilize Pex11pβ structure or protein interactions later on during the division process. To 
clarify that, a time-course experiment with these mutants could be done. Importantly, 
being peroxisomes a shelter for numerous ROS producing/degrading metabolic reactions, 
a redox-sensitive proliferation control system would make much sense. Moreover, 
peroxisome division control has been suggested to be regulated by a signal from inside 
the peroxisome in Yarrowia lipolytica: Guo and colleagues (146, 371) proposed that, in 
mature peroxisomes, an AOx pool binds to Pex16p, cancelling its inhibitory effect on 
peroxisome division. Now, a proliferation-favorable redox-state within peroxisomes could 
be sensed by Pex11pβ via its internal cysteine residues, namely C153 and C216, which 
localize in the inter-transmembrane domains region (Figure 27). Redox-state sensing by 
these cysteines could provoke conformational alterations on Pex11pβ signaling for 
peroxisome proliferation. Thus, cysteines C153 and C216 may represent very interesting 
targets for future investigations on human Pex11pβ activity regulation. 
Pex11p proteins were known to act in concert with the tail-anchored proteins Fis1 and 
Mff for the recruitment of DLP1 and promote final peroxisome scission after elongation 
and constriction (214). However, a very recent study revealed that both yeast and 
mammalian Pex11p/Pex11pβ interact directly with Dnm1/Drp1 (DLP1 yeast and 
mammalian homologs) (222). Moreover, Pex11p/Pex11pβ was shown to function as a 
GTPase-activating protein (GAP) for Dnm1/Drp1. GAPs have the capability to increase the 
hydrolysis rate of GTP into GDP. DLP1 forms oligomeric ring-like structures around 
constricted sites on organelle membranes and, as a large GTPase, its scission activity is 
powered by GTP hydrolysis (222). Given this, Pex11pβ assumes nowadays a new role in 
peroxisome proliferation: that of a direct player in membrane scission. This finding re-
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enforces the need to deeply study the mechanisms of action and, very importantly, the 
mechanisms of regulation of Pex11pβ as it seems to be a crucial player in virtually the 
whole peroxisome proliferation process, from elongation to constriction and final 
scission.  
The recent finding of seven more PEX11B patients (48, 49), which present atypical 
symptoms for a peroxisome biogenesis disorder, brought the urgency of a wider 
comprehension of this peroxin to the front. The peroxisomes from these patients are 
import-competent, although enlarged and undivided. In the case of the patient with a 
newborn lethal mutation in the DLP1 gene, the fibroblasts presented elongated and 
constricted peroxisomes as well as hypertubulated mitochondria. These cases alert for 
the necessity to be aware of the importance of peroxisome (and mitochondria) 
morphology in health and disease, as peroxisomes have been demonstrated to be 
involved in several pathological conditions such as Alzheimer’s disease (55), diabetes (58, 
59) and cancer (64). 
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5 General discussion and future perspectives 
Since the discovery of peroxisomes around 60 years ago (1) that evidences of their pivotal 
role in human health and development have increased, as several devastating disorders 
have been found to be caused by impaired peroxisomal activity or defective peroxisome 
biogenesis (43). Besides, peroxisomes have also been implicated in several non-inherited 
pathological conditions, such as Alzheimer’s disease, diabetes, cancer and viral infection 
(reviewed in (276)). Peroxisomes are involved in numerous metabolic pathways, which 
implies a cooperation with several other subcellular compartments including 
mitochondria, ER, lipid droplets or lysosomes (242, 372, 373). They also constitute an 
important intracellular platform for redox-, lipid-, inflammatory- and antiviral signaling 
(69, 374, 375). Peroxisomes are also dynamic organelles, having the capacity to 
proliferate in response to environmental stimuli and being degraded to maintain default 
numbers when stimuli dissipate. This way, control of peroxisome number must be 
achieved by tight regulation of peroxisome biogenesis, proliferation and degradation (11, 
72, 376). Being protein reversible phosphorylation a major signal transduction mechanism 
in eukaryotic cells (278), we focused our studies in the role of such events in peroxisome 
dynamics, focusing on two key peroxins, Pex16p and Pex11pβ. 
Pex16p is known to be one of the three early peroxins, as its absence provokes the 
absolute inexistence of peroxisomal structures (118, 120). The exact function of Pex16p in 
human cells is still a matter of debate, but evidences have been pointing into a role in 
PMP reception during the early stages of the de novo peroxisome formation at the ER, as 
well as in mature peroxisomes (140, 141, 143, 144). This property appears to be 
conserved at least between mammals and plants (141). On the other hand, Pex11pβ 
belongs to a family of proteins known to control peroxisome proliferation and to regulate 
peroxisome morphology, size and number across fungi, plants and mammals (188, 190-
195). Pex16p and Pex11pβ seem to operate in different stages of peroxisome dynamics 
but they have one thing in common: obscure regulation mechanisms.  
Concerning Pex16p, our project followed the clues that pointed to Pex16p as a putative 
PP1-interacting protein (PIP): Pex16p harbours three putative PP1-binding motifs and it 
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was identified in a yeast two-hybrid screen with PP1. Until now, Akap11 (294) and 
Limkain-b1 (298) are the only evidences of protein kinases/phosphatases or its regulators 
at mammalian peroxisomes. Moreover, PP1 is one of the most abundant serine/threonine 
phosphatases which, together with PP2A, accounts for more than 90% of the protein 
phosphatase activity in eukaryotes (278) and it relies on complex formation with PIPs for 
substrate specificity and binding (313). As a putative PIP, Pex16p presented as a link 
between cell signaling cascades and peroxisome biogenesis as it could bring PP1 into the 
vicinity of dephosphorylation substrates on the peroxisome. Despite our efforts, we could 
not verify the interaction. Several technical barriers stickled our experiments, such as the 
transmembrane topology of Pex16p which, for example, may have hampered its 
expression in bacteria or the activation of reporter genes in the yeast two-hybrid assays. 
In addition, the results of in vitro assays, such as protein membrane overlay, could have 
been affected by denaturing conditions. Moreover, a possible transient nature of this 
putative interaction may have restrained its verification by some methods, like subcellular 
co-localization and co-immunoprecipitation. As previously discussed, several other 
approaches could be used to verify the putative PP1-Pex16p interaction. However, we 
highlight mammalian-membrane two-hybrid assay (MaMTH) as it presents as the best 
native conditions-mimicking for membrane protein-protein interactions (363). This 
technology was recently developed and it is a split ubiquitin-based method, similar to the 
one that already existed for yeast (362). Being a method that uses the activation of 
reporter genes instead of a direct detection of the protein-protein interaction, it is ideal 
for verification of transient interactions. Moreover, it doesn’t depend on the direct 
binding of the protein-protein complex with the nuclear DNA to activate the reporter 
genes (as in the yeast two-hybrid system we used); instead, a membrane bait protein is 
tagged with the C-terminal half of ubiquitin and a chimeric transcription factor, and a 
cytosolic or membrane-bound prey is tagged with the N-terminal half of ubiquitin. Upon 
interaction of bait and prey, the split halves form pseudoubiquitin, which is recognized by 
cytosolic deubiquitination enzymes, resulting in the cleavage of the transcription factor 
and expression of a reporter gene (363). Finally, since the system works in mammalian 
cells, the proteins on study would be as close to the natural environment as possible. This 
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system even allows the tracking of the effect of post-translational modifications (e.g. 
phosphorylation) or stimuli (e.g. ROS) on the interaction (363). Given all this, we think 
that this could be a very interesting method to further verify and manipulate PP1-Pex16p 
putative interaction. Moreover, the method could also be an efficient, fast and cost 
effective method to search for PP1 interactors among other peroxins, primarily the ones 
that revealed to harbor PP1-binding motifs as well (e.g. Pex3p and Pex10p). A search for 
PP1-binding motifs in the proteins of the peroxisome fission machinery revealed that the 
ubiquitin-conjugating enzyme that ubiquitinates Pex5p during the receptor-recycling step 
of matrix protein import (UbcH5a/b/c) (105) also harbors two PP1-binding motifs. Pex14p 
and Pex15p, other members of the matrix import machinery, have been demonstrated to 
be phosphorylated, although the role of this post-translational modification in those 
peroxins is still unclear. Nonetheless, the possibility of UbcH5a/b/c to function as a 
regulator subunit of a PP1 holoenzyme in the vicinity of Pex14p and Pex15p is a very 
interesting matter to be further studied. On the other hand, some PIPs are PP1 substrates 
themselves and their controlled dephosphorylation serves a regulatory function (278), so 
that it would also be interesting to search for potential phosphorylated residues on 
Pex16p (and the other potential peroxisomal PIPs). 
The few studies published so far demonstrating the presence of kinases or phosphatases 
in peroxisomes were carried out in Arabidopsis thaliana (PP2A, MKP1 and CPK1) (300-
302, 304). Being phosphorylation a major regulation and signal transduction mechanism, 
it is urgent to intensify the studies on that matter also in mammalian peroxisomes. 
Indeed, PP1, as well as other kinases and phosphatases (e.g. MKK6 and PP2A) were 
identified in a large scale blot screen in highly purified rat peroxisome fractions. This 
result, not only supported a putative role for PP1 in peroxisomes as it opened new routes 
for further investigations on this field. As a matter of fact, the role of some of those 
kinases and phosphatases on mammalian peroxisomes is being currently investigated by 
other members of our research group.  
Another issue that urges to be explored is whether functional domains are present in the 
C-terminus of Pex16p and what is their contribution to the function of this early peroxin. 
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All PEX16 patients (some with Zellweger syndrome, others with milder phenotypes) 
described up today had mutations that somehow affected the C-terminus of the protein 
(118, 349-351). Nonetheless, none of the mutations directly affected any of the known 
Pex16p functional domains, such as the peroxisome targeting- and the PMP recruitment 
domains (120, 141, 152, 352), which localize in the cytosolic N-terminus. An in silico 
analysis of human Pex16p sequence revealed several putative functional domains, such as 
potentially phosphorylated residues. The clarification of these issues is of primordial 
importance for a full comprehension of Pex16p function and mechanisms of action and 
regulation, which would consequently enlighten us concerning peroxisome biogenesis 
process and regulation.  
In addition to a putative phosphatase regulator (Pex16p), our study also addressed a 
potentially phosphorylated peroxin – Pex11pβ, which is involved in proliferation of 
peroxisomes by membrane remodeling (194) and as a GTPase-activating protein for DLP1 
(222). Nonetheless, its regulation mechanisms remain unclear. While Pex11p proteins 
have been revealed to be regulated by phosphorylation in fungi (220, 290), that has not 
been verified in human Pex11pβ so far. Our studies revealed that serines S11 and S38 are 
not involved in the regulation of Pex11pβ by phosphorylation. However, more exhaustive 
studies are needed to be done, as other residues may have that function. Another aspect 
regarding regulation mechanisms that urges to be extensively analyzed is the capacity of 
Pex11pβ to form dimeric/oligomeric structures (211, 213). Studies from our research 
group suggest that homodimerization of Pex11pβ is a pre-requisite for peroxisomal 
membrane elongation and that amphipathic helix 2 is needed to the self-interaction 
(211). However, this subject is still open for discussion. Using the fact that monomeric 
and dimeric forms of Pex11pβ are extracted from post-fixated peroxisomal membranes 
by Triton X-100 detergent (211), a time-course experiment at, for instance, 24 h, 48 h, 
and 72 h after transfection could elucidate us about which form is predominant in each 
phase of peroxisome proliferation. 
Another important regulation mechanism to be explored in Pex11pβ is possible 
modifications by key cysteines. Cysteines are recognized for having the capacity to 
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establish permanent and transient disulfide bridges that contribute to the protein 
structure and inter-molecular interactions. Moreover, transient conformational changes 
conducted by cysteine residues are often driven by redox-state alterations in protein’s 
environment (366). Given that one of the multiple functions of peroxisomes is peroxide 
and ROS metabolism (12), together with the fact that oxidative stress has been shown to 
induce pronounced peroxisome elongation in a human cell line (377), exhaustive studies 
on the role of Pex11pβ cysteines is a must. Our results suggest that cysteines C18, C25 
and C85, which are localized in the N-terminal region of human Pex11pβ, are not relevant 
for the Pex11pβ-induced peroxisome elongation. However, a time-course experiment 
would clarify if those residues have a role on later proliferation stages, such as 
constriction or fission. Moreover, other Pex11pβ cysteines may also be interesting to 
study, namely the ones that localize in the region between the transmembrane domains. 
In addition, a possible role of these cysteines could only be detectable under redox-state 
destabilizing conditions. So that we suggest that studies such as the ones conducted by 
Schrader and colleagues (377) are repeated using cells expressing cysteine-mutated 
Pex11pβ. 
Several studies have addressed the cytosolic N-terminal region of Pex11 proteins (191, 
211). However, the area in between the transmembrane domains is still a mystery. The 
apparently dispensable glycine-rich stretch localized in this region rises an important 
question: why does it occur in Pex11pβ isoform and not in Pex11pα or Pex11pγ? Does it 
traduce a particular role of Pex11pβ isoform? Is it evolutionarily relevant? An in silico 
analysis of Pex11p homologs in other species is needed to understand the meaning of the 
presence of such an exceptional amino acid stretch in human Pex11pβ. That way, new 
experiments could be designed to figure out the function of this domain. Furthermore, 
our studies have pointed to the necessity to put efforts on the definition of the topology 
of the inter-transmembrane domains area, given that it may not be fully embedded on 
peroxisomal matrix as assumed up to nowadays. The clarification of the exact topology of 
this area – matrix and/or membrane embedded – is very important because it influences 
the putative role of key amino acids (e.g. potentially phosphorylated residues and 
cysteines). 
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The understanding of the mechanisms that regulate peroxisome biogenesis and 
proliferation is extremely valuable to help to comprehend certain pathological processes 
and possibly contribute for better disease diagnostics and treatment. As an example, 
given that peroxisomes represent one of the first defense lines against Aβ(and other 
neurodegenerative conditions)-induced  oxidative stress (56, 378, 379), manipulating 
peroxisome proliferation could eventually be a treatment approach in early-stage 
patients. Hence, the research of such regulation mechanisms is off extreme importance, 
since it is still an underexplored field and it has serious repercussions on human health 
and disease. 
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Supplementary Figure 1: Ubiquitin-conugated 
enzymes E2 UbcH5a/b/c have PP1-binding motifs 
The sequences were collected from UniProtKB 
database and loaded in the ScanProsite program as 
well as the PP1-binding motifs canonical sequences 
listed on Table 5. Green triangles point matches with 
RVxF motifs. Bar, 25 amino acids. For more detailed 
information, such as sequences and position of the 
matches within the proteins see Supplementary Table 
2. 
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Supplementary Table 1: Human peroxins and PP1-binding motifs 
Peroxin 
Accession 
number 
FASTA sequence 
PP1-binding motifs 
(aa x–y) 
Pex1p O43933 
>sp|O43933|PEX1_HUMAN Peroxisome biogenesis factor 1 OS=Homo 
sapiens GN=PEX1 PE=1 SV=1 
MWGSDRLAGAGGGGAAVTVAFTNARDCFLHLPRRLVAQLHLLQNQAIEVVWSHQPAFLSW 
VEGRHFSDQGENVAEINRQVGQKLGLSNGGQVFLKPCSHVVSCQQVEVEPLSADDWEILE 
LHAVSLEQHLLDQIRIVFPKAIFPVWVDQQTYIFIQIVALIPAASYGRLETDTKLLIQPK 
TRRAKENTFSKADAEYKKLHSYGRDQKGMMKELQTKQLQSNTVGITESNENESEIPVDSS 
SVASLWTMIGSIFSFQSEKKQETSWGLTEINAFKNMQSKVVPLDNIFRVCKSQPPSIYNA 
SATSVFHKHCAIHVFPWDQEYFDVEPSFTVTYGKLVKLLSPKQQQSKTKQNVLSPEKEKQ 
MSEPLDQKKIRSDHNEEDEKACVLQVVWNGLEELNNAIKYTKNVEVLHLGKVWIPDDLRK 
RLNIEMHAVVRITPVEVTPKIPRSLKLQPRENLPKDISEEDIKTVFYSWLQQSTTTMLPL 
VISEEEFIKLETKDGLKEFSLSIVHSWEKEKDKNIFLLSPNLLQKTTIQVLLDPMVKEEN 
SEEIDFILPFLKLSSLGGVNSLGVSSLEHITHSLLGRPLSRQLMSLVAGLRNGALLLTGG 
KGSGKSTLAKAICKEAFDKLDAHVERVDCKALRGKRLENIQKTLEVAFSEAVWMQPSVVL 
LDDLDLIAGLPAVPEHEHSPDAVQSQRLAHALNDMIKEFISMGSLVALIATSQSQQSLHP 
LLVSAQGVHIFQCVQHIQPPNQEQRCEILCNVIKNKLDCDINKFTDLDLQHVAKETGGFV 
ARDFTVLVDRAIHSRLSRQSISTREKLVLTTLDFQKALRGFLPASLRSVNLHKPRDLGWD 
KIGGLHEVRQILMDTIQLPAKYPELFANLPIRQRTGILLYGPPGTGKTLLAGVIARESRM 
NFISVKGPELLSKYIGASEQAVRDIFIRAQAAKPCILFFDEFESIAPRRGHDNTGVTDRV 
VNQLLTQLDGVEGLQGVYVLAATSRPDLIDPALLRPGRLDKCVYCPPPDQVSRLEILNVL 
SDSLPLADDVDLQHVASVTDSFTGADLKALLYNAQLEALHGMLLSSGLQDGSSSSDSDLS 
LSSMVFLNHSSGSDDSAGDGECGLDQSLVSLEMSEILPDESKFNMYRLYFGSSYESELGN 
GTSSDLSSQCLSAPSSMTQDLPGVPGKDQLFSQPPVLRTASQEGCQELTQEQRDQLRADI 
SIIKGRYRSQSGEDESMNQPGPIKTRLAISQSHLMTALGHTRPSISEDDWKNFAELYESF 
QNPKRRKNQSGTMFRPGQKVTLA 
135–138: R.IVF 
1
 
384–388: LQVVW 
3
 
Pex2p P28328 
>sp|P28328|PEX2_HUMAN Peroxisome biogenesis factor 2 OS=Homo 
sapiens GN=PEX2 PE=1 SV=2 
MASRKENAKSANRVLRISQLDALELNKALEQLVWSQFTQCFHGFKPGLLARFEPEVKACL 
WVFLWRFTIYSKNATVGQSVLNIKYKNDFSPNLRYQPPSKNQKIWYAVCTIGGRWLEERC 
YDLFRNHHLASFGKVKQCVNFVIGLLKLGGLINFLIFLQRGKFATLTERLLGIHSVFCKP 
QNICEVGFEYMNRELLWHGFAEFLIFLLPLINVQKLKAKLSSWCIPLTGAPNSDNTLATS 
GKECALCGEWPTMPHTIGCEHIFCYFCAKSSFLFDVYFTCPKCGTEVHSLQPLKSGIEMS 
EVNAL 
157–162: FLqRgK 
5
 
Pex3p P56589 
>sp|P56589|PEX3_HUMAN Peroxisomal biogenesis factor 3 OS=Homo 
sapiens GN=PEX3 PE=1 SV=1 
MLRSVWNFLKRHKKKCIFLGTVLGGVYILGKYGQKKIREIQEREAAEYIAQARRQYHFES 
NQRTCNMTVLSMLPTLREALMQQLNSESLTALLKNRPSNKLEIWEDLKIISFTRSTVAVY 
STCMLVVLLRVQLNIIGGYIYLDNAAVGKNGTTILAPPDVQQQYLSSIQHLLGDGLTELI 
TVIKQAVQKVLGSVSLKHSLSLLDLEQKLKEIRNLVEQHKSSSWINKDGSKPLLCHYMMP 
DEETPLAVQACGLSPRDITTIKLLNETRDMLESPDFSTVLNTCLNRGFSRLLDNMAEFFR 
PTEQDLQHGNSMNSLSSVSLPLAKIIPIVNGQIHSVCSETPSHFVQDLLTMEQVKDFAAN 
VYEAFSTPQQLEK 
8–13: FlkRhK 
5
 
108–112: KiISF 
1
 
Pex5p 
P50542 
>sp|P50542|PEX5_HUMAN Peroxisomal targeting signal 1 receptor 
OS=Homo sapiens GN=PEX5 PE=1 SV=3 
MAMRELVEAECGGANPLMKLAGHFTQDKALRQEGLRPGPWPPGAPASEAASKPLGVASED 
ELVAEFLQDQNAPLVSRAPQTFKMDDLLAEMQQIEQSNFRQAPQRAPGVADLALSENWAQ 
EFLAAGDAVDVTQDYNETDWSQEFISEVTDPLSVSPARWAEEYLEQSEEKLWLGEPEGTA 
TDRWYDEYHPEEDLQHTASDFVAKVDDPKLANSEFLKFVRQIGEGQVSLESGAGSGRAQA 
EQWAAEFIQQQGTSDAWVDQFTRPVNTSALDMEFERAKSAIESDVDFWDKLQAELEEMAK 
RDAEAHPWLSDYDDLTSATYDKGYQFEEENPLRDHPQPFEEGLRRLQEGDLPNAVLLFEA 
AVQQDPKHMEAWQYLGTTQAENEQELLAISALRRCLELKPDNQTALMALAVSFTNESLQR 
QACETLRDWLRYTPAYAHLVTPAEEGAGGAGLGPSKRILGSLLSDSLFLEVKELFLAAVR 
LDPTSIDPDVQCGLGVLFNLSGEYDKAVDCFTAALSVRPNDYLLWNKLGATLANGNQSEE 
AVAAYRRALELQPGYIRSRYNLGISCINLGAHREAVEHFLEALNMQRKSRGPRGEGGAMS 
ENIWSTLRLALSMLGQSDAYGAADARDLSTLLTMFGLPQ 
409–413: LAVSF 
3
 
P50542-2 
>sp|P50542-2|PEX5_HUMAN Isoform 2 of Peroxisomal targeting 
signal 1 receptor OS=Homo sapiens GN=PEX5 
MAMRELVEAECGGANPLMKLAGHFTQDKALRQEGLRPGPWPPGAPASEAASKPLGVASED 
ELVAEFLQDQNAPLVSRAPQTFKMDDLLAEMQQIEQSNFRQAPQRAPGVADLALSENWAQ 
EFLAAGDAVDVTQDYNETDWSQEFISEVTDPLSVSPARWAEEYLEQSEEKLWLGEPEGTA 
TDRWYDEYHPEEDLQHTASDFVAKVDDPKLANSEGTSDAWVDQFTRPVNTSALDMEFERA 
KSAIESDVDFWDKLQAELEEMAKRDAEAHPWLSDYDDLTSATYDKGYQFEEENPLRDHPQ 
PFEEGLRRLQEGDLPNAVLLFEAAVQQDPKHMEAWQYLGTTQAENEQELLAISALRRCLE 
LKPDNQTALMALAVSFTNESLQRQACETLRDWLRYTPAYAHLVTPAEEGAGGAGLGPSKR 
ILGSLLSDSLFLEVKELFLAAVRLDPTSIDPDVQCGLGVLFNLSGEYDKAVDCFTAALSV 
RPNDYLLWNKLGATLANGNQSEEAVAAYRRALELQPGYIRSRYNLGISCINLGAHREAVE 
HFLEALNMQRKSRGPRGEGGAMSENIWSTLRLALSMLGQSDAYGAADARDLSTLLTMFGL 
PQ 
372–376: LAVSF 
3
 
P50542-3 
>sp|P50542-3|PEX5_HUMAN Isoform 3 of Peroxisomal targeting 
signal 1 receptor OS=Homo sapiens GN=PEX5 
MAMRELVEAECGGANPLMKLAGHFTQDKALRQEGLRPGPWPPGAPASEAASKPLGVASED 
ELVAEFLQDQNAPLVSRAPQTFKMDDLLAEMQQIEQSNFRQAPQRAPGVADLALSENWAQ 
EFLAAGDAVDVTQDYNETDWSQEFISEVTDPLSVSPARWAEEYLEQSEEKLWLGEPEGTA 
TDRWYDEYHPEEDLQHTASDFVAKVDDPKLANSEFLKFVRQIGEGQVSLESGAGSGRAQA 
EQWAAEFIQQQGTSDAWVDQFTRPVNTSALDMEFERAKSAIELQAELEEMAKRDAEAHPW 
LSDYDDLTSATYDKGYQFEEENPLRDHPQPFEEGLRRLQEGDLPNAVLLFEAAVQQDPKH 
MEAWQYLGTTQAENEQELLAISALRRCLELKPDNQTALMALAVSFTNESLQRQACETLRD 
WLRYTPAYAHLVTPAEEGAGGAGLGPSKRILGSLLSDSLFLEVKELFLAAVRLDPTSIDP 
DVQCGLGVLFNLSGEYDKAVDCFTAALSVRPNDYLLWNKLGATLANGNQSEEAVAAYRRA 
LELQPGYIRSRYNLGISCINLGAHREAVEHFLEALNMQRKSRGPRGEGGAMSENIWSTLR 
LALSMLGQSDAYGAADARDLSTLLTMFGLPQ 
401–405: LAVSF 
3
 
P50542-4 
>sp|P50542-4|PEX5_HUMAN Isoform 4 of Peroxisomal targeting 
signal 1 receptor OS=Homo sapiens GN=PEX5 
MAMRELVEAECGGANPLMKLAGHFTQDKALRQEGLRPGPWPPGAPASEAVSVLEVESPGA 
ASEAASKPLGVASEDELVAEFLQDQNAPLVSRAPQTFKMDDLLAEMQQIEQSNFRQAPQR 
APGVADLALSENWAQEFLAAGDAVDVTQDYNETDWSQEFISEVTDPLSVSPARWAEEYLE 
QSEEKLWLGEPEGTATDRWYDEYHPEEDLQHTASDFVAKVDDPKLANSEFLKFVRQIGEG 
QVSLESGAGSGRAQAEQWAAEFIQQQGTSDAWVDQFTRPVNTSALDMEFERAKSAIESDV 
DFWDKLQAELEEMAKRDAEAHPWLSDYDDLTSATYDKGYQFEEENPLRDHPQPFEEGLRR 
LQEGDLPNAVLLFEAAVQQDPKHMEAWQYLGTTQAENEQELLAISALRRCLELKPDNQTA 
LMALAVSFTNESLQRQACETLRDWLRYTPAYAHLVTPAEEGAGGAGLGPSKRILGSLLSD 
SLFLEVKELFLAAVRLDPTSIDPDVQCGLGVLFNLSGEYDKAVDCFTAALSVRPNDYLLW 
NKLGATLANGNQSEEAVAAYRRALELQPGYIRSRYNLGISCINLGAHREAVEHFLEALNM 
424–428: LAVSF 
3
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Peroxin 
Accession 
number 
FASTA sequence 
PP1-binding motifs 
(aa x–y) 
QRKSRGPRGEGGAMSENIWSTLRLALSMLGQSDAYGAADARDLSTLLTMFGLPQ 
Pex5pL 
Q8IYB4 
sp|Q8IYB4|PEX5R_HUMAN PEX5-related protein OS=Homo sapiens 
GN=PEX5L PE=1 SV=2 
MYQGHMQKSKEQGYGKLSSDEDLEIIVDQKQGKGSRAADKAVAMVMKEIPREESAEEKPL 
LTMTSQLVNEQQESRPLLSPSIDDFLCETKSEAIARPVTSNTAVLTTGLDLLDLSEPVSQ 
TQTKAKKSEPSSKTSSLKKKADGSDLISTDAEQRGQPLRVPETSSLDLDIQTQLEKWDDV 
KFHGDRNTKGHPMAERKSSSSRTGSKELLWSSEHRSQPELSGGKSALNSESASELELVAP 
TQARLTKEHRWGSALLSRNHSLEEEFERAKAAVESDTEFWDKMQAEWEEMARRNWISENQ 
EAQNQVTISASEKGYYFHTENPFKDWPGAFEEGLKRLKEGDLPVTILFMEAAILQDPGDA 
EAWQFLGITQAENENEQAAIVALQRCLELQPNNLKALMALAVSYTNTGHQQDACDALKNW 
IKQNPKYKYLVKSKKGSPGLTRRMSKSPVDSSVLEGVKELYLEAAHQNGDMIDPDLQTGL 
GVLFHLSGEFNRAIDAFNAALTVRPEDYSLWNRLGATLANGDRSEEAVEAYTRALEIQPG 
FIRSRYNLGISCINLGAYREAVSNFLTALSLQRKSRNQQQVPHPAISGNIWAALRIALSL 
MDQPELFQAANLGDLDVLLRAFNLDP 
– 
Q8IYB4-2 
>sp|Q8IYB4-2|PEX5R_HUMAN Isoform 2 of PEX5-related protein 
OS=Homo sapiens GN=PEX5L 
MYQGHMQVVGVTLKKKWHCLQKSDLTLALGKGSRAADKAVAMVMKEIPREESAEEKPLLT 
MTSQLVNEQQESRPLLSPSIDDFLCETKSEAIARPVTSNTAVLTTGLDLLDLSEPVSQTQ 
TKAKKSEPSSKTSSLKKKADGSDLISTDAEQRGQPLRVPETSSLDLDIQTQLEKWDDVKF 
HGDRNTKGHPMAERKSSSSRTGSKELLWSSEHRSQPELSGGKSALNSESASELELVAPTQ 
ARLTKEHRWGSALLSRNHSLEEEFERAKAAVESDTEFWDKMQAEWEEMARRNWISENQEA 
QNQVTISASEKGYYFHTENPFKDWPGAFEEGLKRLKEGDLPVTILFMEAAILQDPGDAEA 
WQFLGITQAENENEQAAIVALQRCLELQPNNLKALMALAVSYTNTGHQQDACDALKNWIK 
QNPKYKYLVKSKKGSPGLTRRMSKSPVDSSVLEGVKELYLEAAHQNGDMIDPDLQTGLGV 
LFHLSGEFNRAIDAFNAALTVRPEDYSLWNRLGATLANGDRSEEAVEAYTRALEIQPGFI 
RSRYNLGISCINLGAYREAVSNFLTALSLQRKSRNQQQVPHPAISGNIWAALRIALSLMD 
QPELFQAANLGDLDVLLRAFNLDP 
– 
Q8IYB4-3 
>sp|Q8IYB4-3|PEX5R_HUMAN Isoform 3 of PEX5-related protein 
OS=Homo sapiens GN=PEX5L 
MYQGHMQKSKEQGYGKLSSDEDLEIIVDQKQLVNEQQESRPLLSPSIDDFLCETKSEAIA 
RPVTSNTAVLTTGLDLLDLSEPVSQTQTKAKKSEPSSKTSSLKKKADGSDLISTDAEQRG 
QPLRVPETSSLDLDIQTQLEKWDDVKFHGDRNTKGHPMAERKSSSSRTGSKELLWSSEHR 
SQPELSGGKSALNSESASELELVAPTQARLTKEHRWGSALLSRNHSLEEEFERAKAAVES 
DTEFWDKMQAEWEEMARRNWISENQEAQNQVTISASEKGYYFHTENPFKDWPGAFEEGLK 
RLKEGDLPVTILFMEAAILQDPGDAEAWQFLGITQAENENEQAAIVALQRCLELQPNNLK 
ALMALAVSYTNTGHQQDACDALKNWIKQNPKYKYLVKSKKGSPGLTRRMSKSPVDSSVLE 
GVKELYLEAAHQNGDMIDPDLQTGLGVLFHLSGEFNRAIDAFNAALTVRPEDYSLWNRLG 
ATLANGDRSEEAVEAYTRALEIQPGFIRSRYNLGISCINLGAYREAVSNFLTALSLQRKS 
RNQQQVPHPAISGNIWAALRIALSLMDQPELFQAANLGDLDVLLRAFNLDP 
– 
Q8IYB4-4 
>sp|Q8IYB4-4|PEX5R_HUMAN Isoform 4 of PEX5-related protein 
OS=Homo sapiens GN=PEX5L 
MYQGHMQLVNEQQESRPLLSPSIDDFLCETKSEAIARPVTSNTAVLTTGLDLLDLSEPVS 
QTQTKAKKSEPSSKTSSLKKKADGSDLISTDAEQRGQPLRVPETSSLDLDIQTQLEKWDD 
VKFHGDRNTKGHPMAERKSSSSRTGSKELLWSSEHRSQPELSGGKSALNSESASELELVA 
PTQARLTKEHRWGSALLSRNHSLEEEFERAKAAVESDTEFWDKMQAEWEEMARRNWISEN 
QEAQNQVTISASEKGYYFHTENPFKDWPGAFEEGLKRLKEGDLPVTILFMEAAILQDPGD 
AEAWQFLGITQAENENEQAAIVALQRCLELQPNNLKALMALAVSYTNTGHQQDACDALKN 
WIKQNPKYKYLVKSKKGSPGLTRRMSKSPVDSSVLEGVKELYLEAAHQNGDMIDPDLQTG 
LGVLFHLSGEFNRAIDAFNAALTVRPEDYSLWNRLGATLANGDRSEEAVEAYTRALEIQP 
GFIRSRYNLGISCINLGAYREAVSNFLTALSLQRKSRNQQQVPHPAISGNIWAALRIALS 
LMDQPELFQAANLGDLDVLLRAFNLDP 
– 
Q8IYB4-5 
>sp|Q8IYB4-5|PEX5R_HUMAN Isoform 5 of PEX5-related protein 
OS=Homo sapiens GN=PEX5L 
MVMKEIPREESAEEKPLLTMTSQLVNEQQESRPLLSPSIDDFLCETKSEAIARPVTSNTA 
VLTTGLDLLDLSEPVSQTQTKAKKSEPSSKTSSLKKKADGSDLISTDAEQRGQPLRVPET 
SSLDLDIQTQLEKWDDVKFHGDRNTKGHPMAERKSSSSRTGSKELLWSSEHRSQPELSGG 
KSALNSESASELELVAPTQARLTKEHRWGSALLSRNHSLEEEFERAKAAVESDTEFWDKM 
QAEWEEMARRNWISENQEAQNQVTISASEKGYYFHTENPFKDWPGAFEEGLKRLKEGDLP 
VTILFMEAAILQDPGDAEAWQFLGITQAENENEQAAIVALQRCLELQPNNLKALMALAVS 
YTNTGHQQDACDALKNWIKQNPKYKYLVKSKKGSPGLTRRMSKSPVDSSVLEGVKELYLE 
AAHQNGDMIDPDLQTGLGVLFHLSGEFNRAIDAFNAALTVRPEDYSLWNRLGATLANGDR 
SEEAVEAYTRALEIQPGFIRSRYNLGISCINLGAYREAVSNFLTALSLQRKSRNQQQVPH 
PAISGNIWAALRIALSLMDQPELFQAANLGDLDVLLRAFNLDP 
– 
Q8IYB4-6 
>sp|Q8IYB4-6|PEX5R_HUMAN Isoform 6 of PEX5-related protein 
OS=Homo sapiens GN=PEX5L 
MYQGHMQGKGSRAADKAVAMVMKEIPREESAEEKPLLTMTSQLVNEQQESRPLLSPSIDD 
FLCETKSEAIARPVTSNTAVLTTGLDLLDLSEPVSQTQTKAKKSEPSSKTSSLKKKADGS 
DLISTDAEQRGQPLRVPETSSLDLDIQTQLEKWDDVKFHGDRNTKGHPMAERKSSSSRTG 
SKELLWSSEHRSQPELSGGKSALNSESASELELVAPTQARLTKEHRWGSALLSRNHSLEE 
EFERAKAAVESDTEFWDKMQAEWEEMARRNWISENQEAQNQVTISASEKGYYFHTENPFK 
DWPGAFEEGLKRLKEGDLPVTILFMEAAILQDPGDAEAWQFLGITQAENENEQAAIVALQ 
RCLELQPNNLKALMALAVSYTNTGHQQDACDALKNWIKQNPKYKYLVKSKKGSPGLTRRM 
SKSPVDSSVLEGVKELYLEAAHQNGDMIDPDLQTGLGVLFHLSGEFNRAIDAFNAALTVR 
PEDYSLWNRLGATLANGDRSEEAVEAYTRALEIQPGFIRSRYNLGISCINLGAYREAVSN 
FLTALSLQRKSRNQQQVPHPAISGNIWAALRIALSLMDQPELFQAANLGDLDVLLRAFNL 
DP 
– 
Q8IYB4-7 
>sp|Q8IYB4-7|PEX5R_HUMAN Isoform 7 of PEX5-related protein 
OS=Homo sapiens GN=PEX5L 
MVMKEIPREESAEEKPLLTMTSQLVNEQQESRPLLSPSIDDFLCETKSEAIARPVTSNTA 
DIQTQLEKWDDVKFHGDRNTKGHPMAERKSSSSRTGSKELLWSSEHRSQPELSGGKSALN 
SESASELELVAPTQARLTKEHRWGSALLSRNHSLEEEFERAKAAVESDTEFWDKMQAEWE 
EMARRNWISENQEAQNQVTISASEKGYYFHTENPFKDWPGAFEEGLKRLKEGDLPVTILF 
MEAAILQDPGDAEAWQFLGITQAENENEQAAIVALQRCLELQPNNLKALMALAVSYTNTG 
HQQDACDALKNWIKQNPKYKYLVKSKKGSPGLTRRMSKSPVDSSVLEGVKELYLEAAHQN 
GDMIDPDLQTGLGVLFHLSGEFNRAIDAFNAALTVRPEDYSLWNRLGATLANGDRSEEAV 
EAYTRALEIQPGFIRSRYNLGISCINLGAYREAVSNFLTALSLQRKSRNQQQVPHPAISG 
NIWAALRIALSLMDQPELFQAANLGDLDVLLRAFNLDP 
– 
Q8IYB4-8 
>sp|Q8IYB4-8|PEX5R_HUMAN Isoform 8 of PEX5-related protein 
OS=Homo sapiens GN=PEX5L 
MAERKSSSSRTGSKELLWSSEHRSQPELSGGKSALNSESASELELVAPTQARLTKEHRWG 
SALLSRNHSLEEEFERAKAAVESDTEFWDKMQAEWEEMARRNWISENQEAQNQVTISASE 
KGYYFHTENPFKDWPGAFEEGLKRLKEGDLPVTILFMEAAILQDPGDAEAWQFLGITQAE 
NENEQAAIVALQRCLELQPNNLKALMALAVSYTNTGHQQDACDALKNWIKQNPKYKYLVK 
SKKGSPGLTRRMSKSPVDSSVLEGVKELYLEAAHQNGDMIDPDLQTGLGVLFHLSGEFNR 
– 
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Peroxin 
Accession 
number 
FASTA sequence 
PP1-binding motifs 
(aa x–y) 
AIDAFNAALTVRPEDYSLWNRLGATLANGDRSEEAVEAYTRALEIQPGFIRSRYNLGISC 
INLGAYREAVSNFLTALSLQRKSRNQQQVPHPAISGNIWAALRIALSLMDQPELFQAANL 
GDLDVLLRAFNLDP 
Pex6p Q13608 
>sp|Q13608|PEX6_HUMAN Peroxisome assembly factor 2 OS=Homo 
sapiens GN=PEX6 PE=1 SV=2 
MALAVLRVLEPFPTETPPLAVLLPPGGPWPAAELGLVLALRPAGESPAGPALLVAALEGP 
DAGTEEQGPGPPQLLVSRALLRLLALGSGAWVRARAVRRPPALGWALLGTSLGPGLGPRV 
GPLLVRRGETLPVPGPRVLETRPALQGLLGPGTRLAVTELRGRARLCPESGDSSRPPPPP 
VVSSFAVSGTVRRLQGVLGGTGDSLGVSRSCLRGLGLFQGEWVWVAQARESSNTSQPHLA 
RVQVLEPRWDLSDRLGPGSGPLGEPLADGLALVPATLAFNLGCDPLEMGELRIQRYLEGS 
IAPEDKGSCSLLPGPPFARELHIEIVSSPHYSTNGNYDGVLYRHFQIPRVVQEGDVLCVP 
TIGQVEILEGSPEKLPRWREMFFKVKKTVGEAPDGPASAYLADTTHTSLYMVGSTLSPVP 
WLPSEESTLWSSLSPPGLEALVSELCAVLKPRLQPGGALLTGTSSVLLRGPPGCGKTTVV 
AAACSHLGLHLLKVPCSSLCAESSGAVETKLQAIFSRARRCRPAVLLLTAVDLLGRDRDG 
LGEDARVMAVLRHLLLNEDPLNSCPPLMVVATTSRAQDLPADVQTAFPHELEVPALSEGQ 
RLSILRALTAHLPLGQEVNLAQLARRCAGFVVGDLYALLTHSSRAACTRIKNSGLAGGLT 
EEDEGELCAAGFPLLAEDFGQALEQLQTAHSQAVGAPKIPSVSWHDVGGLQEVKKEILET 
IQLPLEHPELLSLGLRRSGLLLHGPPGTGKTLLAKAVATECSLTFLSVKGPELINMYVGQ 
SEENVREVFARARAAAPCIIFFDELDSLAPSRGRSGDSGGVMDRVVSQLLAELDGLHSTQ 
DVFVIGATNRPDLLDPALLRPGRFDKLVFVGANEDRASQLRVLSAITRKFKLEPSVSLVN 
VLDCCPPQLTGADLYSLCSDAMTAALKRRVHDLEEGLEPGSSALMLTMEDLLQAAARLQP 
SVSEQELLRYKRIQRKFAAC 
93–96: RARA 
6
 
603–606: SILR 
4
 
791–794: RARA 
6
 
Pex7p O00628 
>sp|O00628|PEX7_HUMAN Peroxisomal targeting signal 2 receptor 
OS=Homo sapiens GN=PEX7 PE=1 SV=1 
MSAVCGGAARMLRTPGRHGYAAEFSPYLPGRLACATAQHYGIAGCGTLLILDPDEAGLRL 
FRSFDWNDGLFDVTWSENNEHVLITCSGDGSLQLWDTAKAAGPLQVYKEHAQEVYSVDWS 
QTRGEQLVVSGSWDQTVKLWDPTVGKSLCTFRGHESIIYSTIWSPHIPGCFASASGDQTL 
RIWDVKAAGVRIVIPAHQAEILSCDWCKYNENLLVTGAVDCSLRGWDLRNVRQPVFELLG 
HTYAIRRVKFSPFHASVLASCSYDFTVRFWNFSKPDSLLETVEHHTEFTCGLDFSLQSPT 
QVADCSWDETIKIYDPACLTIPA 
246–250: RRVKF 
1, 2, 3
 
Pex10p 
O60683 
>sp|O60683|PEX10_HUMAN Peroxisome biogenesis factor 10 
OS=Homo sapiens GN=PEX10 PE=1 SV=1 
MAPAAASPPEVIRAAQKDEYYRGGLRSAAGGALHSLAGARKWLEWRKEVELLSDVAYFGL 
TTLAGYQTLGEEYVSIIQVDPSRIHVPSSLRRGVLVTLHAVLPYLLDKALLPLEQELQAD 
PDSGRPLQGSLGPGGRGCSGARRWMRHHTATLTEQQRRALLRAVFVLRQGLACLQRLHVA 
WFYIHGVFYHLAKRLTGITYLRVRSLPGEDLRARVSYRLLGVISLLHLVLSMGLQLYGFR 
QRQRARKEWRLHRGLSHRRASLEERAVSRNPLCTLCLEERRHPTATPCGHLFCWECITAW 
CSSKAECPLCREKFPPQKLIYLRHYR 
177–181: LHVAW 
3
 
239–244: FrqRqR 
5
 
O60683-2 
>sp|O60683-2|PEX10_HUMAN Isoform 2 of Peroxisome biogenesis 
factor 10 OS=Homo sapiens GN=PEX10 
MAPAAASPPEVIRAAQKDEYYRGGLRSAAGGALHSLAGARKWLEWRKEVELLSDVAYFGL 
TTLAGYQTLGEEYVSIIQVDPSRIHVPSSLRRGVLVTLHAVLPYLLDKALLPLEQELQAD 
PDSGRPLQGSLGPGGRGCSGARRWMRHHTATLTEQQRRALLRAVFVLRQGLACLQRLHVA 
WFYIHGVFYHLAKRLTGITYQALRPDPLRVLMSVAPSALQLRVRSLPGEDLRARVSYRLL 
GVISLLHLVLSMGLQLYGFRQRQRARKEWRLHRGLSHRRASLEERAVSRNPLCTLCLEER 
RHPTATPCGHLFCWECITAWCSSKAECPLCREKFPPQKLIYLRHYR 
177–181: LHVAW 
3
 
259–264: FrqRqR 
5
 
Pex11pα 
O75192 
>sp|O75192|PX11A_HUMAN Peroxisomal membrane protein 11A 
OS=Homo sapiens GN=PEX11A PE=1 SV=1 
MDAFTRFTNQTQGRDRLFRATQYTCMLLRYLLEPKAGKEKVVMKLKKLESSVSTGRKWFR 
LGNVVHAIQATEQSIHATDLVPRLCLTLANLNRVIYFICDTILWVRSVGLTSGINKEKWR 
TRAAHHYYYSLLLSLVRDLYEISLQMKRVTCDRAKKEKSASQDPLWFSVAEEETEWLQSF 
LLLLFRSLKQHPPLLLDTVKNLCDILNPLDQLGIYKSNPGIIGLGGLVSSIAGMITVAYP 
QMKLKTR 
93–97: RvIYF 
1
 
O75192-2 
>sp|O75192-2|PX11A_HUMAN Isoform 2 of Peroxisomal membrane 
protein 11A OS=Homo sapiens GN=PEX11A 
MDAFTRFTNQTQGRDRLFRATQYTCMLLRYLLEPKAGKEKVVMKLKKLESSVSTGRKSNL 
NRVIYFICDTILWVRSVGLTSGINKEKWRTRAAHHYYYSLLLSLVRDLYEISLQMKRVTC 
DRAKKEKSASQDPLWFSVAEEETEWLQSFLLLLFRSLKQHPPLLLDTVKNLCDILNPLDQ 
LGIYKSNPGIIGLGGLVSSIAGMITVAYPQMKLKTR 
62–66: RvIYF 
1
 
Pex11pβ 
O96011 
>sp|O96011|PX11B_HUMAN Peroxisomal membrane protein 11B 
OS=Homo sapiens GN=PEX11B PE=1 SV=1 
MDAWVRFSAQSQARERLCRAAQYACSLLGHALQRHGASPELQKQIRQLESHLSLGRKLLR 
LGNSADALESAKRAVHLSDVVLRFCITVSHLNRALYFACDNVLWAGKSGLAPRVDQEKWA 
QRSFRYYLFSLIMNLSRDAYEIRLLMEQESSACSRRLKGSGGGVPGGSETGGLGGPGTPG 
GGLPQLALKLRLQVLLLARVLRGHPPLLLDVVRNACDLFIPLDKLGLWRCGPGIVGLCGL 
VSSILSILTLIYPWLRLKP 
– 
O96011-2 
>sp|O96011-2|PX11B_HUMAN Isoform 2 of Peroxisomal membrane 
protein 11B OS=Homo sapiens GN=PEX11B 
MGKLRAAQYACSLLGHALQRHGASPELQKQIRQLESHLSLGRKLLRLGNSADALESAKRA 
VHLSDVVLRFCITVSHLNRALYFACDNVLWAGKSGLAPRVDQEKWAQRSFRYYLFSLIMN 
LSRDAYEIRLLMEQESSACSRRLKGSGGGVPGGSETGGLGGPGTPGGGLPQLALKLRLQV 
LLLARVLRGHPPLLLDVVRNACDLFIPLDKLGLWRCGPGIVGLCGLVSSILSILTLIYPW 
LRLKP 
– 
Pex11pγ 
Q96HA9 
>sp|Q96HA9|PX11C_HUMAN Peroxisomal membrane protein 11C 
OS=Homo sapiens GN=PEX11G PE=1 SV=1 
MASLSGLASALESYRGRDRLIRVLGYCCQLVGGVLVEQCPARSEVGTRLLVVSTQLSHCR 
TILRLFDDLAMFVYTKQYGLGAQEEDAFVRCVSVLGNLADQLYYPCEHVAWAADARVLHV 
DSSRWWTLSTTLWALSLLLGVARSLWMLLKLRQRLRSPTAPFTSPLPRGKRRAMEAQMQS 
EALSLLSNLADLANAVHWLPRGVLWAGRFPPWLVGLMGTISSILSMYQAARAGGQAEATT 
P 
201–205: RgVLW 
1
 
Q96HA9-2 
>sp|Q96HA9-2|PX11C_HUMAN Isoform 2 of Peroxisomal membrane 
protein 11C OS=Homo sapiens GN=PEX11G 
MFVYTKQYGLGAQEEDAFVRCVSVLGNLADQLYYPCEHVAWAADARVLHVDSSRWWTLST 
TLWALSLLLGVARSLWMLLKLRQRLRSPTAPFTSPLPRGKRRAMEAQMQSEALSLLSNLA 
DLANAVHWLPRGVLWAGRFPPWLVGLMGTISSILSMYQAARAGGQAEATTP 
131–135: RgVLW 
1
 
Pex12p O00623 
>sp|O00623|PEX12_HUMAN Peroxisome assembly protein 12 OS=Homo 
sapiens GN=PEX12 PE=1 SV=1 
MAEHGAHFTAASVADDQPSIFEVVAQDSLMTAVRPALQHVVKVLAESNPTHYGFLWRWFD 
EIFTLLDLLLQQHYLSRTSASFSENFYGLKRIVMGDTHKSQRLASAGLPKQQLWKSIMFL 
VLLPYLKVKLEKLVSSLREEDEYSIHPPSSRWKRFYRAFLAAYPFVNMAWEGWFLVQQLR 
YILGKAQHHSPLLRLAGVQLGRLTVQDIQALEHKPAKASMMQQPARSVSEKINSALKKAV 
GGVALSLSTGLSVGVFFLQFLDWWYSSENQETIKSLTALPTPPPPVHLDYNSDSPLLPKM 
KTVCPLCRKTRVNDTVLATSGYVFCYRCVFHYVRSHQACPITGYPTEVQHLIKLYSPEN 
115–119: KsIMF 
1
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Accession 
number 
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PP1-binding motifs 
(aa x–y) 
Pex13p Q92968 
>sp|Q92968|PEX13_HUMAN Peroxisomal membrane protein PEX13 
OS=Homo sapiens GN=PEX13 PE=1 SV=2 
MASQPPPPPKPWETRRIPGAGPGPGPGPTFQSADLGPTLMTRPGQPALTRVPPPILPRPS 
QQTGSSSVNTFRPAYSSFSSGYGAYGNSFYGGYSPYSYGYNGLGYNRLRVDDLPPSRFVQ 
QAEESSRGAFQSIESIVHAFASVSMMMDATFSAVYNSFRAVLDVANHFSRLKIHFTKVFS 
AFALVRTIRYLYRRLQRMLGLRRGSENEDLWAESEGTVACLGAEDRAATSAKSWPIFLFF 
AVILGGPYLIWKLLSTHSDEVTDSINWASGEDDHVVARAEYDFAAVSEEEISFRAGDMLN 
LALKEQQPKVRGWLLASLDGQTTGLIPANYVKILGKRKGRKTVESSKVSKQQQSFTNPTL 
TKGATVADSLDEQEAAFESVFVETNKVPVAPDSIGKDGEKQDL 
171–175: LKIHF 
1, 3
 
Pex14p 
O75381 
>sp|O75381|PEX14_HUMAN Peroxisomal membrane protein PEX14 
OS=Homo sapiens GN=PEX14 PE=1 SV=1 
MASSEQAEQPSQPSSTPGSENVLPREPLIATAVKFLQNSRVRQSPLATRRAFLKKKGLTD 
EEIDMAFQQSGTAADEPSSLGPATQVVPVQPPHLISQPYSPAGSRWRDYGALAIIMAGIA 
FGFHQLYKKYLLPLILGGREDRKQLERMEAGLSELSGSVAQTVTQLQTTLASVQELLIQQ 
QQKIQELAHELAAAKATTSTNWILESQNINELKSEINSLKGLLLNRRQFPPSPSAPKIPS 
WQIPVKSPSPSSPAAVNHHSSSDISPVSNESTSSSPGKEGHSPEGSTVTYHLLGPQEEGE 
GVVDVKGQVRMEVQGEEEKREDKEDEEDEEDDDVSHVDEEDCLGVQREDRRGGDGQINEQ 
VEKLRRPEGASNESERD 
– 
O75381-2 
>sp|O75381-2|PEX14_HUMAN Isoform 2 of Peroxisomal membrane 
protein PEX14 OS=Homo sapiens GN=PEX14 
MASSEQAEQPSQPSSTPGSENVLPREPLIATAVKFLQNSRVRQSPLATRRAFLKKKGPAG 
SRWRDYGALAIIMAGIAFGFHQLYKKYLLPLILGGREDRKQLERMEAGLSELSGSVAQTV 
TQLQTTLASVQELLIQQQQKIQELAHELAAAKATTSTNWILESQNINELKSEINSLKGLL 
LNRRQFPPSPSAPKIPSWQIPVKSPSPSSPAAVNHHSSSDISPVSNESTSSSPGKEGHSP 
EGSTVTYHLLGPQEEGEGVVDVKGQVRMEVQGEEEKREDKEDEEDEEDDDVSHVDEEDCL 
GVQREDRRGGDGQINEQVEKLRRPEGASNESERD 
– 
Pex16p 
Q9Y5Y5 
>sp|Q9Y5Y5|PEX16_HUMAN Peroxisomal membrane protein PEX16 
OS=Homo sapiens GN=PEX16 PE=1 SV=2 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGFSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALVQLAK 
AVLRMLLLLWFKAGLQTSPPIVPLDRETQAQPPDGDHSPGNHEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQREGRQQQHHEELSATPTPLGLQETIAEFLYIARPLLHLLSLGLWGQ 
RSWKPWLLAGVVDVTSLSLLSDRKGLTRRERRELRRRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLADHVPGVGLVTRPLMDYLPTWQKIYFYSWG 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
329–332: K.IYF 
1
 
Q9Y5Y5-2 
>sp|Q9Y5Y5-2|PEX16_HUMAN Isoform 2 of Peroxisomal membrane 
protein PEX16 OS=Homo sapiens GN=PEX16 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGFSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALVQLAK 
AVLRMLLLLWFKAGLQTSPPIVPLDRETQAQPPDGDHSPGNHEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQREGRQQQHHEELSATPTPLGLQETIAEFLYIARPLLHLLSLGLWGQ 
RSWKPWLLAGVVDVTSLSLLSDRKGLTRRERRELRRRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLADHVPGVGLVTTSQRAASPCLPARPHTQPWSPPAFLPGHP 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
Pex19p 
P40855 
>sp|P40855|PEX19_HUMAN Peroxisomal biogenesis factor 19 
OS=Homo sapiens GN=PEX19 PE=1 SV=1 
MAAAEEGCSVGAEADRELEELLESALDDFDKAKPSPAPPSTTTAPDASGPQKRSPGDTAK 
DALFASQEKFFQELFDSELASQATAEFEKAMKELAEEEPHLVEQFQKLSEAAGRVGSDMT 
SQQEFTSCLKETLSGLAKNATDLQNSSMSEEELTKAMEGLGMDEGDGEGNILPIMQSIMQ 
NLLSKDVLYPSLKEITEKYPEWLQSHRESLPPEQFEKYQEQHSVMCKICEQFEAETPTDS 
ETTQKARFEMVLDLMQQLQDLGHPPKELAGEMPPGLNFDLDALNLSGPPGASGEQCLIM 
– 
P40855-5 
>sp|P40855-5|PEX19_HUMAN Isoform 5 of Peroxisomal biogenesis 
factor 19 OS=Homo sapiens GN=PEX19 
PPLRKAVVSGPKRTGNWRSFWKDALFASQEKFFQELFDSELASQATAEFEKAMKELAEEE 
PHLVEQFQKLSEAAGRVGSDMTSQQEFTSCLKETLSGLAKNATDLQNSSMSEEELTKAME 
GLGMDEGDGEGNILPIMQSIMQNLLSKDVLYPSLKEITEKYPEWLQSHRESLPPEQFEKY 
QEQHSVMCKICEQFEAETPTDSETTQKARFEMVLDLMQQLQDLGHPPKELAGEMPPGLNF 
DLDALNLSGPPGASGEQCLIM 
– 
Pex26p 
Q7Z412 
>sp|Q7Z412|PEX26_HUMAN Peroxisome assembly protein 26 OS=Homo 
sapiens GN=PEX26 PE=1 SV=2 
MKSDSSTSAAPLRGLGGPLRSSEPVRAVPARAPAVDLLEEAADLLVVHLDFRAALETCER 
AWQSLANHAVAEEPAGTSLEVKCSLCVVGIQALAEMDRWQEVLSWVLQYYQVPEKLPPKV 
LELCILLYSKMQEPGAVLDVVGAWLQDPANQNLPEYGALAEFHVQRVLLPLGCLSEAEEL 
VVGSAAFGEERRLDVLQAIHTARQQQKQEHSGSEEAQKPNLEGSVSHKFLSLPMLVRQLW 
DSAVSHFFSLPFKKSLLAALILCLLVVRFDPASPSSLHFLYKLAQLFRWIRKAAFSRLYQ 
LRIRD 
265–269: LVVRF 
3
 
Q7Z412-2 
>sp|Q7Z412-2|PEX26_HUMAN Isoform 2 of Peroxisome assembly 
protein 26 OS=Homo sapiens GN=PEX26 
MKSDSSTSAAPLRGLGGPLRSSEPVRAVPARAPAVDLLEEAADLLVVHLDFRAALETCER 
AWQSLANHAVAEEPAGTSLEVKCSLCVVGIQALAEMDRWQEVLSWVLQYYQVPEKLPPKV 
LELCILLYSKMQEPGAVLDVVGAWLQDPANQNLPEYGALAEFHVQRVLLPLGCLSEAEEL 
VVGSAAFGEERRLDVLQAIHTARQQQKQEHSGSEEAQKPNLEASPSSLHFLYKLAQLFRW 
IRKAAFSRLYQLRIRD 
– 
The sequences were collected from UniProtKB database and loaded in ScanProsite program as well as the 
PP1-binding motifs canonical sequences listed on Table 5. The green- and blue-high lightened residues 
correspond to matches with the canonical sequences of RVxF and RVxF-cooperating motifs, respectively. 
1
matches with the sequence [RK]-X(0,1)-[VI]-{P}-[FW]; 
2
matches with the sequence [HKR]-[ACHKMNQRSTV]-
V-[CHKNQRST]-[FW]; 
3
matches with the sequence [KRL]-[KRSTAMVHNQ]-[VI]-{FIMYDP}-[FW]; 
4
matches with 
the sequence [GS]-I-L-[RK]; 
5
matches with the sequence F-X-X-[RK]-X-[RK]; 
6
matches with the sequence R-A-
R-A. Other canonical sequences were screened, with no hits (R-X-X-Q-[VIL]-[KR]-X-[YW], R-[KR]-X-H-Y, K-S-Q-
K-W and R-N-Y-F). A graphic resume of this screening is depicted on Figure 9. 
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Supplementary Table 2: Human ubiquitin-conjugating enzymes and PP1-binding motifs 
Ubiquitin-
conjugating 
enzyme 
Accession 
number 
FASTA sequence 
PP1-binding motifs 
(aa x–y) 
UbcH5a P51668 
>sp|P51668|UB2D1_HUMAN Ubiquitin-conjugating enzyme E2 D1 
OS=Homo sapiens GN=UBE2D1 PE=1 SV=1 
MALKRIQKELSDLQRDPPAHCSAGPVGDDLFHWQATIMGPPDSAYQGGVFFLTVHFPTDY 
PFKPPKIAFTTKIYHPNINSNGSICLDILRSQWSPALTVSKVLLSICSLLCDPNPDDPLV 
PDIAQIYKSDKEKYNRHAREWTQKYAM 
52–56: LTVHF 
1
 
66–69: K.IAF 
2
 
UbcH5b 
P62837 
>sp|P62837|UB2D2_HUMAN Ubiquitin-conjugating enzyme E2 D2 
OS=Homo sapiens GN=UBE2D2 PE=1 SV=1 
MALKRIHKELNDLARDPPAQCSAGPVGDDMFHWQATIMGPNDSPYQGGVFFLTIHFPTDY 
PFKPPKVAFTTRIYHPNINSNGSICLDILRSQWSPALTISKVLLSICSLLCDPNPDDPLV 
PEIARIYKTDREKYNRIAREWTQKYAM 
52–56: LTIHF 
1
 
66–69: K.VAF 
2
 
P62837-2 
>sp|P62837-2|UB2D2_HUMAN Isoform 2 of Ubiquitin-conjugating 
enzyme E2 D2 OS=Homo sapiens GN=UBE2D2 
MFHWQATIMGPNDSPYQGGVFFLTIHFPTDYPFKPPKVAFTTRIYHPNINSNGSICLDIL 
RSQWSPALTISKVLLSICSLLCDPNPDDPLVPEIARIYKTDREKYNRIAREWTQKYAM 
23–27: LTIHF 
1
 
37–40: K.VAF 
2
 
UbcH5c 
P61077 
>sp|P61077|UB2D3_HUMAN Ubiquitin-conjugating enzyme E2 D3 
OS=Homo sapiens GN=UBE2D3 PE=1 SV=1 
MALKRINKELSDLARDPPAQCSAGPVGDDMFHWQATIMGPNDSPYQGGVFFLTIHFPTDY 
PFKPPKVAFTTRIYHPNINSNGSICLDILRSQWSPALTISKVLLSICSLLCDPNPDDPLV 
PEIARIYKTDRDKYNRISREWTQKYAM 
52–56: LTIHF 
1
 
66–69: K.VAF 
2
 
P61077-2 
>sp|P61077-2|UB2D3_HUMAN Isoform 2 of Ubiquitin-conjugating 
enzyme E2 D3 OS=Homo sapiens GN=UBE2D3 
MALKRINKELSDLARDPPAQCSAGPVGDDMFHWQATIMGPNDSPYQGGVFFLTIHFPTDY 
PFKPPKVAFTTRIYHPNINSNGSICLDILRSQWSPALTISKVLLSICSLLCDPNPDDPLV 
PEIARIYKTDRDKYNRLAREWTEKYAML 
52–56: LTIHF 
1
 
66–69: K.VAF 
2
 
P61077-3 
>sp|P61077-3|UB2D3_HUMAN Isoform 3 of Ubiquitin-conjugating 
enzyme E2 D3 OS=Homo sapiens GN=UBE2D3 
MLSNRKCLSKELSDLARDPPAQCSAGPVGDDMFHWQATIMGPNDSPYQGGVFFLTIHFPT 
DYPFKPPKVAFTTRIYHPNINSNGSICLDILRSQWSPALTISKVLLSICSLLCDPNPDDP 
LVPEIARIYKTDRDKYNRISREWTQKYAM 
54–58: LTIHF 
1
 
68–71: K.VAF 
2
 
The sequences were collected from UniProtKB database and loaded in ScanProsite program as well as the 
PP1-binding motifs canonical sequences listed on Table 5. The green-lightened residues correspond to 
matches with the canonical sequences of RVxF motifs. 
1
matches with the sequence [KRL]-[KRSTAMVHNQ]-
[VI]-{FIMYDP}-[FW]; 
2
matches with the sequence [RK]-X(0,1)-[VI]-{P}-[FW]. Other canonical sequences were 
screened, with no hits ([HKR]-[ACHKMNQRSTV]-V-[CHKNQRST]-[FW], [GS]-I-L-[RK], F-X-X-[RK]-X-[RK], R-A-R-
A , R-X-X-Q-[VIL]-[KR]-X-[YW], R-[KR]-X-H-Y, K-S-Q-K-W and R-N-Y-F). A graphic resume of this screening is 
depicted on Supplementary Figure 1. 
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Supplementary Table 3: Proteins involved in peroxisome fission don't have PP1-binding motifs 
Fission 
machinery 
protein 
Accession 
number 
FASTA sequence 
PP1-binding motifs 
(aa x–y) 
DLP1 
O00429 
>sp|O00429|DNM1L_HUMAN Dynamin-1-like protein OS=Homo sapiens 
GN=DNM1L PE=1 SV=2 
MEALIPVINKLQDVFNTVGADIIQLPQIVVVGTQSSGKSSVLESLVGRDLLPRGTGIVTR 
RPLILQLVHVSQEDKRKTTGEENGVEAEEWGKFLHTKNKLYTDFDEIRQEIENETERISG 
NNKGVSPEPIHLKIFSPNVVNLTLVDLPGMTKVPVGDQPKDIELQIRELILRFISNPNSI 
ILAVTAANTDMATSEALKISREVDPDGRRTLAVITKLDLMDAGTDAMDVLMGRVIPVKLG 
IIGVVNRSQLDINNKKSVTDSIRDEYAFLQKKYPSLANRNGTKYLARTLNRLLMHHIRDC 
LPELKTRINVLAAQYQSLLNSYGEPVDDKSATLLQLITKFATEYCNTIEGTAKYIETSEL 
CGGARICYIFHETFGRTLESVDPLGGLNTIDILTAIRNATGPRPALFVPEVSFELLVKRQ 
IKRLEEPSLRCVELVHEEMQRIIQHCSNYSTQELLRFPKLHDAIVEVVTCLLRKRLPVTN 
EMVHNLVAIELAYINTKHPDFADACGLMNNNIEEQRRNRLARELPSAVSRDKSSKVPSAL 
APASQEPSPAASAEADGKLIQDSRRETKNVASGGGGVGDGVQEPTTGNWRGMLKTSKAEE 
LLAEEKSKPIPIMPASPQKGHAVNLLDVPVPVARKLSAREQRDCEVIERLIKSYFLIVRK 
NIQDSVPKAVMHFLVNHVKDTLQSELVGQLYKSSLLDDLLTESEDMAQRRKEAADMLKAL 
QGASQIIAEIRETHLW 
– 
O00429-2 
>sp|O00429-2|DNM1L_HUMAN Isoform 4 of Dynamin-1-like protein 
OS=Homo sapiens GN=DNM1L 
MEALIPVINKLQDVFNTVGADIIQLPQIVVVGTQSSGKSSVLESLVGRDLLPRGTGIVTR 
RPLILQLVHVSQEDKRKTTGEENGVEAEEWGKFLHTKNKLYTDFDEIRQEIENETERISG 
NNKGVSPEPIHLKIFSPNVVNLTLVDLPGMTKVPVGDQPKDIELQIRELILRFISNPNSI 
ILAVTAANTDMATSEALKISREVDPDGRRTLAVITKLDLMDAGTDAMDVLMGRVIPVKLG 
IIGVVNRSQLDINNKKSVTDSIRDEYAFLQKKYPSLANRNGTKYLARTLNRLLMHHIRDC 
LPELKTRINVLAAQYQSLLNSYGEPVDDKSATLLQLITKFATEYCNTIEGTAKYIETSEL 
CGGARICYIFHETFGRTLESVDPLGGLNTIDILTAIRNATGPRPALFVPEVSFELLVKRQ 
IKRLEEPSLRCVELVHEEMQRIIQHCSNYSTQELLRFPKLHDAIVEVVTCLLRKRLPVTN 
EMVHNLVAIELAYINTKHPDFADACGLMNNNIEEQRRNRLARELPSAVSRDKSSKVPSAL 
APASQEPSPAASAEADGKVASGGGGVGDGVQEPTTGNWRGMLKTSKAEELLAEEKSKPIP 
IMPASPQKGHAVNLLDVPVPVARKLSAREQRDCEVIERLIKSYFLIVRKNIQDSVPKAVM 
HFLVNHVKDTLQSELVGQLYKSSLLDDLLTESEDMAQRRKEAADMLKALQGASQIIAEIR 
ETHLW 
– 
O00429-3 
>sp|O00429-3|DNM1L_HUMAN Isoform 2 of Dynamin-1-like protein 
OS=Homo sapiens GN=DNM1L 
MEALIPVINKLQDVFNTVGADIIQLPQIVVVGTQSSGKSSVLESLVGRDLLPRGTGIVTR 
RPLILQLVHVSQEDKRKTTGEENGVEAEEWGKFLHTKNKLYTDFDEIRQEIENETERISG 
NNKGVSPEPIHLKIFSPNVVNLTLVDLPGMTKVPVGDQPKDIELQIRELILRFISNPNSI 
ILAVTAANTDMATSEALKISREVDPDGRRTLAVITKLDLMDAGTDAMDVLMGRVIPVKLG 
IIGVVNRSQLDINNKKSVTDSIRDEYAFLQKKYPSLANRNGTKYLARTLNRLLMHHIRDC 
LPELKTRINVLAAQYQSLLNSYGEPVDDKSATLLQLITKFATEYCNTIEGTAKYIETSEL 
CGGARICYIFHETFGRTLESVDPLGGLNTIDILTAIRNATGPRPALFVPEVSFELLVKRQ 
IKRLEEPSLRCVELVHEEMQRIIQHCSNYSTQELLRFPKLHDAIVEVVTCLLRKRLPVTN 
EMVHNLVAIELAYINTKHPDFADACGLMNNNIEEQRRNRLARELPSAVSRDKLIQDSRRE 
TKNVASGGGGVGDGVQEPTTGNWRGMLKTSKAEELLAEEKSKPIPIMPASPQKGHAVNLL 
DVPVPVARKLSAREQRDCEVIERLIKSYFLIVRKNIQDSVPKAVMHFLVNHVKDTLQSEL 
VGQLYKSSLLDDLLTESEDMAQRRKEAADMLKALQGASQIIAEIRETHLW 
– 
O00429-4 
>sp|O00429-4|DNM1L_HUMAN Isoform 3 of Dynamin-1-like protein 
OS=Homo sapiens GN=DNM1L 
MEALIPVINKLQDVFNTVGADIIQLPQIVVVGTQSSGKSSVLESLVGRDLLPRGTGIVTR 
RPLILQLVHVSQEDKRKTTGEENGVEAEEWGKFLHTKNKLYTDFDEIRQEIENETERISG 
NNKGVSPEPIHLKIFSPNVVNLTLVDLPGMTKVPVGDQPKDIELQIRELILRFISNPNSI 
ILAVTAANTDMATSEALKISREVDPDGRRTLAVITKLDLMDAGTDAMDVLMGRVIPVKLG 
IIGVVNRSQLDINNKKSVTDSIRDEYAFLQKKYPSLANRNGTKYLARTLNRLLMHHIRDC 
LPELKTRINVLAAQYQSLLNSYGEPVDDKSATLLQLITKFATEYCNTIEGTAKYIETSEL 
CGGARICYIFHETFGRTLESVDPLGGLNTIDILTAIRNATGPRPALFVPEVSFELLVKRQ 
IKRLEEPSLRCVELVHEEMQRIIQHCSNYSTQELLRFPKLHDAIVEVVTCLLRKRLPVTN 
EMVHNLVAIELAYINTKHPDFADACGLMNNNIEEQRRNRLARELPSAVSRDKVASGGGGV 
GDGVQEPTTGNWRGMLKTSKAEELLAEEKSKPIPIMPASPQKGHAVNLLDVPVPVARKLS 
AREQRDCEVIERLIKSYFLIVRKNIQDSVPKAVMHFLVNHVKDTLQSELVGQLYKSSLLD 
DLLTESEDMAQRRKEAADMLKALQGASQIIAEIRETHLW 
– 
O00429-5 
>sp|O00429-5|DNM1L_HUMAN Isoform 5 of Dynamin-1-like protein 
OS=Homo sapiens GN=DNM1L 
MEALIPVINKLQDVFNTVGADIIQLPQIVVVGTQSSGKSSVLESLVGRDLLPRGTGIVTR 
RPLILQLVHVSQEDKRKTTGEENGVEAEEWGKFLHTKNKLYTDFDEIRQEIENETERISG 
NNKGVSPEPIHLKIFSPNVVNLTLVDLPGMTKVPVGDQPKDIELQIRELILRFISNPNSI 
ILAVTAANTDMATSEALKISREVDPDGRRTLAVITKLDLMDAGTDAMDVLMGRVIPVKLG 
IIGVVNRSQLDINNKKSVTDSIRDEYAFLQKKYPSLANRNGTKYLARTLNRLLMHHIRDC 
LPELKTRINVLAAQYQSLLNSYGEPVDDKSATLLQLITKFATEYCNTIEGTAKYIETSEL 
CGGARICYIFHETFGRTLESVDPLGGLNTIDILTAIRNATGPRPALFVPEVSFELLVKRQ 
IKRLEEPSLRCVELVHEEMQRIIQHCSNYSTQELLRFPKLHDAIVEVVTCLLRKRLPVTN 
EMVHNLVAIELAYINTKHPDFADACGLMNNNIEEQRRNRLARELPSAVSRDKSSKVPSAL 
APAVASGGGGVGDGVQEPTTGNWRGMLKTSKAEELLAEEKSKPIPIMPASPQKGHAVNLL 
DVPVPVARKLSAREQRDCEVIERLIKSYFLIVRKNIQDSVPKAVMHFLVNHVKDTLQSEL 
VGQLYKSSLLDDLLTESEDMAQRRKEAADMLKALQGASQIIAEIRETHLW 
– 
O00429-6 
>sp|O00429-6|DNM1L_HUMAN Isoform 6 of Dynamin-1-like protein 
OS=Homo sapiens GN=DNM1L 
MEALIPVINKLQDVFNTVGADIIQLPQIVVVGTQSSGKSSVLESLVGRDLLPRGTGIVTR 
RPLILQLVHVSQEDKRKTTGEENDPATWKNSRHLSKGVEAEEWGKFLHTKNKLYTDFDEI 
RQEIENETERISGNNKGVSPEPIHLKIFSPNVVNLTLVDLPGMTKVPVGDQPKDIELQIR 
ELILRFISNPNSIILAVTAANTDMATSEALKISREVDPDGRRTLAVITKLDLMDAGTDAM 
DVLMGRVIPVKLGIIGVVNRSQLDINNKKSVTDSIRDEYAFLQKKYPSLANRNGTKYLAR 
TLNRLLMHHIRDCLPELKTRINVLAAQYQSLLNSYGEPVDDKSATLLQLITKFATEYCNT 
IEGTAKYIETSELCGGARICYIFHETFGRTLESVDPLGGLNTIDILTAIRNATGPRPALF 
VPEVSFELLVKRQIKRLEEPSLRCVELVHEEMQRIIQHCSNYSTQELLRFPKLHDAIVEV 
VTCLLRKRLPVTNEMVHNLVAIELAYINTKHPDFADACGLMNNNIEEQRRNRLARELPSA 
VSRDKSSKVPSALAPASQEPSPAASAEADGKLIQDSRRETKNVASGGGGVGDGVQEPTTG 
NWRGMLKTSKAEELLAEEKSKPIPIMPASPQKGHAVNLLDVPVPVARKLSAREQRDCEVI 
ERLIKSYFLIVRKNIQDSVPKAVMHFLVNHVKDTLQSELVGQLYKSSLLDDLLTESEDMA 
QRRKEAADMLKALQGASQIIAEIRETHLW 
– 
O00429-7 
>sp|O00429-7|DNM1L_HUMAN Isoform 7 of Dynamin-1-like protein 
OS=Homo sapiens GN=DNM1L 
MFHKKINGKQQEKKMTLLHGKTQDTFLKGWKQKNGVNFFTPKIRSQLDINNKKSVTDSIR 
39–44: FtpKiR 
1
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Fission 
machinery 
protein 
Accession 
number 
FASTA sequence 
PP1-binding motifs 
(aa x–y) 
DEYAFLQKKYPSLANRNGTKYLARTLNRLLMHHIRDCLPELKTRINVLAAQYQSLLNSYG 
EPVDDKSATLLQLITKFATEYCNTIEGTAKYIETSELCGGARICYIFHETFGRTLESVDP 
LGGLNTIDILTAIRNATGPRPALFVPEVSFELLVKRQIKRLEEPSLRCVELVHEEMQRII 
QHCSNYSTQELLRFPKLHDAIVEVVTCLLRKRLPVTNEMVHNLVAIELAYINTKHPDFAD 
ACGLMNNNIEEQRRNRLARELPSAVSRDKSSKVPSALAPASQEPSPAASAEADGKLIQDS 
RRETKNVASGGGGVGDGVQEPTTGNWRGMLKTSKAEELLAEEKSKPIPIMPASPQKGHAV 
NLLDVPVPVARKLSAREQRDCEVIERLIKSYFLIVRKNIQDSVPKAVMHFLVNHVKDTLQ 
SELVGQLYKSSLLDDLLTESEDMAQRRKEAADMLKALQGASQIIAEIRETHLW 
O00429-8 
>sp|O00429-8|DNM1L_HUMAN Isoform 8 of Dynamin-1-like protein 
OS=Homo sapiens GN=DNM1L 
MEALIPVINKLQDVFNTVGADIIQLPQIVVVGTQSSGKSSVLESLVGRDLLPRGTGIVTR 
RPLILQLVHVSQEDKRKTTGEENDPATWKNSRHLSKGVEAEEWGKFLHTKNKLYTDFDEI 
RQEIENETERISGNNKGVSPEPIHLKIFSPNVVNLTLVDLPGMTKVPVGDQPKDIELQIR 
ELILRFISNPNSIILAVTAANTDMATSEALKISREVDPDGRRTLAVITKLDLMDAGTDAM 
DVLMGRVIPVKLGIIGVVNRSQLDINNKKSVTDSIRDEYAFLQKKYPSLANRNGTKYLAR 
TLNRLLMHHIRDCLPELKTRINVLAAQYQSLLNSYGEPVDDKSATLLQLITKFATEYCNT 
IEGTAKYIETSELCGGARICYIFHETFGRTLESVDPLGGLNTIDILTAIRNATGPRPALF 
VPEVSFELLVKRQIKRLEEPSLRCVELVHEEMQRIIQHCSNYSTQELLRFPKLHDAIVEV 
VTCLLRKRLPVTNEMVHNLVAIELAYINTKHPDFADACGLMNNNIEEQRRNRLARELPSA 
VSRDKSSKVPSALAPASQEPSPAASAEADGKVASGGGGVGDGVQEPTTGNWRGMLKTSKA 
EELLAEEKSKPIPIMPASPQKGHAVNLLDVPVPVARKLSAREQRDCEVIERLIKSYFLIV 
RKNIQDSVPKAVMHFLVNHVKDTLQSELVGQLYKSSLLDDLLTESEDMAQRRKEAADMLK 
ALQGASQIIAEIRETHLW 
– 
Fis1 Q9Y3D6 
>sp|Q9Y3D6|FIS1_HUMAN Mitochondrial fission 1 protein OS=Homo 
sapiens GN=FIS1 PE=1 SV=2 
MEAVLNELVSVEDLLKFEKKFQSEKAAGSVSKSTQFEYAWCLVRSKYNDDIRKGIVLLEE 
LLPKGSKEEQRDYVFYLAVGNYRLKEYEKALKYVRGLLQTEPQNNQAKELERLIDKAMKK 
DGLVGMAIVGGMALGVAGLAGLIGLAVSKSKS 
– 
GDAP1 
Q8TB36 
>sp|Q8TB36|GDAP1_HUMAN Ganglioside-induced differentiation-
associated protein 1 OS=Homo sapiens GN=GDAP1 PE=1 SV=3 
MAERQEEQRGSPPLRAEGKADAEVKLILYHWTHSFSSQKVRLVIAEKALKCEEHDVSLPL 
SEHNEPWFMRLNSTGEVPVLIHGENIICEATQIIDYLEQTFLDERTPRLMPDKESMYYPR 
VQHYRELLDSLPMDAYTHGCILHPELTVDSMIPAYATTRIRSQIGNTESELKKLAEENPD 
LQEAYIAKQKRLKSKLLDHDNVKYLKKILDELEKVLDQVETELQRRNEETPEEGQQPWLC 
GESFTLADVSLAVTLHRLKFLGFARRNWGNGKRPNLETYYERVLKRKTFNKVLGHVNNIL 
ISAVLPTAFRVAKKRAPKVLGTTLVVGLLAGVGYFAFMLFRKRLGSMILAFRPRPNYF 
– 
Q8TB36-2 
>sp|Q8TB36-2|GDAP1_HUMAN Isoform 2 of Ganglioside-induced 
differentiation-associated protein 1 OS=Homo sapiens GN=GDAP1 
MRLNSTGEVPVLIHGENIICEATQIIDYLEQTFLDERTPRLMPDKESMYYPRVQHYRELL 
DSLPMDAYTHGCILHPELTVDSMIPAYATTRIRSQIGNTESELKKLAEENPDLQEAYIAK 
QKRLKSKLLDHDNVKYLKKILDELEKVLDQVETELQRRNEETPEEGQQPWLCGESFTLAD 
VSLAVTLHRLKFLGFARRNWGNGKRPNLETYYERVLKRKTFNKVLGHVNNILISAVLPTA 
FRVAKKRAPKVLGTTLVVGLLAGVGYFAFMLFRKRLGSMILAFRPRPNYF 
– 
Mff 
Q9GZY8 
>sp|Q9GZY8|MFF_HUMAN Mitochondrial fission factor OS=Homo 
sapiens GN=MFF PE=1 SV=1 
MSKGTSSDTSLGRVSRAAFPSPTAAEMAEISRIQYEMEYTEGISQRMRVPEKLKVAPPNA 
DLEQGFQEGVPNASVIMQVPERIVVAGNNEDVSFSRPADLDLIQSTPFKPLALKTPPRVL 
TLSERPLDFLDLERPPTTPQNEEIRAVGRLKRERSMSENAVRQNGQLVRNDSLWHRSDSA 
PRNKISRFQAPISAPEYTVTPSPQQARVCPPHMLPEDGANLSSARGILSLIQSSTRRAYQ 
QILDVLDENRRPVLRGGSAAATSNPHHDNVRYGISNIDTTIEGTSDDLTVVDAASLRRQI 
IKLNRRLQLLEEENKERAKREMVMYSITVAFWLLNSWLWFRR 
– 
Q9GZY8-2 
>sp|Q9GZY8-2|MFF_HUMAN Isoform 2 of Mitochondrial fission 
factor OS=Homo sapiens GN=MFF 
MAEISRIQYEMEYTEGISQRMRVPEKLKVAPPNADLEQGFQEGVPNASVIMQVPERIVVA 
GNNEDVSFSRPADLDLIQSTPFKPLALKTPPRVLTLSERPLDFLDLERPPTTPQNEEIRA 
VGRLKRERSMSENAVRQNGQLVRNDSLVTPSPQQARVCPPHMLPEDGANLSSARGILSLI 
QSSTRRAYQQILDVLDENRRPVLRGGSAAATSNPHHDNVRYGISNIDTTIEGTSDDLTVV 
DAASLRRQIIKLNRRLQLLEEENKERAKREMVMYSITVAFWLLNSWLWFRR 
– 
Q9GZY8-3 
>sp|Q9GZY8-3|MFF_HUMAN Isoform 3 of Mitochondrial fission 
factor OS=Homo sapiens GN=MFF 
MAEISRIQYEMEYTEGISQRMRVPEKLKVAPPNADLEQGFQEGVPNASVIMQVPERIVVA 
GNNEDVSFSRPADLDLIQSTPFKPLALKTPPRVLTLSERPLDFLDLERPPTTPQNEEIRA 
VGRLKRERSMSENAVRQNGQLVRNDSLWHRSDSAPRNKISRFQAPISAPEYTYGISNIDT 
TIEGTSDDLTVVDAASLRRQIIKLNRRLQLLEEENKERAKREMVMYSITVAFWLLNSWLW 
FRR 
– 
Q9GZY8-4 
>sp|Q9GZY8-4|MFF_HUMAN Isoform 4 of Mitochondrial fission 
factor OS=Homo sapiens GN=MFF 
MAEISRIQYEMEYTEGISQRMRVPEKLKVAPPNADLEQGFQEGVPNASVIMQVPERIVVA 
GNNEDVSFSRPADLDLIQSTPFKPLALKTPPRVLTLSERPLDFLDLERPPTTPQNEEIRA 
VGRLKRERSMSENAVRQNGQLVRNDSLYGISNIDTTIEGTSDDLTVVDAASLRRQIIKLN 
RRLQLLEEENKERAKREMVMYSITVAFWLLNSWLWFRR 
– 
Q9GZY8-5 
>sp|Q9GZY8-5|MFF_HUMAN Isoform 5 of Mitochondrial fission 
factor OS=Homo sapiens GN=MFF 
MAEISRIQYEMEYTEGISQRMRVPEKLKVAPPNADLEQGFQEGVPNASVIMQVPERIVVA 
GNNEDVSFSRPADLDLIQSTPFKPLALKTPPRVLTLSERPLDFLDLERPPTTPQNEEIRA 
VGRLKRERSMSENAVRQNGQLVRNDSLPVLRGGSAAATSNPHHDNVRYGISNIDTTIEGT 
SDDLTVVDAASLRRQIIKLNRRLQLLEEENKERAKREMVMYSITVAFWLLNSWLWFRR 
– 
The sequences were collected from UniProtKB database and loaded in ScanProsite program as well as the 
PP1-binding motifs canonical sequences listed on Table 5. All the proteins returned no hits for all canonical 
sequences for PP1-binding motifs ([RK]-X(0,1)-[VI]-{P}-[FW], [HKR]-[ACHKMNQRSTV]-V-[CHKNQRST]-[FW], 
[KRL]-[KRSTAMVHNQ]-[VI]-{FIMYDP}-[FW], [GS]-I-L-[RK], F-X-X-[RK]-X-[RK], R-X-X-Q-[VIL]-[KR]-X-[YW], R-A-R-
A, R-[KR]-X-H-Y, K-S-Q-K-W, R-N-Y-F).
 1
isoform 7 of DLP1 returned one hit for an RVxF-cooperating motif 
which, alone, was considered irrelevant.  
A
p
p
e
n
d
ix
 
 
1
6
9
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
1:sp|O94516|PEX16_SCHPO 100.00 21.96 18.66 21.69 22.12 16.52 14.33 17.98 17.51 18.24 19.15 15.56 16.07 17.06 17.44 16.73 17.51 18.51 18.86 18.51 18.51 18.51 18.15 18.15 17.79 17.79 17.58 17.00 17.44 15.41
2:tr|Q5KG96|Q5KG96_CRYNJ 21.96 100.00 28.98 30.49 29.59 14.29 22.30 14.86 20.41 22.07 22.42 25.65 25.81 22.38 25.00 23.57 21.09 22.86 23.93 23.93 23.93 22.86 22.86 22.86 23.93 23.21 23.90 23.89 21.58 22.46
3:sp|P78980|PEX16_YARLI 18.66 28.98 100.00 34.25 34.84 15.19 22.36 17.01 24.69 20.86 24.18 25.26 24.41 23.89 25.67 24.25 23.16 24.33 25.00 24.67 24.33 23.59 23.26 22.92 25.00 24.33 25.17 25.37 20.40 22.92
4:tr|Q7SD18|Q7SD18_NEUCR 21.69 30.49 34.25 100.00 52.59 16.53 19.81 20.53 22.26 21.30 27.30 25.09 26.26 23.66 25.17 23.83 22.96 23.83 24.50 24.16 23.83 23.83 23.49 22.82 24.83 23.83 25.34 24.81 24.83 22.33
5:tr|Q4WJ13|Q4WJ13_ASPFU 22.12 29.59 34.84 52.59 100.00 15.06 21.54 21.72 22.67 20.99 28.43 29.07 27.42 27.43 27.67 25.91 24.26 27.33 27.67 27.33 27.00 26.58 26.25 25.91 27.33 27.00 28.23 27.99 24.58 25.74
6:tr|Q22X13|Q22X13_TETTS 16.52 14.29 15.19 16.53 15.06 100.00 20.46 21.03 22.14 12.62 19.41 21.30 20.59 20.26 20.08 19.67 20.33 21.34 20.92 20.92 20.92 20.16 19.76 19.76 22.18 21.76 22.94 24.15 21.10 21.40
7:sp|Q8S8S1|PEX16_ARATH 14.33 22.30 22.36 19.81 21.54 20.46 100.00 45.69 22.99 16.27 21.32 23.70 23.27 23.81 23.82 23.12 23.49 23.82 23.51 23.51 23.20 22.50 21.88 21.56 24.76 24.14 24.44 24.74 21.43 21.74
8:tr|Q0E4E2|Q0E4E2_ORYSJ 17.98 14.86 17.01 20.53 21.72 21.03 45.69 100.00 25.00 4.88 27.60 25.39 25.39 24.49 26.29 24.62 25.26 25.77 24.74 25.26 25.26 22.56 22.56 22.56 25.26 26.29 28.72 29.05 18.46 24.62
9:sp|Q550G0|PEX16_DICDI 17.51 20.41 24.69 22.26 22.67 22.14 22.99 25.00 100.00 17.98 25.00 24.37 26.54 28.14 27.47 25.85 27.36 27.47 28.70 27.78 27.47 27.08 26.15 25.85 28.70 28.70 28.71 28.18 21.21 20.30
10:tr|H2XTV0|H2XTV0_CIOIN 18.24 22.07 20.86 21.30 20.99 12.62 16.27 4.88 17.98 100.00 33.33 30.54 32.57 28.85 30.29 30.29 24.49 30.86 32.00 31.43 30.86 31.43 31.43 30.86 32.00 30.86 30.86 30.87 26.40 29.28
11:sp|B0JYZ2|PEX16_XENTR 19.15 22.42 24.18 27.30 28.43 19.41 21.32 27.60 25.00 33.33 100.00 51.70 57.36 58.08 60.78 55.99 48.69 56.59 57.49 57.19 56.89 53.29 52.99 52.69 57.78 57.49 57.98 57.33 34.58 36.67
12:tr|H3CGN5|H3CGN5_TETNG 15.56 25.65 25.26 25.09 29.07 21.30 23.70 25.39 24.37 30.54 51.70 100.00 65.85 58.96 62.77 57.85 54.55 62.15 62.77 63.08 62.77 58.46 58.46 58.15 62.46 63.08 64.47 63.70 36.10 35.22
13:sp|Q4QRH7|PEX16_DANRE 16.07 25.81 24.41 26.26 27.42 20.59 23.27 25.39 26.54 32.57 57.36 65.85 100.00 68.20 71.04 66.57 61.24 67.76 68.06 68.36 68.06 64.48 64.48 64.18 69.85 68.06 69.82 69.21 37.15 39.63
14:tr|E1BVC0|E1BVC0_CHICK 17.06 22.38 23.89 23.66 27.43 20.26 23.81 24.49 28.14 28.85 58.08 58.96 68.20 100.00 78.63 72.14 72.90 72.52 75.19 75.57 74.81 69.47 70.23 69.47 72.90 74.43 75.59 75.44 36.25 38.28
15:tr|F6W6D8|F6W6D8_MONDO 17.44 25.00 25.67 25.17 27.67 20.08 23.82 26.29 27.47 30.29 60.78 62.77 71.04 78.63 100.00 94.94 71.75 86.01 86.01 86.31 86.01 82.14 82.14 81.85 83.63 84.82 86.59 86.42 35.29 38.72
16:tr|F6WKY7|F6WKY7_MONDO 16.73 23.57 24.25 23.83 25.91 19.67 23.12 24.62 25.85 30.29 55.99 57.85 66.57 72.14 94.94 100.00 66.88 81.25 81.55 81.85 81.55 81.90 82.20 81.90 79.17 80.36 82.01 81.46 32.41 36.47
17:tr|Q5FVJ9|Q5FVJ9_RAT 17.51 21.09 23.16 22.96 24.26 20.33 23.49 25.26 27.36 24.49 48.69 54.55 61.24 72.90 71.75 66.88 100.00 78.90 79.87 79.55 79.22 75.32 74.68 74.35 86.04 80.84 81.00 79.56 32.20 35.00
18:tr|F6ZXH5|F6ZXH5_HORSE 18.51 22.86 24.33 23.83 27.33 21.34 23.82 25.77 27.47 30.86 56.59 62.15 67.76 72.52 86.01 81.25 78.90 100.00 91.96 92.56 92.26 88.10 88.39 88.10 89.88 91.96 93.29 92.38 37.46 37.20
19:tr|H9G207|H9G207_MACMU 18.86 23.93 25.00 24.50 27.67 20.92 23.51 24.74 28.70 32.00 57.49 62.77 68.06 75.19 86.01 81.55 79.87 91.96 100.00 98.21 97.92 94.94 93.45 93.15 91.07 92.56 92.99 93.05 37.15 38.41
20:tr|K7AV99|K7AV99_PANTR 18.51 23.93 24.67 24.16 27.33 20.92 23.51 25.26 27.78 31.43 57.19 63.08 68.36 75.57 86.31 81.85 79.55 92.56 98.21 100.00 99.40 93.75 95.24 94.64 91.07 92.86 92.99 92.72 37.46 38.11
21:sp|Q9Y5Y5|PEX16_HUMAN 18.51 23.93 24.33 23.83 27.00 20.92 23.20 25.26 27.47 30.86 56.89 62.77 68.06 74.81 86.01 81.55 79.22 92.26 97.92 99.40 100.00 93.45 94.64 95.24 90.77 92.56 92.68 92.38 37.15 37.80
22:tr|F7DTL5|F7DTL5_MACMU 18.51 22.86 23.59 23.83 26.58 20.16 22.50 22.56 27.08 31.43 53.29 58.46 64.48 69.47 82.14 81.90 75.32 88.10 94.94 93.75 93.45 100.00 97.40 96.82 86.90 88.10 88.72 88.08 34.26 36.17
23:tr|H2Q3H2|H2Q3H2_PANTR 18.15 22.86 23.26 23.49 26.25 19.76 21.88 22.56 26.15 31.43 52.99 58.46 64.48 70.23 82.14 82.20 74.68 88.39 93.45 95.24 94.64 97.40 100.00 99.13 86.61 88.10 88.41 87.75 34.57 36.17
24:sp|q9y5y5-2|PEX16_HUMAN 18.15 22.86 22.92 22.82 25.91 19.76 21.56 22.56 25.85 30.86 52.69 58.15 64.18 69.47 81.85 81.90 74.35 88.10 93.15 94.64 95.24 96.82 99.13 100.00 86.31 87.80 88.11 87.42 34.26 35.87
25:sp|Q91XC9|PEX16_MOUSE 17.79 23.93 25.00 24.83 27.33 22.18 24.76 25.26 28.70 32.00 57.78 62.46 69.85 72.90 83.63 79.17 86.04 89.88 91.07 91.07 90.77 86.90 86.61 86.31 100.00 92.26 91.77 91.39 36.22 39.63
26:tr|E2RES1|E2RES1_CANFA 17.79 23.21 24.33 23.83 27.00 21.76 24.14 26.29 28.70 30.86 57.49 63.08 68.06 74.43 84.82 80.36 80.84 91.96 92.56 92.86 92.56 88.10 88.10 87.80 92.26 100.00 94.82 94.04 37.15 38.41
27:sp|Q2KII7|PEX16_BOVIN 17.58 23.90 25.17 25.34 28.23 22.94 24.44 28.72 28.71 30.86 57.98 64.47 69.82 75.59 86.59 82.01 81.00 93.29 92.99 92.99 92.68 88.72 88.41 88.11 91.77 94.82 100.00 99.67 36.56 38.15
28:sp|Q2KII7-2|PEX16_BOVIN 17.00 23.89 25.37 24.81 27.99 24.15 24.74 29.05 28.18 30.87 57.33 63.70 69.21 75.44 86.42 81.46 79.56 92.38 93.05 92.72 92.38 88.08 87.75 87.42 91.39 94.04 99.67 100.00 35.71 38.80
29:tr|Q9VPB9|Q9VPB9_DROME 17.44 21.58 20.40 24.83 24.58 21.10 21.43 18.46 21.21 26.40 34.58 36.10 37.15 36.25 35.29 32.41 32.20 37.46 37.15 37.46 37.15 34.26 34.57 34.26 36.22 37.15 36.56 35.71 100.00 44.21
30:tr|Q7QKE2|Q7QKE2_ANOGA 15.41 22.46 22.92 22.33 25.74 21.40 21.74 24.62 20.30 29.28 36.67 35.22 39.63 38.28 38.72 36.47 35.00 37.20 38.41 38.11 37.80 36.17 36.17 35.87 39.63 38.41 38.15 38.80 44.21 100.00
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Supplementary Table 5: Pex16p homologs and PP1-binding motifs 
Species 
(common name) 
Accession 
number 
FASTA sequence 
PP1-binding motifs 
(aa x–y) 
Anopheles 
gambiae 
(african malaria 
mosquito) 
Q7QKE2 
>tr|Q7QKE2|Q7QKE2_ANOGA AGAP002283-PA OS=Anopheles gambiae 
GN=AGAP002283 PE=4 SV=3 
MSSPLAEVQNLYERYVKWVSGNPSALADVELTVKWLSYFVAGKINNSSAVSELVYSLSNL 
LVFFNDRIIEKASKKTPDDTQPLERHLNVLLTTLEYCEVFIELSAHKVWGTSGRWFFIVV 
IQTIKCIGRLILTLFCQNTKIIRNPPIPALNRKTIQTDNHHHDHPQSDNASFRDNLADGS 
SAIVLKRSGRVMRKVNCSPSLTSRSWKPPATGSSSHQPAVYGGKFLVSAEMLYIAKPLIH 
LASMRKFGTRSWTSYLIALALDSASLRMYYKNREVLSKDQRVELSRRCVSMLLYLMRSPF 
YDRYTHDKIACLLNGIGNNVPLTGSIARLILSYIPHWQETYFYMWST 
14–18: RyVKW 
1
 
31–35: LTVKW 
3
 
Arabidopsis 
thaliana 
(mouse-ear cress) 
Q8S8S1 
>sp|Q8S8S1|PEX16_ARATH Peroxisome biogenesis protein 16 
OS=Arabidopsis thaliana GN=PEX16 PE=1 SV=1 
MEAYKQWVWRNREYVQSFGSFANGLTWLLPEKFSASEIGPEAVTAFLGIFSTINEHIIEN 
APTPRGHVGSSGNDPSLSYPLLIAILKDLETVVEVAAEHFYGDKKWNYIILTEAMKAVIR 
LALFRNSGYKMLLQGGETPNEEKDSNQSESQNRAGNSGRNLGPHGLGNQNHHNPWNLEGR 
AMSALSSFGQNARTTTSSTPGWSRRIQHQQAVIEPPMIKERRRTMSELLTEKGVNGALFA 
IGEVLYITRPLIYVLFIRKYGVRSWIPWAISLSVDTLGMGLLANSKWWGEKSKQVHFSGP 
EKDELRRRKLIWALYLMRDPFFTKYTRQKLESSQKKLELIPLIGFLTEKIVELLEGAQSR 
YTYISGS 
293–297: KQVHF 
1, 2, 3
 
Bos taurus 
(bovine) 
Q2KII7 
>sp|Q2KII7|PEX16_BOVIN Peroxisomal membrane protein PEX16 
OS=Bos taurus GN=PEX16 PE=2 SV=2 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGLSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPMSLSQQRLLTWLSVLECVEVFMEMGATKVWGEVGRWLVIALIQLAK 
AVLRMFLLIWFKAGLQTSPPIVPLDREIQAQSRDGDHSSGSQEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQREELGVAPTPLGLQETIAESLHIARPLLHLLSLGLWGQRSWTPWLL 
SGVVDVTSLSLLSDRKGLTRRERLELRRRTILLLYYLLRSPFYDRFSEAKILFLLQLLAD 
HVPGIGLVTRPLMDYLPNWQKIYFYSWG 
63–66: GILR 
4
 
290–293: K.ILF 
1 
321–324: K.IYF 
1 
Q2KII7-2 
>sp|Q2KII7-2|PEX16_BOVIN Isoform 2 of Peroxisomal membrane 
protein PEX16 OS=Bos taurus GN=PEX16 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGLSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPMSLSQQRLLTWLSVLECVEVFMEMGATKVWGEVGRWLVIALIQLAK 
EIQAQSRDGDHSSGSQEQSYVGKRSNRVVRTLQNTPSLHSRHWGAPQQREELGVAPTPLG 
LQETIAESLHIARPLLHLLSLGLWGQRSWTPWLLSGVVDVTSLSLLSDRKGLTRRERLEL 
RRRTILLLYYLLRSPFYDRFSEAKILFLLQLLADHVPGIGLVTRPLMDYLPNWQKIYFYS 
WG 
63–66: GILR 
4
 
264–267: K.ILF 
1
 
295–298: K.IYF 
1
 
Canis familiaris 
(dog) 
E2RES1 
>tr|E2RES1|E2RES1_CANFA Uncharacterized protein OS=Canis 
familiaris GN=PEX16 PE=4 SV=1 
MEKLRLLSLRYQEYVTRHPAATAQLETAVRGLSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVPLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALIQLAK 
AVLRMFLLIWFKAGLQTSPPIVPLDRETQAQSPDGDQSSGSQEQSYVGKRSNRVVRTLQN 
TPSLHTRHWGAPQQREGRQQQQREELNVPPTPLGLQETIAESLYIARPLLHLLSLGLWGQ 
RSWTPWLLSGVVDVTSLSLLSDRKGLTRRERLELRRRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLTDHVPGIGVVARPLMDYLPTWQKIYFYSWG 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
329–332: K.IYF 
1
 
Ciona intestinalis 
(transparent sea 
squirt) 
H2XTV0 
>tr|H2XTV0|H2XTV0_CIOIN Uncharacterized protein OS=Ciona 
intestinalis GN=LOC100175223 PE=4 SV=1 
MSDILKSARDRLNENLMEIKQAYVNFVSQNPEMVDQIEKTVKTSSYLFEALSKNYDNSIF 
ISELITSACNLFAYANTKILLKTRNLISQTDENKFVAKLKQALTVVEFSQAFLELSAGRL 
GGSGARWAVIVVITIIKTILRCLLLYMFDSGLQSPALVTMINKTNIATQATNSDENENIY 
IGRRTGHQMATLSSSYSK 
95–100: FvaKlK 
5
 
Cryptococcus 
neoformans 
Q5KG96 
>tr|Q5KG96|Q5KG96_CRYNJ Peroxisomal membrane protein pex16, 
putative OS=Cryptococcus neoformans var. neoformans serotype 
D (strain JEC21 / ATCC MYA-565) GN=CNE04390 PE=4 SV=1 
MSPLEAYHSFLLSNLSAVQTIESSISNITWLLPGRFEDAEVASEGLYALLSLVAGYHDKI 
LSSHLSSSLSLPPHPFAKPRTPTEPLSASQESVTTRIHPLLPPPSDHARYTRYWTESSSL 
YEKASRALSTISYLELLVEMVARKKLGDRRRWKVVLGLESLKTFLRLLLMLKTRRPVLSQ 
PTPQREFDLASVPSEVLDPSSSQPQDGNNPVTPQLPAYSPLRSHLFPMAGNLPEKYLEHP 
LDLIPQLKGSEYIAEAVACCVGLARIYLLIRTSRQEVTRPYNPSSLPTLSRSMSPYLIPL 
ALLLLSRRLRSKSESPLLMSHYAQQDKKLALQAFMTGPMWIGWTRPKIVSVARALERLPI 
LGLVGDLVEGYLPLVDDYFFYTTS 
– 
Danio rerio 
(zebrafish) 
Q4QRH7 
>sp|Q4QRH7|PEX16_DANRE Peroxisomal membrane protein PEX16 
OS=Danio rerio GN=pex16 PE=2 SV=1 
MEKLTRVFERYQEYVRTSPAAASHLESTVRALSYLIAGRFSDSHEISELVYSASNLLVLL 
NDGILRKNLSRTLPMSISQQKLLTWLSVLEYVEVFVEMAAAKMWGDAGRWLVIVLIQIAK 
AVLRCLLLFWYKSGIQTSPPIIPLDRDSQLCSQDNNEEEDDEDSSFVGQRSGRVVRPLGS 
APSLQSRLWGLPRKKKVSRNQEEELHSSPTPLGLQETIAESLYIARPLLHLASLGICGKR 
SWKPWILSGLLEITSFSLLSDMKALNRRERAEMRRRAFLLLYYLLRSPFYDRYSETKILF 
LLRFLADYVPGVGLVARPLMEYLPIWQKIYFYNWG 
63–66: GILR 
4
 
297–300: K.ILF 
1
 
328–331: K.IYF 
1
 
Dictyostelium 
discoideum 
(slime mold) 
Q550G0 
>sp|Q550G0|PEX16_DICDI Peroxisome biogenesis factor 16 
OS=Dictyostelium discoideum GN=pex16 PE=3 SV=1 
MIPKQPKSNILIFLLENSDHLGLLKSLITFLPGRYGDSELFSEGLYSVANILQSYLDYRS 
SGILLSNNIDKISNGEKVPPPYYLTTLRWITTVQSLELFFEMLATKKGEQHDDSNSNNNN 
SNNNIKKMIIFIIELLKAILRLKLLIKTNGDMLVHHSFYVPSKDVKTILENNRNQQKQFQ 
NKRPAVTMSINNNNNINNNDNNNINNNNNTNDDNFNNNNNNNNNRRTLSDQIFEQQRIVN 
QENNLLYQQQRELQQNESTLIKLLPPPPPKDYNTKTIGEILFIFRPVIYWVSYCIFGKKS 
WKPWFLSLVTELLSKSFSEYGNFKQKIRLTLLEAKELNRRKKLLFFYLIRSPFYEKFIGD 
GLLNKFLNFLKKIHIFKTLIDILINYLNVYRTRYFYTSAS 
127–131: KmIIF 
1
 
323–328: FkqKiR 
5
 
Drosophila 
melanogaster 
(fruit fly) 
Q9VPB9 
>tr|Q9VPB9|Q9VPB9_DROME LD20358p OS=Drosophila melanogaster 
GN=Pex16 PE=2 SV=1 
MDTLKGMLKAYEAWVGKNPDVVGDFETTAKWVSYFIAGRISSSNVVSELVYTLSNMLVFY 
NDRIIEKARNSEENSVIHLQSKLCYRLKVTLTTLEYSEVFIEISARRLFGQSGKWLVIAL 
IQAFKAAGRFFILKHSTSDIITSPPIAALNRRAKQRKNSGDGVASSTNDLLQSQHSITFQ 
LKRSGRVIRKVEGAPPLQYRDFKLHIDNNEAAKTQIPRKLLQAEYLYISKPLIHLVAMGL 
FGRRSWKQYMVALSIDLYSIHLYRQHRDLMSKQQKLELSRRCINIMYFLVRSPFYDSFTK 
SRLERILDFVATSVPIAKVVAKPLKDYIPTWQSTYFYLWST 
– 
Equus caballus 
(horse) 
F6ZXH5 
>tr|F6ZXH5|F6ZXH5_HORSE Uncharacterized protein OS=Equus 
caballus GN=PEX16 PE=4 SV=1 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGLSYLLAGRFTDSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALIQLAK 
AVLRMFLLIWFKAGLQTSPPIVPLDREAQAQPPGGGHSPGSQEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQQEGRPRPHQEELSITPTPLGLQETIAESLYIARPLLHLLSLGLWGQ 
RSWTPWFLSGVVDVTSLSLLSDRRGLTRRERLELRHRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLADHVPGIGLVTKPLMDYLPTWQKIYFYNWG 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
329–332: K.IYF 
1
 
Gallus gallus E1BVC0 
>tr|E1BVC0|E1BVC0_CHICK Uncharacterized protein OS=Gallus 
gallus GN=PEX16 PE=4 SV=1 226–229: R.ILF 
1
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Species 
(common name) 
Accession 
number 
FASTA sequence 
PP1-binding motifs 
(aa x–y) 
(chicken) MSLPQQKLLTWLSVLECVEVFAEMGTARVWGEMGRWTIIVLIQLAKAILRLLLLLWYKAG 
IQTSPPIVPLNREQQQSLHSEDVEGSSSGKDQTFVGRRSSRVVRSLQNTPSLQSRHWGSP 
QQREETQSRRAEEMNQPPTPLGLQETIAESIYVTRPLLHLLSLGVWGQRSWKPWLLSAVL 
DISSLSLLSDLKDLNRRERAELRRRTILLLYYLLRSPFYDRYSEARILFLLRLLADYVPG 
LGFVTRPLMDYLPAWQKIYFYNWG 
257–260: K.IYF 
1
 
Homo sapiens 
(human) 
Q9Y5Y5 
>sp|Q9Y5Y5|PEX16_HUMAN Peroxisomal membrane protein PEX16 
OS=Homo sapiens GN=PEX16 PE=1 SV=2 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGFSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALVQLAK 
AVLRMLLLLWFKAGLQTSPPIVPLDRETQAQPPDGDHSPGNHEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQREGRQQQHHEELSATPTPLGLQETIAEFLYIARPLLHLLSLGLWGQ 
RSWKPWLLAGVVDVTSLSLLSDRKGLTRRERRELRRRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLADHVPGVGLVTRPLMDYLPTWQKIYFYSWG 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
329–332: K.IYF 
1
 
Q9Y5Y5-2 
>sp|q9y5y5-2|PEX16_HUMAN Isoform 2 of Peroxisomal membrane 
protein PEX16 OS=Homo sapiens GN=PEX16 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGFSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALVQLAK 
AVLRMLLLLWFKAGLQTSPPIVPLDRETQAQPPDGDHSPGNHEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQREGRQQQHHEELSATPTPLGLQETIAEFLYIARPLLHLLSLGLWGQ 
RSWKPWLLAGVVDVTSLSLLSDRKGLTRRERRELRRRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLADHVPGVGLVTTSQRAASPCLPARPHTQPWSPPAFLPGHP 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
Macaca mulatta 
(rhesus monkey) 
H9G207 
>tr|H9G207|H9G207_MACMU Peroxisomal biogenesis factor 16 
isoform 1 OS=Macaca mulatta GN=PEX16 PE=2 SV=1 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGLSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALIQLAK 
AILRMLLLLWFKAGLQTSPPIVPLDRETQAQPPDGDHSHGSHEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQREGWQQQHHEELSATPTPLGLQETIAEFLYIARPLLHLLSLGLWGQ 
RSWKPWLLAGVVDVTSLSLLSDRKGLTRRERRELRRRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLADHIPGVGLVTRPLMDYLPTWQKIYFYSWG 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
329–332: K.IYF 
1
 
F7DTL5 
>tr|F7DTL5|F7DTL5_MACMU Uncharacterized protein OS=Macaca 
mulatta GN=PEX16 PE=4 SV=1 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGLSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALIQLAK 
AVLRMLLLLWFKAGLQTSPPIVPLDRETQAQPPDGDHSHGSHEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQREGWQQQHHEELSATPTPLGLQETIAEFLYIARPLLHLLSLGLWGQ 
RSWKPWLLAGVVDVTSLSLLSDRKGLTRRERRELRRRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLADHIPGVGLVTTSQRAAFPCLPARPCTQPWSPPAFFPGPS 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
Monodelphis 
domestica 
(gray short-tailed 
opossum) 
F6W6D8 
>tr|F6W6D8|F6W6D8_MONDO Uncharacterized protein 
OS=Monodelphis domestica GN=PEX16 PE=4 SV=1 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGLSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRQSLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEMGRWLIIVLIQLAK 
AVLRILLLLWYKAGLQTSPPIVPLDREMQLHSQGGEHNLGSQDRPYVGKRSNRVVRSLQS 
TPSLHSRHWGVPQQQEGRLSHRGEELEAGPTPLGLQETIAESVYIARPLLHLLSLGLWGQ 
RSWKPWLLSAILDVTSLSLLSDKKGLTRRERLELRRRTILLLYYLLRSPFYDRFSEDRIL 
FLLRLLADYVPGVGLVTRPLMDYLPAWQKIYFYNWG 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
329–332: K.IYF 
1
 
F6WKY7 
>tr|F6WKY7|F6WKY7_MONDO Uncharacterized protein 
OS=Monodelphis domestica GN=PEX16 PE=4 SV=1 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGLSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRQSLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEMGRWLIIVLIQLAK 
AVLRILLLLWYKAGLQTSPPIVPLDREMQLHSQGGEHNLGSQDRPYVGKRSNRVVRSLQS 
TPSLHSRHWGVPQQQEGRLSHRGEELEAGPTPLGLQETIAESVYIARPLLHLLSLGLWGQ 
RSWKPWLLSAILDVTSLSLLSDKKGLTRRERLELRRRTILLLYYLLRSPFYDRFSEDRIL 
FLLRLLADYVPGVGLVTRKYQAAHPFSPSAPLPHSIPATMPKPASLPGEP 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
Mus musculus 
(mouse) 
Q91XC9 
>sp|Q91XC9|PEX16_MOUSE Peroxisomal membrane protein PEX16 
OS=Mus musculus GN=Pex16 PE=2 SV=2 
MEKLRLLSLRYQEYVTRHPAATAQLETAVRGLSYLLAGRFSDSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALIQLAK 
AVLRMLLLIWFKAGIQTSPPIVPLDRETQAQPLDGDHNPGSQEPSYVGKRSHRVVRTLQN 
SPSLHSRYWGAPQQREIRQKQQQEELSTPPTPLGLQETIAESLYIARPLLHLLSLGLWGQ 
RSWTPWLLSGVVDMTSLSLLSDRKNLTRRERLELRRRTILLLYYLLRSPFYDRFSEAKIL 
FLLQLLTDHIPGVGLVARPLMDYLPSWQKIYFYSWG 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
329–332: K.IYF 
1
 
Neosartorya 
fumigata 
Q4WJ13 
>tr|Q4WJ13|Q4WJ13_ASPFU Peroxisomal membrane protein pex16 
(Peroxin-16) OS=Neosartorya fumigata (strain ATCC MYA-4609 / 
Af293 / CBS 101355 / FGSC A1100) GN=AFUA_1G07610 PE=4 SV=1 
MNSDLKSHSPVSATLLQPSKWLTMYEDFVMKNASSVGQVESALRSLTYIIPGRYRDSEIS 
SESVHSGVQLLSLYHDSLVSRVIARLPSTVPRPAPTPHSRYTKYWISHSALYHQVALTLQ 
MVRYTELLWEMIARRRGEKVRWRVVVLIEIIKATCRLLLLRLTNSRPLVSPPLPEREVDP 
RSTEEEASDWNGMQTPVSERSADLSWTMPRTGLSLPSLPDANDISNFLISKVLTADDIKP 
PKSLLHRVSGQGQLAEVLHILRPVIYALALQRWRQDKRSWRPWLIGFAMEYGCRQLAKSD 
FRERVAGGLRGLTGLEREELRKRGWAMGWWLMRGAFYENITKSWLKGLTSKMKGKPLLDL 
VGSVIEDYEYLWENFYFSTATL 
139–142: K.VRW 
1
 
Neurospora crassa Q7SD18 
>tr|Q7SD18|Q7SD18_NEUCR Peroxisomal membrane protein pex16 
OS=Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 
708.71 / DSM 1257 / FGSC 987) GN=pex16 PE=4 SV=3 
MSTAADVPRFKGPNPIIQSMSATKRSTTSTDVKSTMSTNWLGAYGNFITKNNHQVSQIES 
TLRSLTYIIPGRFRDAEIASESIHSGVQLLSLYHDTLLFRASSKLSQPSLANAPSPHKRY 
IRFWFLKSPLYRRVAYLLQIVNYVELLIEMAAKRRGERMRWRAVIIIEAIKAFCKLLLLR 
ITKSRPLITPVLPEREPLPEAPTDEESAFQGDDSGYASASGSPQQSSPDGEWTMPRTGMS 
LPTLPSPGDISSYLLSRVLTADDIKPAAKLVNQLQGSAQVAEILHILSPLAFAVAMARSK 
DKRKAWAPWVLGLAIELVARQLRDRSLRTTPLEREEWSRRGWALGWWMMRGAFYENITKS 
MVEGVRKRMPSLIGGILEDYEYLWENYHFSTSP 
119–123: RyIRF 
1
 
Oryza sativa 
(rice) 
Q0E4E2 
>tr|Q0E4E2|Q0E4E2_ORYSJ Os02g0123200 protein OS=Oryza sativa 
subsp. japonica GN=Os02g0123200 PE=2 SV=1 
MLLQGGEVANEEEINILDENFGAKSNGVPVIYPMNGHFQNGHGVASNGLDGKAGFVSKSL 
EGRAVAALNKFGQNAKMTSDPMWMKKALPPPDPPAMVVEKPTLASIWSAKGISGRLFLLG 
EVVHIFRPLLYVLLIKKFGIKSWTPWLVSLAVEITSLGIHSRATDLHQRGGKVHQLSSAE 
RDELKRRKMMWALYVMRDPFFTRYTKRHLQKAEKVLDPVPLIGFLTGKLVELVEGAQTRY 
TYTSGS 
– 
Pan troglodytes 
(chimpanzee) 
K7AV99 
>tr|K7AV99|K7AV99_PANTR Peroxisomal biogenesis factor 16 
OS=Pan troglodytes GN=PEX16 PE=2 SV=1 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGFSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALIQLAK 
AVLRMLLLLWFKAGLQTSPPIVPLDRETQAQPPDGDHSPGGHEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQREGRQQQHHEELSATPTPLGLQETIAEFLYIARPLLHLLSLGLWGQ 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
329–332: K.IYF 
1
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Species 
(common name) 
Accession 
number 
FASTA sequence 
PP1-binding motifs 
(aa x–y) 
RSWKPWLLAGVVDVTSLSLLSDRKGLTRRERRELRRRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLADHVPGVGLVTRPLMDYLPTWQKIYFYSWG 
H2Q3H2 
>tr|H2Q3H2|H2Q3H2_PANTR Uncharacterized protein OS=Pan 
troglodytes GN=PEX16 PE=4 SV=1 
MEKLRLLGLRYQEYVTRHPAATAQLETAVRGFSYLLAGRFADSHELSELVYSASNLLVLL 
NDGILRKELRKKLPVSLSQQKLLTWLSVLECVEVFMEMGAAKVWGEVGRWLVIALIQLAK 
AVLRMLLLLWFKAGLQTSPPIVPLDRETQAQPPDGDHSPGGHEQSYVGKRSNRVVRTLQN 
TPSLHSRHWGAPQQREGRQQQHHEELSATPTPLGLQETIAEFLYIARPLLHLLSLGLWGQ 
RSWKPWLLAGVVDVTSLSLLSDRKGLTRRERRELRRRTILLLYYLLRSPFYDRFSEARIL 
FLLQLLADHVPGVGLVTTSQRAASPCLPARPHTQPWSPPAFLPGPP 
63–66: GILR 
4
 
298–301: R.ILF 
1
 
Rattus norvegicus 
(rat) 
Q5FVJ9 
>tr|Q5FVJ9|Q5FVJ9_RAT Peroxisomal biogenesis factor 16 
OS=Rattus norvegicus GN=Pex16 PE=2 SV=1 
MRKLGGNLDLPFKVASPIPTSCLSWCTLPLTCLCCSMTGSFGRSFEKKLPVSLSQQKLLT 
WLSVLECVEVFMEMGAAKVWGEVGRWLVIALIQLAKAVLRMFLLIWFKTGIQTSPPIVPL 
DRETQAQPLDGDHNLGSPEPSYVGKRSNRVVRTLQNSPSLHSRHWGAPQQREIRQKQQQE 
ELSTPPTPLGLQETIAESLYIARPLLHLLSLGLWGQRSWAPWLLSGVVDMTSLSLLSDRK 
NLTRRERLELRRRTILLLYYLLRSPFYDRFSEAKILFLLQLLADHIPGIGLVARPLMDYL 
PSWQKIYFYSWG 
274–277: K.ILF 
1
 
305–308: K.IYF 
1
 
Schizosaccharomy
ces pombe 
(fission yeast) 
O94516 
>sp|O94516|PEX16_SCHPO Peroxisomal membrane protein PEX16 
OS=Schizosaccharomyces pombe (strain 972 / ATCC 24843) 
GN=pex16 PE=1 SV=2 
MKPLAYYEDQLLKDEKSFLKVTEIERLLSYAAYLLPAEFRDDQLKSQTITSILLLLHQFH 
TGLLFRKIAELPKTEQAILKSERTQYLEYFRKKNPSFEKVSELLYFLNISTFPIELVISK 
YNPSRQYDSVLFLESVKFLLRVHIMWTTGGDLPLSNPVLQRDFNVKTFIHLHKKYSNSGS 
AVVLKNSKKVVPRLNTVNSSLDFLQNRTPRLSSILPDEIFTKRLPNLRIFSNFIKVCRPL 
IYMLFMWHWKRKQKSSSLKVRPWGPWIVAFVFEVISQLIDRRCESATSSRQGFGLERRTN 
QSQFQHFVVWAFTQGRFYDEFTKHWINRSLSWVNSIPVFGKYLLLSVEERQKSLENYISS 
VRNY 
– 
Tetrahymena 
thermophila 
Q22X13 
>tr|Q22X13|Q22X13_TETTS Peroxisomal membrane protein 
OS=Tetrahymena thermophila (strain SB210) GN=TTHERM_00633400 
PE=4 SV=2 
MDSQQENKSSQIYQSFQQYQHINKSLNKLVSFEFLLEQTLNYISNKSTFFNKDRFLEILS 
LSQFVKVYFKLQKMNISQKQIYISEGNMQEELDEQNRQKSEAFEKFFTEDYIEKYRNLQP 
EEQIQKMAETLERIKNRQQNGMTFNEDFEEELQRSHKRVGLLSKLPIPKDLLETKQPNQK 
KSDYMIFVGEVLFIVRPLIYCILLRMFGVKSYTPYMISLIIDLFRLILQRKIKFYQPAQR 
EEFKTRNKEMILNYLLRNPFYSHIFRNKVLIPMLDSLFGSRLQFLKSFILGIIEMRCSIC 
LLL 
28–32: KlVSF 
1
 
49–54: FfnKdR 
5
 
66–69: K.VYF 
1
 
230–234: RKIKF 
1, 3
 
243–248: FktRnK 
5
 
Tetraodon 
nigroviridis 
(spotted green 
pufferfish) 
H3CGN5 
>tr|H3CGN5|H3CGN5_TETNG Uncharacterized protein OS=Tetraodon 
nigroviridis PE=4 SV=1 
MEKASRYYERYSEFVRRNPAATAQLEGTVRTLSYLIAGRFTASHEMSELVYSASNLLVLL 
NDSILRRDLRWTGSMPVSQQRLLTWLEMGACKLWGKVGRWLVIALIQIFKAVLRLVLLLW 
YRSGIQTSPPIIPLDRSAELSPSDGERGQQEDSACFVGQRSGRVVRPLNRSAAPSPLTRR 
WGAPRPRTQPSSNMEKLLSRPTPLNLQETVGECVYIGRPLSAVLCLGLCGKQSWKPWLAC 
GCLSVGSVALLSEAKFQNGYERAEMRRRTFLLLYYLLRSPFYDKFSQGKILFLLRLLADH 
VPGIGLVARPLMDYLPTWQKIYFYNWG 
63–66: SILR 
4
 
289–292: K.ILF 
1
 
320–323: K.IYF 
1
 
Xenopus troplicalis 
(western clawed 
frog) 
B0JYZ2 
>sp|B0JYZ2|PEX16_XENTR Peroxisomal membrane protein PEX16 
OS=Xenopus tropicalis GN=pex16 PE=2 SV=1 
MAARYWDKLQDLSQKYKDYVIQNPTGATQLESAVRMLSYLIAGRFADSHELSELVYSASN 
LLALLNDGILRKELLAPPPTEGSRRRLLTWLGVLESLEVFIEIGAARAWGDRTRWAAILI 
IQLLKACLRIVLLFWYRAGIQSSPPVTPLDREGILNQAEDNSNSGSSCFVGRRSSRAVRS 
LDDSASSHRRFWRSPQIHDGKQRNTGETESDKDGSELGTLGTLAEAIHILRPITHLLSLA 
TWGQKSWKPWMVAAALDITSISLLSDVRNLSHRERAELRRRMFLLLYYLLRSPFYNHYTE 
TRLLLLLRLLGDYVPGVGLVARPLMDYLPVWQKIYFYNWG 
68–71: GILR 
4
 
333–336: K.IYF 
1
 
Yarrowia lipolytica P78980 
>sp|P78980|PEX16_YARLI Peroxisomal membrane protein PEX16 
OS=Yarrowia lipolytica (strain CLIB 122 / E 150) GN=PEX16 
PE=3 SV=1 
MTDKLVKVMQKKKSAPQTWLDSYDKFLVRNAASIGSIESTLRTVSYVLPGRFNDVEIATE 
TLYAVLNVLGLYHDTIIARAVAASPNAAAVYRPSPHNRYTDWFIKNRKGYKYASRAVTFV 
KFGELVAEMVAKKNGGEMARWKCIIGIEGIKAGLRIYMLGSTLYQPLCTTPYPDREVTGE 
LLETICRDEGELDIEKGLMDPQWKMPRTGRTIPEIAPTNVEGYLLTKVLRSEDVDRPYNL 
LSRLDNWGVVAELLSILRPLIYACLLFRQHVNKTVPASTKSKFPFLNSPWAPWIIGLVIE 
ALSRKMMGSWLLRQRQSGKTPTALDQMEVKGRTNLLGWWLFRGEFYQAYTRPLLYSIVAR 
LEKIPGLGLFGALISDYLYLFDRYYFTASTL 
aa 115–119: RAVTF 
1
 
aa 255–258: SILR 
4
 
The sequences of the organisms listed on PeroxisomeDB 2.0 as having Pex16p homologs were collected 
from UniProtKB database and loaded in ScanProsite program as well as the PP1-binding motifs canonical 
sequences listed on Table 5. The sequences are alphabetically ordered by species Latin name. The green- 
and blue-high lightened residues correspond to matches with the canonical sequences of RVxF and RVxF-
cooperating motifs, respectively. 
1
matches with the sequence [RK]-X(0,1)-[VI]-{P}-[FW]; 
2
matches with the 
sequence [HKR]-[ACHKMNQRSTV]-V-[CHKNQRST]-[FW]; 
3
matches with the sequence [KRL]-[KRSTAMVHNQ]-
[VI]-{FIMYDP}-[FW]; 
4
matches with the sequence [GS]-I-L-[RK]; 
5
matches with the sequence F-X-X-[RK]-X-
[RK]. Other canonical sequences were screened, with no hits (R-X-X-Q-[VIL]-[KR]-X-[YW], R-A-R-A, R-[KR]-X-
H-Y, K-S-Q-K-W and R-N-Y-F). A graphic resume of this screening is depicted on Figure 11. 
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Supplementary Figure 2: Glycine-rich region of human Pex11pβ is absent in Pex11pα and Pex11pγ 
The sequences were collected from UniProtKB database and aligned using the program Clustal Omega 
(version 1.2.1). Blue residues correspond to glycine-rich region.  
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Supplementary Figure 3: Determination of potential phosphorylation sites within HsPex11pβ 
(A) Overview of multiple hits for different amino acid positions. Several online screening tools were used to 
determine potential phosphorylation sites in the sequence of human Pex11pβ. The various tools were 
plotted against the positions given. (B) Scheme depicting phosphorylation-sites chosen for subsequent 
studies. Based on the screening, several putative phosphorylation sites were selected whose location is 
indicated in the upper scheme (potential sites). Based on our findings regarding the topology of Pex11pβ, 
intra-peroxisomal sites were excluded (extraperoxisomal sites). Furthermore, based in the studies regarding 
deletions of the N-terminus, the phosphorylation sites listed on the bottom were chosen. (C) Overview of 
conserved amino acids within Pex11pβ protein sequences across species. The putative phosphorylation-
sites are depicted in red brackets. Note that position S11 is highly conserved. From (211).  
